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bAckground
Eczema is the most common inflammatory skin disease among children of developed 
countries, with an estimated lifetime prevalence of 15–30 %.1 The prevalence of child-
hood eczema varies considerably worldwide2, and seems to increase in the majority of 
developing countries while leveling off or even decreasing in some developed coun-
tries.3, 4 In the Netherlands, 8.1 % of all children aged 13–14 years report symptoms of 
eczema in the last year.5 The mean annual societal costs of eczema treatment in the 
Netherlands are as high as €981–1,409 per child.6
Eczema is a complex chronic disease, characterized by intense itching and recurrent 
eczematous lesions that may affect any part of the body, but typically show a morphol-
ogy and distribution that varies with age.7 Also, generalized skin dryness resulting from 
impaired epidermal barrier function is a common feature. Because no specific laboratory 
biomarker or histological finding for eczema is known, the diagnosis relies exclusively 
on clinical features. Several sets of diagnostic criteria have been proposed in the past 
decades, such as the Hanifin and Rajka criteria, which are useful in clinical settings.8 In 
population-based studies, the diagnosis of eczema is often based on a parental-reported 
physician diagnosis.9 Originally, the pathogenesis of eczema was mainly attributed to 
abnormalities in the adaptive immune system, such as a dysregulation of type 1 and 
type 2 T-helper cells, immunoglobulin E (IgE) production and mast cell hyperactivity.10 
However, recent epidemiological and genetic studies have directed more toward a 
central role of epidermal barrier dysfunction.1, 10 Interaction of epidermal barrier impair-
ment and pro-inflammatory cytokines from keratinocytes also promotes percutaneous 
allergic sensitization.1, 7
Eczema is suggested to be the initial manifestation of atopy and the first step of the 
alleged atopic march that may ultimately lead to inhalant allergy and allergic asthma. 
Eczema may occur solely or coincide with allergic sensitization and symptoms of allergy 
as part of an atopic constitution.11 In the Netherlands, allergic sensitization is present 
in 26.4 % of children aged 7–14 years.12 In the first 2 years of life, up to two-thirds of 
children with moderate to severe eczema are sensitized to food allergens13, but only 
a minority of these children develop IgE-mediated food allergy.7 As children grow 
older, the allergic sensitisation pattern shifts toward inhalant allergens.14 Approximately 
5–10 % and 7–20 % of Western European children aged 6–7 years and 13–14 years, 
respectively, report symptoms of inhalant allergy. Furthermore, the prevalence of self-
reported symptoms of food allergy among Dutch school-age children is 7.2 %.15
Childhood eczema may partly has its origin in fetal life and infancy.16, 17 Environmental 
exposures that are known to be associated with eczema include housing conditions, 
urban or rural living, dietary and feeding habits, air pollution, and microbial exposure.17 
However, large population-based observational studies on the role of exposures during 
critical periods in early life on childhood eczema and related allergic sensitization and 
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allergy are scarce. This thesis focuses on the associations of detailed fetal and infant 
exposures with the risk of eczema from birth until school-age, and inhalant and food 
allergic sensitization and allergy at school-age in children from the general population.
FetAl exPosures
Scientific knowledge on the role of environmental exposures in the developmental 
origins of health and disease increases rapidly.18 Because future health care costs are 
likely to be unaffordable, there is a global imperative to develop and implement power-
ful prevention strategies. New insights into environmental exposures during fetal life 
and infancy that affect childhood eczema may provide novel opportunities to develop 
preventive measures at times when they are most effective.
Maternal psychiatric symptoms during pregnancy, which partly reflect maternal 
stress, have been associated with an increased risk of asthma-related symptoms, includ-
ing wheezing, in preschool-age children19, but exact underlying biological mechanisms 
are unclear. It is hypothesized that sustained excessive levels of maternal stress-induced 
hormones, particularly glucocorticoids, may influence T-helper cell phenotype differen-
tiation and, subsequently, atopic inflammation, eczema and allergy in the child.20 How-
ever, associations of maternal psychiatric symptoms during pregnancy with childhood 
eczema and allergy might be confounded by social, behavioral or environmental factors. 
Information on both maternal and paternal psychiatric symptoms could disentangle 
potential intrauterine and confounding mechanisms19, 21, but has previously not been 
examined.
Maternal vitamin and fatty acid status during pregnancy, including vitamin E, folate 
and n-3 or n-6 polyunsaturated fatty acid levels, have been associated with the risk of 
childhood eczema.22, 23 Exposure to low vitamin D levels during pregnancy (< 50 nmol/L) 
may affect the child’s developing adaptive and innate immune system in early life and, 
subsequently, increase the risk of eczema.24 Vitamin D is suggested to play a role in the 
cutaneous production of antimicrobial peptides in keratinocytes.25 Deficient expression 
of such peptides may increase susceptibility to skin infections with Staphylococcus 
aureus, an important pathogen associated with eczema.26, 27 In mice, vitamin D receptor 
activation induces the expression of antimicrobial peptides and epidermal barrier genes, 
including filaggrin (FLG), and improved allergen-triggered eczema.28 Loss-of-function 
mutations in the gene encoding filaggrin, an indispensable protein for keratinocyte 
differentiation and maintenance of an optimal epidermal barrier, are well known to be 
associated with eczema.29 However, data from longitudinal population-based studies 
relating both maternal and fetal vitamin D levels with childhood eczema remain scarce.
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inFAnt exPosures
Recently, it was observed that structural and functional epidermal barrier characteristics 
differ between adults of African American, Caucasian and East Asian descent.30 East 
Asian skin had the weakest epidermal barrier properties, but without skin dryness and 
scaliness due to high levels of stratum corneum lipids. African American skin showed a 
stronger epidermal barrier, but skin dryness due to low levels of stratum corneum lipids 
and low serine protease activity. Also, the prevalence of eczema varies considerably 
among children of different ethnic origin5, which might be explained by environmental 
and genetic exposures. However, data from multi-ethnic longitudinal studies relating 
early-life environmental and genetic exposures with eczema in children from the gen-
eral population are not fully clear.
Potential infant dietary exposures associated with the risk of childhood eczema 
include breastfeeding habits and timing or diversity of allergenic food introduction.17 
Underlying biological mechanisms for the associations of breastfeeding with eczema 
and allergy are not fully understood. They might involve complex interactions of hu-
man milk components, including secretory immunoglobulin A, cytokines, chemokines, 
long-chain polyunsaturated fatty acids and polyamines, which modulate the child’s 
developing immune system and alter the balance between pro-inflammatory and anti-
inflammatory signals.31, 32 Also, human milk oligosaccharides with prebiotic properties 
are suggested to influence the development of eczema and allergy by modulating gut 
microbiota diversity.33 The effects of breastfeeding on eczema, allergic sensitization 
and allergy in school-age children are less clear.34, 35 Also, the effects of disease-related 
modification of the exposure, meaning that early symptoms of eczema or allergy in the 
child may encourage a mother to alter breastfeeding habits36, and the modifying effects 
of child’s atopic susceptibility on these associations are less known.35, 37, 38
Timing or diversity of allergenic food introduction in relationship to eczema, allergic 
sensitization and allergy is a much debated topic. An accumulating body of evidence 
suggests that at age 4–6 months an early window of immunological opportunity exists 
to expose children to food proteins and induce immune tolerance.39, 40 Recently, the 
LEAP trial showed that peanut introduction in high-risk children aged 4–11 months 
was associated with a decreased risk of peanut allergy.41 However, less is known about 
the effects of introduction practices of allergenic foods in early life on eczema, allergic 
sensitization and allergy in older children from the general population.
hyPothesis
The hypothesis of this thesis is that fetal and infant exposures modulate the child’s de-
veloping immune system or impair the epidermal barrier function, potentially leading 
to eczema, allergic sensitization and allergy (Figure 1).
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obJectives
The main aims of this thesis are:
1. To assess the associations of fetal exposures with childhood eczema, allergic sensi-
tization or allergy. The exposures of interest include maternal psychiatric symptoms 
during pregnancy, and maternal and fetal vitamin D levels.
2. To assess the associations of infant exposures with childhood eczema, allergic sen-
sitization or allergy. The exposures of interest include ethnic origin, breastfeeding 
duration and exclusiveness, and timing or diversity of allergenic food introduction.
generAl design
The Generation R Study is a population-based prospective cohort study in Rotterdam, 
The Netherlands, following pregnant women and their children from fetal life onwards 
(www.generationr.nl).42 The study was designed to identify early environmental and 
genetic factors and causal pathways leading to normal and abnormal growth, develop-
ment and health during fetal life, childhood and adulthood. Enrollment was aimed in 
first trimester, but was allowed until birth of the child. In total, 9,778 mothers with a 
delivery date from April 2002 until January 2006 were enrolled in the study, and the 
response at baseline was 61 %. Data collection for this thesis comprised questionnaires 
for parental psychiatric symptoms during pregnancy and after delivery (Figure  2). 
Biological samples included maternal and umbilical cord blood for measurement of 
maternal and fetal 25-hydroxyvitamin D levels in mid-gestation and at birth, respec-
Figure 1. Overview of the origins of childhood eczema, allergic sensitization and allergy, and the specific 
fetal and infant exposures studied in this thesis.
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tively. Total maternal and fetal 25-hydroxyvitamin D levels were reported as the sums of 
25-hydroxyvitamin D2 and D3 species quantified in plasma using isotope dilution liquid 
chromatography-tandem mass spectrometry.43 Child’s DNA samples obtained from 
umbilical cord blood were genotyped by modified Taqman allelic discrimination assays 
for four common loss-of-function mutations in the FLG gene (2282del4, R2447X, R501X, 
and S3247X).44 Information on breastfeeding or allergenic food introduction practices 
was obtained from postal questionnaires at ages 2, 6 and 12 months. Parental question-
naires, including questions adapted from the International Study on Asthma and Allergy 
in Childhood45, provided information on physician-diagnosed eczema from birth until 
age 10 years. At age 10 years, inhalant (house dust mite, 5-grass mixture, birch, cat and 
dog) and food (hazelnut, cashew nut, peanut and peach) allergic sensitization were 
measured skin prick tests using the scanned area method46, and parental questionnaires 
provided information on physician-diagnosed inhalant and food allergy. Information 
on covariates, including demographic, socioeconomic, and health-related and lifestyle 
factors, was mainly obtained by postal questionnaires in the first year of life.
Figure 2. Data collection in the Generation R Study for this thesis.
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outline oF this thesis
chapter 2 focuses on associations of fetal exposures with childhood eczema, allergic 
sensitization or allergy. In Chapter 2.1, the associations of maternal psychiatric symptoms 
during pregnancy with eczema, allergic sensitization and physician-diagnosed inhalant 
or food allergy in school-age children are presented. The associations of maternal and 
fetal vitamin D levels and eczema in preschool-age children are explored in Chapter 
2.2. chapter 3 focuses on associations of infant exposures with childhood eczema, 
allergic sensitization or allergy. In Chapter 3.1, the role of environmental exposures 
and FLG genotype on the associations of ethnic origin with eczema in preschool-age 
children is described. The associations of duration and exclusiveness of breastfeeding 
with eczema, allergic sensitization and physician-diagnosed inhalant or food allergy 
in school-age children are presented in Chapter 3.2. In Chapter 3.3, the associations of 
timing or diversity of allergenic food introduction with eczema, allergic sensitization 
and physician-diagnosed inhalant or food allergy are described. chapter 4 includes a 
general discussion that outlines the main findings and discusses the clinical implications 
of the studies described in this thesis, followed by an English and a Dutch summary in 
chapter 5.
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AbstrAct
background Maternal psychiatric symptoms during pregnancy might affect the devel-
oping immune system and subsequent risk of childhood atopic diseases.
objective Our aim was to examine the associations of maternal psychiatric symptoms 
during pregnancy with allergic sensitization, allergy and eczema in children until age 
10 years.
methods This study among 5,205 children was performed in a population-based pro-
spective cohort from fetal life onwards. We assessed maternal and paternal psychiatric 
symptoms (overall, depressive and anxiety) during pregnancy and at 36 months after 
delivery, and maternal psychiatric symptoms at 2 and 6 months after delivery using the 
Brief Symptom Inventory. Inhalant and food allergic sensitization were measured by skin 
prick tests, and physician-diagnosed inhalant and food allergy or eczema by question-
naires from birth until age 10 years. We used multivariate logistic regression, multinomial 
logistic regression or generalized estimating equation models where appropriate.
results We observed no association of maternal psychiatric symptoms during preg-
nancy with allergic sensitization. Maternal overall psychiatric, depressive and anxiety 
symptoms during pregnancy were associated with an increased risk of inhalant allergy 
only (adjusted odds ratio (95 % confidence interval): 1.96 (1.44, 2.65), 1.58 (1.25, 1.98), 
and 1.61 (1.27, 2.03), respectively, per 1-unit increase). Maternal overall psychiatric and 
anxiety symptoms during pregnancy were associated with an increased risk of eczema 
(1.21 (1.05, 1.39) and 1.15 (1.02, 1.29), respectively, per 1-unit increase). Effect estimates 
did not materially change when maternal psychiatric symptoms after delivery, or pater-
nal psychiatric symptoms during pregnancy and after delivery were taken into account.
conclusions and clinical relevance Maternal psychiatric symptoms during pregnancy 
were associated with increased risks of childhood inhalant allergy and eczema, inde-
pendent of maternal psychiatric symptoms after delivery and of paternal psychiatric 
symptoms.
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introduction
Childhood atopic diseases such as inhalant or food allergy and eczema are suggested 
to have their origin in fetal life.1, 2 Maternal stress during pregnancy may increase the 
risk of inhalant or food allergy and eczema in the child3, but the exact underlying bio-
logical mechanisms are unclear. Animal studies showed that stress during pregnancy 
can activate the fetal hypothalamic-pituitary-adrenal axis and sympathetic adreno-
medullary system leading to sustained excessive glucocorticoids and catecholamines 
levels, respectively.4, 5 Glucocorticoids and catecholamines may induce a type 2 T-helper 
(Th2) cell predominance leading to increased secretion of pro-inflammatory and Th2 
cytokines.6, 7 This may promote immunoglobulin E (IgE) production and, subsequently, 
atopic inflammation and diseases.8, 9 Associations of maternal psychiatric symptoms 
during pregnancy, which partly reflect maternal stress, with childhood inhalant or food 
allergy and eczema might be confounded by social, behavioral or environmental factors. 
Information on both maternal and paternal psychiatric symptoms could disentangle 
potential intrauterine and confounding mechanisms.10, 11 Stronger effect estimates for 
the association of maternal than paternal psychiatric symptoms during pregnancy with 
childhood inhalant or food allergy and eczema suggest underlying intrauterine mecha-
nisms, while similar effect estimates indicate that these associations may result from 
residual confounding of unmeasured factors. In a previous study, we demonstrated that 
maternal psychiatric symptoms during pregnancy are associated with an increased risk 
of childhood wheezing until age 4 years.11
We now examined among 5,205 children and their parents participating in a popula-
tion-based prospective cohort study the associations of maternal psychiatric symptoms 
during pregnancy with allergic sensitization, inhalant or food allergy and eczema until 
age 10 years, and assessed whether these associations were independent of paternal 
psychiatric symptoms during pregnancy, and maternal and paternal psychiatric symp-
toms after delivery.
methods
general design
This study was embedded in the Generation R Study, a population-based prospective 
cohort study from fetal life onwards.12, 13 The study has been approved by the Medical 
Ethical Committee of the Erasmus Medical Center, Rotterdam, The Netherlands (MEC-
2012–165). Written informed consent was obtained from both parents or legal guard-
ians. For the current study, twins (n = 208) were excluded because of high correlation, 
as well as children without data on maternal psychiatric symptoms during pregnancy 
(n = 2,381), and allergic sensitization, allergy and eczema (n = 650), leaving a total of 
5,205 children for the analyses (Supplementary Figure).
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maternal and paternal psychiatric symptoms
Information on maternal and paternal psychiatric symptoms was obtained by question-
naires, completed in the second trimester of pregnancy and at 36 months after delivery. 
Maternal psychiatric symptoms were also assessed at 2 and 6 months after delivery. 
Parents each answered their own questionnaires. We used the Brief Symptom Inventory, 
a validated 53-item self-report questionnaire covering a broad spectrum of psychiatric 
symptoms experienced in the last 7 days.14, 15 A global scale (Global Severity Index) and 
two symptom scales (depressive and anxiety) were defined.11 At 6 and 36 months after 
delivery, only depressive and anxiety symptoms were measured. The Global Severity 
Index is a measure of the current level or the depth of symptoms and denotes overall 
psychiatric symptoms. All 53 items were rated on a 5-point unidimensional scale ranging 
from 0 (‘not at all’) to 4 (‘extremely’). Total scores for each scale were calculated by sum-
ming the item scores and dividing this by the number of endorsed symptoms. Based on 
Dutch cut-off values, mothers and fathers were categorized as having clinically relevant 
psychiatric symptoms (no; yes) when having a score of ≥ 0.71 or ≥ 0.66 on the global 
scale, ≥  0.80 or ≥  0.71 on the depressive symptom scale and ≥  0.71 or ≥  0.65 on the 
anxiety scale, respectively.16 We focused primarily on depressive and anxiety symptoms, 
because these are generally considered the most common psychiatric symptoms during 
pregnancy.
Allergic sensitization, allergy and eczema
At a median age of 9.7 years (2.5–97.5th percentile: 9.3–10.7), children visited our 
research center. Allergic sensitization was measured by skin prick tests on the volar 
surface of the left forearm with single-use sterile 1-mm-tip metal lancets (ALK-Abelló 
A/S, Hørsholm, Denmark). Histamine dihydrochloride (10 mg/mL) and a saline solution 
(NaCl 0.9 %) served as two positive controls and one negative control, respectively. In-
halant allergens comprised house dust mite (Dermatophagoides pteronyssinus), 5-grass 
mixture (Dactylis glomerata, Festuca pratensis, Lolium perenne, Phleum pratense and Poa 
pratensis), birch (Betula verrucosa), cat (Felis catus) and dog (Canis familiaris) (ALK-Abelló 
B.V., Almere, The Netherlands). Food allergens comprised hazelnut, cashew nut, peanut 
and peach extracts.17–19 For all food allergens, appropriate aliquots were stored at −20°C 
and were defrosted for 1 h prior to the skin prick test. Skin responses were recorded 15 
min after applying allergens to the skin by measuring the area of the wheal (in mm2) 
using the Precise Automated Area Measurement of Skin Test (PAAMOST) software and 
considered positive if the area of the wheal was ≥ 40 % of the histamine response (i.e., 
histamine equivalent prick index area ≥ 0.40).19 A skin prick test was not performed if 
children could not omit antihistamine intake or corticosteroid ointment ≤ 72 h and ≤ 48 
h prior to the test, respectively, used oral prednisone ≥ 10 mg daily or had eczema on 
the volar surface of the left forearm (n = 51). We grouped children into inhalant or food 
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allergic sensitization (no; yes). We used questions adapted from the International Study 
of Asthma and Allergies in Childhood (ISAAC) core questionnaires to obtain information 
on allergy and eczema.20 Physician-diagnosed allergy was parental-reported at age 10 
years (“Was your child ever diagnosed with an allergy to pollen (hay fever)/house dust 
mite/cat/dog/cashew nut/peanut?”) (no; yes) and categorized into inhalant or food al-
lergy (no; yes). A child was considered to have an inhalant allergic sensitization when 
sensitized to at least one inhalant allergen and to have inhalant allergy when diagnosed 
for at least one inhalant allergen, irrespective of a possible food allergic sensitization 
or food allergy. Similar considerations were made for food allergic sensitization and 
physician-diagnosed food allergy. Categorization into other groups (‘no allergic sensiti-
zation’, ‘inhalant allergic sensitization only’, ‘food allergic sensitization only’, ‘inhalant and 
food allergic sensitization’) was not feasible mainly due to the low number of children 
with food allergic sensitization only (n = 16) or food allergy only (n = 20). However, group 
sizes allowed categorization into ‘no allergic sensitization and no allergy’, ‘any allergic 
sensitization, but no allergy’, ‘no allergic sensitization, but any allergy’ and ‘any allergic 
sensitization and any allergy’. Physician-diagnosed eczema was parental-reported at 
ages 6 months and 1, 2, 3, 4 and 10 years (“Was your child diagnosed with eczema in the 
last 6 months/last year?”) (no; yes). Response rates of questionnaires were 73 %, 71 %, 
76 %, 72 %, 73 % and 75 %, respectively.
covariates
Information on maternal and paternal age, education (primary or secondary; higher), 
ethnic origin (European; non-European), and history of allergy, eczema or asthma (no; 
yes), and maternal parity (nulliparous; multiparous) and pet keeping (no; yes) was ob-
tained by questionnaires at enrollment. Maternal and paternal body mass index (BMI) 
was calculated using weight and height measured at enrollment. Information on ma-
ternal and paternal smoking (no; yes) was obtained by postal questionnaires multiple 
times during pregnancy. Information on child’s sex, gestational age at birth and birth 
weight was obtained from obstetric and midwife records at birth. Delivery reports and 
postal questionnaires completed by the mother when the child was 2, 6 and 12 months 
old provided data on ever breastfeeding (no; yes). We obtained information on day care 
attendance (no; yes) and current asthma (no; yes) by questionnaires at ages 1 year and 
10 years, respectively.
statistical analysis
We compared children included in the analyses and those lost to follow-up using in-
dependent samples T-tests, Mann-Whitney U-tests, and Pearson’s Chi-square tests. We 
used logistic regression models to examine the associations of maternal psychiatric 
symptoms with the risk of allergic sensitization and physician-diagnosed allergy at age 
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10 years. We used multinomial logistic regression models to examine the associations 
of maternal psychiatric symptoms with the risk of combined allergic sensitization and 
physician-diagnosed allergy groups. We used generalized estimating equation models 
to examine the associations of maternal psychiatric symptoms with the longitudinal 
odds of eczema at ages 6 months and 1, 2, 3, 4 and 10 years independently and overall, 
taking into account correlations between repeated measurements of eczema within 
the same child. First, we adjusted for potential confounders, including maternal age at 
enrollment, education, ethnic origin, parity, pet keeping, BMI at enrollment, smoking 
and history of allergy, eczema or asthma, and child’s sex, gestational age and birth 
weight. We considered this the main model. Second, child’s ever breastfeeding and 
day care attendance were considered as intermediates and additionally adjusted for in 
the model. Third, to disentangle the effects of psychiatric symptoms during pregnancy 
from the effects of psychiatric symptoms after delivery on the various outcomes, we 
additionally adjusted for maternal psychiatric symptoms at 2, 6 and 36 months after 
delivery, and for paternal psychiatric symptoms during pregnancy and 36 months after 
delivery by adding each variable separately to the models. We also used information 
on paternal psychiatric symptoms during pregnancy to address residual confounding 
of unmeasured social, behavioral and environmental factors. We used similar models 
to assess the associations of paternal psychiatric symptoms during pregnancy with 
allergic sensitization, physician-diagnosed allergy and eczema, adjusting for maternal 
psychiatric symptoms during pregnancy. Finally, we tested the interactions between 
maternal psychiatric symptoms during pregnancy and maternal history of allergy, 
eczema or asthma, and child’s current asthma at age 10 years as proxies for atopic 
susceptibility. Confounders were included in the models based on previous literature, 
if they were associated with both the determinant and the outcome, or if they changed 
the effect estimates with ≥  10 %. Analyses with inhalant or food allergic sensitization 
or allergy as the outcomes were mutually adjusted for each other. To reduce potential 
bias and improve efficiency, we performed a multiple imputation analysis of covariates 
and eczema generating 25 independent datasets using the Markov chain Monte Carlo 
method, and calculated pooled estimates.21 No major differences in the magnitude or 
direction of the effect estimates were observed between analyses with imputed data 
and complete cases only (data not shown). We present results based on imputed analy-
ses only. Measures of association are presented as adjusted odds ratios (aOR) with their 
95 % confidence intervals (CI). Statistical analyses were performed using SPSS 21.0.0.1 
for Windows (IBM Corp., Armonk, NY, USA) and SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
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results
general
Of the participating mothers, 9.0 % (n  =  468) had overall psychiatric symptoms, 8.9 % 
(n = 461) depressive symptoms and 9.8 % (n = 511) anxiety symptoms during pregnancy 
(Table  1).The median scores for maternal overall, depressive and anxiety symptoms 
were 0.15 (0–1.33), 0 (0–1.67) and 0.17 (0–1.50), respectively (Supplementary Table 1). 
In children, inhalant or food allergic sensitization was present in 32.6 % (n = 994) and 
7.5 % (n  =  228), respectively, while physician-diagnosed inhalant or food allergy was 
present in 12.2 % (n = 438) and 2.3 % (n = 79), respectively (Table 2 and Supplementary 
Table 1). The prevalence of eczema declined from 17.2 % (n = 895) at age 6 months to 
8.5 % (n = 444) at age 10 years. Of the children with physician-diagnosed inhalant allergy 
(n = 438), 29.2 % (n = 128) had asthma, 56.6 % (n = 248) had hay fever and 15.5 % (n = 68) 
had eczema in the last 12 months before age 10 years. Of the children with physician-
diagnosed food allergy (n = 79), 38.0 % (n = 30) had asthma, 51.9 % (n = 41) had hay fever 
and 24.1 % (n = 19) had eczema at age 10 years. The prevalence of asthma, hay fever and 
eczema differed between children with and without inhalant or food allergy (p-values 
table 1. Characteristics of mothers and fathers.
n = 5,205
mother Father
Age at enrollment (years)* 30.7 (4.8) 33.2 (5.6)
Education, higher (%) 50.4 (2,624) 50.1 (2,607)
Ethnic origin, European (%) 67.7 (3,470) 65.2 (3,395)
History of allergy, eczema or asthma, yes (%) 38.6 (2,008) 34.3 (1,786)
Parity, ≥ 1 (%) 41.2 (2,142) -
Pet keeping during pregnancy, yes (%) 34.9 (1,815) -
Body mass index at enrollment (kg/m2)† 23.7 (18.8–35.6) 25.0 (19.6–33.2)
Smoking during pregnancy, yes (%) 24.6 (1,282) 43.4 (2,259)
Overall psychiatric symptoms during pregnancy, yes (%) 9.0 (468) 3.5 (181)
Depressive symptoms during pregnancy, yes (%) 8.9 (461) 3.7 (192)
Anxiety symptoms during pregnancy, yes (%) 9.8 (511) 7.1 (371)
Overall psychiatric symptoms at 2 months after delivery, yes (%) 8.2 (429) -
Depressive symptoms at 2 months after delivery, yes (%) 8.7 (451) -
Anxiety symptoms at 2 months after delivery, yes (%) 8.3 (430) -
Depressive symptoms at 6 months after delivery, yes (%) 8.6 (450) -
Anxiety symptoms at 6 months after delivery, yes (%) 9.8 (511) -
Depressive symptoms at 36 months after delivery, yes (%) 5.3 (275) 4.1 (211)
Anxiety symptoms at 36 months after delivery, yes (%) 5.1 (267) 7.4 (387)
Values are *means (SD), †medians (2.5–97.5th percentile) or percentages (absolute numbers) based on im-
puted data.
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for difference < 0.05; data not shown). Children without follow-up data at age 10 years 
had younger, lower educated parents who were more often of non-European origin and 
smoked more during pregnancy, had mothers with higher parity, pet exposure during 
pregnancy and BMI at enrollment, and were less often female, had a lower gestational 
age at birth and birth weight and less often attended day care until age 1 year than 
those children with follow-up data (Supplementary Table 2).
maternal psychiatric symptoms during pregnancy and childhood atopic diseases
We observed no associations of maternal psychiatric symptoms during pregnancy 
with food or inhalant allergic sensitization (Table  3). Children of mothers with overall 
psychiatric, depressive or anxiety symptoms during pregnancy had an increased risk of 
table 2. Characteristics of children.
n = 5,205
Sex, female (%) 50.7 (2,637)
Gestational age at birth (weeks)† 40.1 (36.0–42.4)
Birth weight (grams)* 3,449 (550)
Breastfed ever, yes (%) 91.2 (4,745)
Day care attendance until age 1 year, yes (%) 54.8 (2,853)
Asthma current at age 10 years, yes (%) 5.7 (298)
Allergic sensitization at age 10 years, yes (%)
Inhalant 32.6 (994)
Food 7.5 (228)
Physician-diagnosed allergy at age 10 years, yes (%)
Inhalant 12.2 (438)
Food 2.3 (79)
Allergic sensitization and allergy combined at age 10 years (%)
No allergic sensitization and no allergy 66.2 (1,678)
Any allergic sensitization, but no allergy 22.8 (578)
No allergic sensitization, but any allergy 1.3 (33)
Any allergic sensitization and any allergy 9.7 (246)
Eczema, yes (%)
Age 6 months 17.2 (895)
Age 1 year 13.6 (710)
Age 2 years 14.7 (763)
Age 3 years 11.0 (574)
Age 4 years 9.3 (485)
Age 10 years 8.5 (444)
Values are *means (SD), †medians (2.5–97.5th percentile) or percentages (absolute numbers) based on im-
puted data. Data on allergic sensitizations and physician-diagnosed allergies are not imputed.
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physician-diagnosed inhalant allergy (aOR (95 % CI): 1.96 (1.44, 2.65), 1.58 (1.25, 1.98), 
and 1.61 (1.27, 2.03), respectively, per 1-unit increase), but not of physician-diagnosed 
food allergy (Table 4). Children of mothers with overall psychiatric or depressive symp-
toms, but not with anxiety symptoms during pregnancy, had an increased risk of any 
table 3. Associations of maternal and paternal psychiatric symptoms during pregnancy with allergic sen-
sitizations in children at age 10 years.
odds ratio (95 % confidence interval)
for allergic sensitization
inhalant*
n = 3,052
Food†
n = 3,044
maternal psychiatric symptoms
Overall psychiatric symptoms
No Reference Reference
Yes 1.10 (0.82, 1.48) 1.05 (0.58, 1.91)
Per 1-unit increase 1.03 (0.80, 1.32) 1.02 (0.62, 1.66)
Depressive symptoms
No Reference Reference
Yes 1.20 (0.90, 1.61) 0.90 (0.49, 1.65)
Per 1-unit increase 1.08 (0.90, 1.30) 0.96 (0.66, 1.40)
Anxiety symptoms
No Reference Reference
Yes 1.08 (0.81, 1.42) 1.06 (0.59, 1.90)
Per 1-unit increase 1.08 (0.89, 1.32) 0.92 (0.60, 1.41)
Paternal psychiatric symptoms‡
Overall psychiatric symptoms
No Reference Reference
Yes 1.06 (0.62, 1.82) 1.69 (0.64, 4.48)
Per 1-unit increase 1.16 (0.76, 1.76) 1.50 (0.69, 3.25)
Depressive symptoms
No Reference Reference
Yes 1.01 (0.58, 1.75) 1.10 (0.42, 2.89)
Per 1-unit increase 1.09 (0.78, 1.51) 1.04 (0.57, 1.88)
Anxiety symptoms
No Reference Reference
Yes 0.98 (0.68, 1.42) 1.54 (0.74, 3.20)
Per 1-unit increase 1.21 (0.89, 1.64) 1.33 (0.70, 2.52)
Values are odds ratios (95 % confidence interval) from logistic regression models based on imputed data. 
Parental psychiatric symptoms are treated as dichotomous variables based on clinical cut-off values (no; 
yes) and as continuous variables (per 1-unit increase). Models are adjusted for maternal age at enrollment, 
education, ethnic origin, history of allergy, eczema or asthma, parity, pet keeping, body mass index at en-
rollment, smoking, and child’s sex, gestational age and birth weight. *Additionally adjusted for food allergic 
sensitization. †Additionally adjusted for inhalant allergic sensitization. ‡Additionally adjusted for maternal 
psychiatric symptoms during pregnancy.
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allergic sensitization and any allergy combined (1.60 (1.10, 2.33) and 1.42 (1.07, 1.88), 
respectively, per 1-unit increase), compared with children without any allergic sensitiza-
tion and any allergy combined (Table  5). Children of mothers with overall psychiatric 
table 4. Associations of maternal and paternal psychiatric symptoms during pregnancy with physician-
diagnosed allergies in children at age 10 years.
odds ratio (95 % confidence interval)
for physician-diagnosed allergy
inhalant*
n = 3,576
Food†
n = 3,503
maternal psychiatric symptoms
Overall psychiatric symptoms
No Reference Reference
Yes 1.91 (1.32, 2.77) 0.52 (0.18, 1.49)
Per 1-unit increase 1.96 (1.44, 2.65) 0.58 (0.25, 1.33)
Depressive symptoms
No Reference Reference
Yes 2.07 (1.43, 2.97) 0.75 (0.29, 1.97)
Per 1-unit increase 1.58 (1.25, 1.98) 0.79 (0.41, 1.54)
Anxiety symptoms
No Reference Reference
Yes 1.51 (1.06, 2.16) 0.43 (0.14, 1.32)
Per 1-unit increase 1.61 (1.27, 2.03) 0.52 (0.25, 1.08)
Paternal psychiatric symptoms‡
Overall psychiatric symptoms
No Reference Reference
Yes 1.29 (0.69, 2.40) 1.23 (0.26, 5.85)
Per 1-unit increase 1.38 (0.85, 2.23) 0.86 (0.20, 3.73)
Depressive symptoms
No Reference Reference
Yes 1.58 (0.89, 2.80) 0.87 (0.18, 4.14)
Per 1-unit increase 1.31 (0.91, 1.88) 1.11 (0.39, 3.15)
Anxiety symptoms
No Reference Reference
Yes 1.38 (0.89, 2.15) 0.56 (0.14, 2.32)
Per 1-unit increase 1.22 (0.82, 1.83) 0.54 (0.14, 2.18)
Values are odds ratios (95 % confidence interval) from logistic regression models based on imputed data. 
Bold values indicate statistical significance at the α = 0.05 level. Parental psychiatric symptoms are treated 
as dichotomous variables based on clinical cut-off values (no; yes) and as continuous variables (per 1-unit 
increase). Models are adjusted for maternal age at enrollment, education, ethnic origin, parity, pet keeping, 
body mass index at enrollment, smoking and history of allergy, eczema or asthma, and child’s sex, gesta-
tional age and birth weight, and mutually for physician-diagnosed inhalant or food allergy. *Additionally 
adjusted for physician-diagnosed food allergy. †Additionally adjusted for physician-diagnosed inhalant al-
lergy. ‡Additionally adjusted for maternal psychiatric symptoms during pregnancy.
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or anxiety symptoms, but not with depressive symptoms during pregnancy, had an 
overall increased risk of eczema until age 10 years (1.21 (1.05, 1.39) and 1.15 (1.02, 1.29), 
respectively, per 1-unit increase) (Figure and Supplementary Table 3). Additional adjust-
ment for intermediates (data not shown), maternal psychiatric symptoms at 2, 6 and 
36 months after delivery, and paternal psychiatric symptoms during pregnancy and at 
36 months after delivery separately did not materially affect the size and the direction 
of the effect estimates (Supplementary Tables 4–9). Paternal psychiatric symptoms 
during pregnancy (Tables 3 and 4, and Figure), and maternal and paternal psychiatric 
symptoms after delivery were not associated with childhood atopic diseases (p-values 
> 0.05; data not shown). We observed no modifying effect of maternal history of allergy, 
eczema or asthma and child’s current asthma on the associations of maternal psychiatric 
symptoms during pregnancy with child’s allergic sensitization, physician-diagnosed al-
lergy, or eczema (p-values for interaction > 0.05).
discussion
In this large prospective population-based study, we observed that children of moth-
ers with overall psychiatric, depressive or anxiety symptoms during pregnancy had an 
table 5. Associations of maternal and paternal psychiatric symptoms during pregnancy with combined 
allergic sensitization and physician-diagnosed allergy groups in children at age 10 years.
odds ratio (95 % confidence interval) for any allergic 
sensitization and any physician-diagnosed allergy combined
Any allergic 
sensitization, but 
no allergy
n = 578
no allergic 
sensitization, but 
any allergy
n = 33
Any allergic 
sensitization and 
any allergy
n = 246
maternal psychiatric symptoms
Overall psychiatric symptoms 0.74 (0.52, 1.06) 1.58 (0.73, 3.40) 1.60 (1.10, 2.33)
Depressive symptoms 0.91 (0.70, 1.18) 1.14 (0.60, 2.17) 1.42 (1.07, 1.88)
Anxiety symptoms 0.79 (0.60, 1.04) 1.23 (0.61, 2.46) 1.34 (0.99, 1.80)
Paternal psychiatric symptoms*
Overall psychiatric symptoms 1.08 (0.65, 1.77) 0.67 (0.12, 3.68) 1.21 (0.64, 2.31)
Depressive symptoms 1.04 (0.70, 1.53) 0.30 (0.02, 4.61) 1.22 (0.76, 1.97)
Anxiety symptoms 1.16 (0.81, 1.68) 1.50 (0.56, 4.04) 1.22 (0.72, 2.08)
Values are odds ratios (95 % confidence interval) from multinomial logistic regression models based on 
imputed data. Bold values indicate statistical significance at the α = 0.05 level. Reference group is children 
without any allergic sensitization and any physician-diagnosed allergy (n  =  1,678). Parental psychiatric 
symptoms are treated as continuous variables (per 1-unit increase). Models are adjusted for maternal age at 
enrollment, education, ethnic origin, parity, pet keeping, body mass index at enrollment, smoking and his-
tory of allergy, eczema or asthma, and child’s sex, gestational age and birth weight. *Additionally adjusted 
for maternal psychiatric symptoms during pregnancy.
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increased risk of physician-diagnosed inhalant allergy, and children of mothers with 
overall psychiatric or anxiety sympt oms during pregnancy an increased risk of eczema. 
Results were independent of maternal psychiatric symptoms after delivery, and of pa-
ternal psychiatric symptoms during pregnancy and after delivery. Maternal psychiatric 
symptoms during pregnancy were not associated with childhood allergic sensitization 
and physician-diagnosed food allergy.
comparison of main findings with other studies
Studies that used IgE levels to identify allergic sensitization observed conflicting results 
for the association of maternal stress during pregnancy with childhood allergic sensiti-
zation.22–27 Four birth cohort studies showed that maternal stress during pregnancy was 
associated with elevated umbilical cord blood total or serum allergen-specific IgE22, 24, 25, 27, 
while two other birth cohort studies did not find such an association.23, 26 This discrep-
ancy might be explained by differences in the definition of maternal stress (psychosocial 
stress, distress, psychiatric symptoms, or adverse life events), time point during preg-
nancy at which stress was examined, type of allergen-specific IgE that was measured, 
and age at which IgE levels were measured. Only one previous birth cohort study used 
skin prick test responses to identify common inhalant and food allergic sensitization, 
and like our study also observed no association of maternal stress during pregnancy 
with childhood allergic sensitization.23 One previous birth cohort study among 516 chil-
dren combined outcome data on food-specific serum IgE levels and information from 
a physician-administered questionnaire on food allergy and observed no association 
of maternal distress during pregnancy with food allergy.28 Due to the low number of 
children with food allergic sensitization only (n  =  16) or food allergy only (n  =  20), a 
similar approach was not feasible in our study. To our knowledge, there is no literature 
on the association of maternal psychiatric symptoms during pregnancy with inhalant 
allergy. Previous birth cohort studies reported inconsistent results regarding the as-
sociation of maternal stress during pregnancy with childhood eczema.22, 23, 29–32 Several 
studies showed that prenatally stressed children had an up to 4.19-fold increased risk 
of eczema, compared with prenatally unstressed children22, 29, 31, 32, while only one study 
observed no association of maternal stress during pregnancy with eczema.30 Our study 
aimed to address methodological differences of previous studies and additionally used 
a well-known definition of psychiatric symptoms commonly used in epidemiological 
studies, and measured both psychiatric symptoms and eczema at multiple time points.
interpretation of results
Our results showed that maternal psychiatric symptoms during pregnancy were associ-
ated with an increased risk of physician-diagnosed inhalant allergy, with mostly current 
hay fever, and eczema in children until age 10 years, but not with allergic sensitization 
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and physician-diagnosed food allergy. Differences in observed associations of maternal 
psychiatric symptoms during pregnancy with eczema and allergic sensitizations or phy-
sician-diagnosed allergies might be due to differences in the timing of these outcome 
measurements. Eczema was measured longitudinally, while allergic sensitizations and 
physician-diagnosed allergy were assessed at one time point only. Parents of children 
who were sensitized to inhalant allergens did not report a physician-diagnosed inhalant 
allergy for 25 % of children. This may suggest that the skin prick test method at the popu-
lation level is less sensitive, showing children who are sensitized but do not experience 
symptoms of inhalant allergy. This could explain the differences in observed associations 
of maternal psychiatric symptoms during pregnancy with physician-diagnosed inhalant 
allergy but not with inhalant allergic sensitization, and with allergic sensitization and 
physician-diagnosed allergy combined but not separately. With 80.5 % of participating 
mothers reported living together with their partner during pregnancy, paternal psychi-
atric symptoms during pregnancy were not associated with childhood atopic diseases, 
although size and direction of the effect estimates were similar as for associations of ma-
ternal psychiatric symptoms with childhood atopic diseases. Still, an independent effect 
of maternal psychiatric symptoms on childhood atopic diseases could be considered 
because maternal and paternal psychiatric symptoms after delivery were not associated 
with childhood atopic diseases, and adjustment for a large set of potential confound-
ing factors and additional adjustment for maternal and paternal psychiatric symptoms 
after delivery and for paternal psychiatric symptoms during pregnancy did not materi-
ally affect the results. Potential early-life underlying pathophysiological mechanisms 
for associations of maternal psychiatric symptoms with the child’s risk of developing 
atopic diseases may include fetal growth33, 34, altered intestinal microbiota35, 36, oxidative 
stress22, 36, and epigenetic programming.37 Specifically, maternal psychiatric symptoms 
during pregnancy might impair fetal growth33, and children of low and high birth weight 
are associated with a higher and lower risk of eczema, respectively.34 However, our results 
did not change after adjusting for birth weight and gestational age at birth. Recently, 
maternal stress during pregnancy was found to be associated with the child’s intestinal 
microbiota composition and colonization pattern, which appeared to predispose the 
child to allergic reactions.35 The intestinal microbiota may influence the metabolism of 
the antioxidant glutathione36, which could play a mediating role in the association of 
maternal stress during pregnancy with eczema.22 Finally, maternal depressive or anxiety 
symptoms during pregnancy are associated with increased neonatal methylation of the 
glucocorticoid receptor gene NR3C1 and altered stress reactivity of the hypothalamic-
pituitary-adrenal axis during infancy.37 Future studies are needed to explore potential 
microbiomic, oxidative and epigenetic mechanisms for the association of maternal 
psychiatric symptoms during pregnancy with childhood atopic diseases.
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strengths and limitations
The major strengths of this study are the use of a population-based prospective study 
design from fetal life onwards with a large number of participants, the assessment of 
maternal and paternal psychiatric symptoms during pregnancy and after delivery us-
ing the same instrument at similar time points, and detailed information on allergic 
sensitization, allergy and eczema. Also, we adjusted for multiple social, behavioral and 
environmental factors. However, some methodological limitations should be consid-
ered. First, characteristics of non-responders for phase 3 of the Generation R Study and 
those lost to follow-up differed from those included in the study. Non-included subjects 
were more often of non-European origin and non-affluent background, and less healthy. 
This selective loss to follow-up might have led to bias if the associations of maternal 
psychiatric symptoms during pregnancy with allergic sensitization, allergy and eczema 
were different between those included and not included in the study. It is unlikely that 
these differences led to selection bias but this cannot be excluded.38 However, these 
differences should be taken into account regarding the generalizability of our results. 
Second, the presence of maternal psychiatric symptoms may have influenced the 
recognition and reporting of allergies and eczema in the child despite unawareness of 
our specific research question, which could have potentially lead to differential misclas-
sification of the self-reported outcomes and, subsequently, might have led to overesti-
mation of our results. Maternal psychiatric symptoms were measured only once during 
pregnancy and, therefore, their intensity and persistence may have varied throughout 
pregnancy. We obtained information on parental psychiatric symptoms using the Brief 
Symptom Inventory, a widely used self-report questionnaire that has been validated 
in the Dutch population.39 However, whether used clinical cut-off values also apply to 
pregnant women should be carefully considered before our results could be used for 
prevention strategies. For allergic sensitization, we used an advanced software tool to 
calculate the histamine equivalent prick index, which is considered to be more accurate 
than measuring the average wheal diameter and corrects for interobserver variability 
and ethnic differences in skin response to histamine.19 We selected a panel of common 
inhalant and food allergens relevant to children at age 10 years. Food allergens such as 
milk and egg were not taken into account because of low sensitization rates at this age.40 
We were not able to use an accepted and validated allergy questionnaire but used ques-
tions adapted from the ISAAC core questionnaires instead.20 Information on eczema was 
obtained by parental questionnaires, consisting widely accepted and commonly used 
questions that reliably reflect the prevalence of eczema in young children at the popula-
tion level.20, 41 Furthermore, self-reported diagnosis of eczema in the last year based on a 
single question seems sufficiently valid for studying current childhood eczema.42 We had 
no additional information on eczema from medical records or physical examinations. 
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Finally, we did not have data on other possible confounding and mediating factors, such 
as housing conditions or current air pollution.22, 35, 43
In conclusion, our results suggest a possible intrauterine programming effect of ma-
ternal psychiatric symptoms that increases the child’s risk of developing atopic diseases. 
Therefore, future studies are needed to examine potential underlying mechanisms and 
potential primary prevention strategies focused on reducing maternal psychiatric symp-
toms during pregnancy to reduce development of atopic diseases in children.
Detailed acknowledgements and additional supporting information can be found in the 
published article online: http://onlinelibrary.wiley.com/doi/10.1111/cea.12889/suppinfo.
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supplementary Figure. Flowchart of participants.
 
n = 650 
Children without data on allergic sensitization, 
allergy or eczema excluded 
n = 2,589 
Twins (n = 208) and children without data on 
maternal psychiatric symptoms during 
pregnancy (n = 2,381) excluded 
n = 8,444 
Children with consent until phase 3 of the 
Generation R Study 
n = 5,855 
Children with data on maternal psychiatric 
symptoms during pregnancy available 
n = 5,205 
Children with any data on allergic sensitization, 
allergy or eczema available 
 
Allergic sensitization at age 10 years 
 Inhalant  n = 3,052 
 Food   n = 3,044 
Physician-diagnosed allergy at age 10 years 
 Inhalant  n = 3,576 
 Food   n = 3,503 
Eczema 
 Age 6 months  n = 3,106 
 Age 1 year  n = 3,777 
 Age 2 years  n = 3,801 
 Age 3 years  n = 3,567 
 Age 4 years  n = 3,524 
 Age 10 years  n = 3,643 
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supplementary table 1. Characteristics of mothers, fathers and children (n = 5,205).
observed imputed
maternal characteristics
Age at enrollment (years)* 30.7 (4.8) 30.7 (4.8)
Missing 0 (0) 0 (0)
Education (%)
Primary or secondary 48.9 (2,460) 49.6 (2,581)
Higher 51.1 (2,575) 50.4 (2,624)
Missing 3.3 (170) 0 (0)
Ethnic origin (%)
European 67.2 (3,467) 67.7 (3,470)
Non-European 32.8 (1,691) 33.3 (1,735)
Missing 0.9 (47) 0 (0)
History of allergy, eczema or asthma (%)
No 60.6 (2,659) 61.4 (3,197)
Yes 39.4 (1,728) 38.6 (2,008)
Missing 15.7 (818) 0 (0)
Parity (%)
0 59.1 (3,061) 58.8 (3,063)
≥ 1 40.9 (2,120) 41.2 (2,142)
Missing 0.5 (24) 0 (0)
Pet keeping during pregnancy (%)
No 65.6 (3,020) 65.1 (3,390)
Yes 34.4 (1,585) 34.9 (1,815)
Missing 11.5 (600) 0 (0)
Body mass index at enrollment (kg/m2)† 23.7 (18.8–35.6) 23.7 (18.8–35.6)
Missing 0.6 (33) 0 (0)
Smoking during pregnancy (%)
No 75.4 (3,600) 75.4 (3,923)
Yes 24.6 (1,172) 24.6 (1,282)
Missing 8.3 (433) 0 (0)
Overall psychiatric symptoms during pregnancy (%)
No 91.0 (4,732) 91.0 (4,737)
Yes 9.0 (467) 9.0 (468)
Continuous† 0.15 (0–1.33) 0.15 (0–1.33)
Missing 0.1 (6) 0 (0)
Depressive symptoms during pregnancy (%)
No 91.2 (4,738) 91.1 (4,744)
Yes 8.8 (457) 8.9 (461)
Continuous† 0 (0–1.67) 0 (0–1.67)
Missing 0.2 (10) 0 (0)
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supplementary table 1. Characteristics of mothers, fathers and children (n = 5,205). (continued)
observed imputed
Anxiety symptoms during pregnancy (%)
No 90.2 (4,689) 90.2 (4,694)
Yes 9.8 (507) 9.8 (511)
Continuous† 0.17 (0–1.50) 0.17 (0–1.50)
Missing 0.2 (9) 0 (0)
Overall psychiatric symptoms at 2 months after delivery (%)
No 92.7 (3,448) 91.8 (4,776)
Yes 7.3 (272) 8.2 (429)
Continuous† 0.12 (0–1.23) 0.13 (0–1.33)
Missing 28.5 (1,485) 0 (0)
Depressive symptoms at 2 months after delivery (%)
No 92.4 (3,432) 91.3 (4,754)
Yes 7.6 (282) 8.7 (451)
Continuous† 0 (0–1.50) 0 (0–1.67)
Missing 28.6 (1,491) 0 (0)
Anxiety symptoms at 2 months after delivery (%)
No 92.5 (3,443) 91.7 (4,775)
Yes 7.5 (278) 8.3 (430)
Continuous† 0 (0–1.50) 0 (0–1.50)
Missing 28.5 (1,484) 0 (0)
Depressive symptoms at 6 months after delivery (%)
No 92.0 (3,046) 91.4 (4,755)
Yes 8.0 (264) 8.6 (450)
Continuous† 0 (0–1.67) 0 (0–1.83)
Missing 36.4 (1,895) 0 (0)
Anxiety symptoms at 6 months after delivery (%)
No 90.7 (3,005) 90.2 (4,694)
Yes 9.3 (307) 9.8 (511)
Continuous† 0.17 (0–1.67) 0.17 (0–1.83)
Missing 36.4 (1,893) 0 (0)
Depressive symptoms at 36 months after delivery (%)
No 95.8 (3,458) 94.7 (4,930)
Yes 4.2 (152) 5.3 (275)
Continuous† 0 (0–1.00) 0 (0–1.17)
Missing 30.6 (1,595) 0 (0)
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supplementary table 1. Characteristics of mothers, fathers and children (n = 5,205). (continued)
observed imputed
Anxiety symptoms at 36 months after delivery (%)
No 95.7 (3,455) 94.9 (4,938)
Yes 4.3 (154) 5.1 (267)
Continuous† 0 (0–1.00) 0 (0–1.17)
Missing 30.7 (1,596) 0 (0)
Paternal characteristics
Age at enrollment (years)* 33.3 (5.4) 33.2 (5.6)
Missing 18.9 (986) 0 (0)
Education (%)
Primary or secondary 45.4 (1,758) 49.9 (2,598)
Higher 54.6 (2,111) 50.1 (2,607)
Missing 25.7 (1,336) 0 (0)
Ethnic origin (%)
European 66.9 (3,362) 65.2 (3,395)
Non-European 33.1 (1,666) 34.8 (1,810)
Missing 3.4 (177) 0 (0)
History of allergy, eczema or asthma (%)
No 67.1 (2,426) 65.7 (3,419)
Yes 32.9 (1,188) 34.3 (1,786)
Missing 30.6 (1,591) 0 (0)
Body mass index at enrollment (kg/m2)† 24.9 (19.6–32.7) 25.0 (19.6–33.2)
Missing 19.1 (994) 0 (0)
Smoking during pregnancy (%)
No 56.9 (2,691) 56.6 (2,946)
Yes 43.1 (2,037) 43.4 (2,259)
Missing 9.2 (477) 0 (0)
Overall psychiatric symptoms during pregnancy (%)
No 97.2 (3,663) 96.5 (5,024)
Yes 2.8 (106) 3.5 (181)
Continuous† 0.06 (0–0.73) 0.08 (0–0.80)
Missing 27.6 (1,436) 0 (0)
Depressive symptoms during pregnancy (%)
No 97.0 (3,651) 96.3 (5,013)
Yes 3.0 (113) 3.7 (192)
Continuous† 0 (0–0.83) 0 (0–1.00)
Missing 27.7 (1,441) 0 (0)
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supplementary table 1. Characteristics of mothers, fathers and children (n = 5,205). (continued)
observed imputed
Anxiety symptoms during pregnancy (%)
No 93.5 (3,524) 92.9 (4,834)
Yes 6.5 (245) 7.1 (371)
Continuous† 0 (0–0.83) 0 (0–1.00)
Missing 27.6 (1,436) 0 (0)
Depressive symptoms at 36 months after delivery (%)
No 97.3 (2,851) 95.9 (4,994)
Yes 2.7 (80) 4.1 (211)
Continuous† 0 (0–0.83) 0 (0–1.17)
Missing 43.7 (2,274) 0 (0)
Anxiety symptoms at 36 months after delivery (%)
No 94.0 (2,757) 92.6 (4,818)
Yes 6.0 (177) 7.4 (387)
Continuous† 0 (0–0.83) 0 (0–1.00)
Missing 43.6 (2,271) 0 (0)
child characteristics
Sex (%)
Male 49.3 (2,568) 49.3 (2,568)
Female 50.7 (2,637) 50.7 (2,637)
Missing 0 (0) 0 (0)
Gestational age at birth (weeks)† 40.1 (36.0–42.4) 40.1 (36.0–42.4)
Missing 0 (0) 0 (0)
Birth weight (grams)* 3,450 (549) 3,449 (550)
Missing 0.1 (4) 0 (0)
Breastfed ever (%)
No 8.1 (369) 8.8 (460)
Yes 91.9 (4,161) 91.2 (4,745)
Missing 13.0 (675) 0 (0)
Day care attendance until age 1 year (%)
No 39.8 (1,407) 45.2 (2,352)
Yes 60.2 (2,131) 54.8 (2,853)
Missing 32.0 (1,667) 0 (0)
Asthma ever at age 10 years (%)
No 90.3 (3,217) 88.6 (4,611
Yes 9.7 (346) 11.4 (594)
Missing 31.5 (1,642) 0 (0)
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supplementary table 1. Characteristics of mothers, fathers and children (n = 5,205). (continued)
observed imputed
Allergic sensitization at age 10 years – inhalant (%)
No 67.4 (2,058) 67.4 (2,058)
Yes 32.6 (994) 32.6 (994)
Missing 41.4 (2,153) 41.4 (2,153)
Allergic sensitization at age 10 years – food (%)
No 92.5 (2,816) 92.5 (2,816)
Yes 7.5 (228) 7.5 (228)
Missing 41.5 (2,161) 41.5 (2,161)
Physician-diagnosed allergy at age 10 years – inhalant (%)
No 87.8 (3,138) 87.8 (3,138)
Yes 12.2 (438) 12.2 (438)
Missing 31.3 (1,629) 31.3 (1,629)
Physician-diagnosed allergy at age 10 years – food (%)
No 97.7 (3,424) 97.7 (3,424)
Yes 2.3 (79) 2.3 (79)
Missing 32.7 (1,702) 32.7 (1,702)
Allergic sensitization and allergy combined at age 10 years (%)
No allergic sensitization and no allergy 66.2 (1,678) 66.2 (1,678)
Any allergic sensitization, but no allergy 22.8 (578) 22.8 (578)
No allergic sensitization, but any allergy 1.3 (33) 1.3 (33)
Any allergic sensitization and any allergy 9.7 (246) 9.7 (246)
Missing 51.3 (2,670) 51.3 (2,670)
Eczema last 6 months at age 6 months (%)
No 83.7 (2,599) 82.8 (4,310)
Yes 16.3 (507) 17.2 (895)
Missing 40.3 (2,099) 0 (0)
Eczema last 6 months at age 1 year (%)
No 87.1 (3,289) 86.4 (4,495)
Yes 12.9 (488) 13.6 (710)
Missing 27.4 (1,428) 0 (0)
Eczema last 12 months at age 2 years (%)
No 86.2 (3,278) 85.3 (4,442)
Yes 13.8 (523) 14.7 (763)
Missing 27.0 (1,404) 0 (0)
Eczema last 12 months at age 3 years (%)
No 90.4 (3,225) 89.0 (4,631)
Yes 9.6 (342) 11.0 (574)
Missing 31.5 (1,638) 0 (0)
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supplementary table 1. Characteristics of mothers, fathers and children (n = 5,205). (continued)
observed imputed
Eczema last 12 months at age 4 years (%)
No 92.2 (3,248) 90.7 (4,720)
Yes 7.8 (276) 9.3 (485)
Missing 32.3 (1,681) 0 (0)
Eczema last 12 months at age 10 years (%)
No 92.9 (3,383) 91.5 (4,761)
Yes 7.1 (260) 8.5 (444)
Missing 30.0 (1,562) 0 (0)
Values are *means (SD), †medians (2.5–97.5th percentile) or percentages (absolute numbers) based on ob-
served and imputed data. Data on allergic sensitizations and physician-diagnosed allergies are not im-
puted.
supplementary table 2. Characteristics of mothers, fathers and children included and not included in the 
study.
included
n = 5,205
not included
n = 3,239
P-value for 
difference
maternal characteristics
Age at enrollment (years)* 30.7 (4.8) 29.5 (5.8) < 0.001
Missing 0 (0) 0.03 (1)
Education (%) < 0.001
Primary or secondary 48.9 (2,460) 67.4 (1,711)
Higher 51.1 (2,575) 32.6 (826)
Missing 3.3 (170) 21.7 (702)
Ethnic origin (%) < 0.001
European 67.2 (3,467) 48.9 (1,424)
Non-European 32.8 (1,691) 51.1 (1,490)
Missing 0.9 (47) 10.0 (325)
History of allergy, eczema or asthma (%) 0.25
No 60.6 (2,659) 62.1 (1,400)
Yes 39.4 (1,728) 37.9 (856)
Missing 15.7 (818) 30.3 (983)
Parity (%) < 0.001
0 59.1 (3,061) 49.0 (1,456)
≥ 1 40.9 (2,120) 51.0 (1,518)
Missing 0.5 (24) 8.2 (265)
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supplementary table 2. Characteristics of mothers, fathers and children included and not included in 
the study. (continued)
included
n = 5,205
not included
n = 3,239
P-value for 
difference
Pet keeping during pregnancy (%) < 0.01
No 65.6 (3,020) 69.8 (1,304)
Yes 34.4 (1,585) 30.2 (565)
Missing 11.5 (600) 42.3 (1,370)
Body mass index at enrollment (kg/m2)† 23.7 (18.8–35.6) 24.4 (18.6–37.4) < 0.001
Missing 0.6 (33) 25.5 (826)
Smoking during pregnancy (%) < 0.001
No 75.4 (3,600) 71.2 (1,768)
Yes 24.6 (1,172) 28.8 (715)
Missing 8.3 (433) 23.3 (756)
Paternal characteristics
Age at enrollment (years)* 33.3 (5.4) 32.0 (6.1) < 0.001
Missing 18.9 (986) 56.3 (1,822)
Education (%) < 0.001
Primary or secondary 45.4 (1,758) 59.1 (556)
Higher 54.6 (2,111) 40.9 (385)
Missing 25.7 (1,336) 70.9 (2,298)
Ethnic origin (%) < 0.001
European 66.9 (3,362) 50.8 (1,282)
Non-European 33.1 (1,666) 49.2 (1,240)
Missing 3.4 (177) 22.1 (717)
History of allergy, eczema or asthma (%) 0.58
No 67.1 (2,426) 66.3 (841)
Yes 32.9 (1,188) 33.7 (428)
Missing 30.6 (1,591) 60.8 (1,970)
Body mass index at enrollment (kg/m2)† 24.9 (19.6–32.7) 25.0 (19.2–34.0) 0.21
Missing 19.1 (994) 56.5 (1,830)
Smoking during pregnancy (%) < 0.001
No 56.9 (2,691) 50.1 (965)
Yes 43.1 (2,037) 49.9 (960)
Missing 9.2 (477) 40.6 (1,314)
child characteristics
Sex (%) < 0.01
Male 49.3 (2,568) 52.3 (1,695)
Female 50.7 (2,637) 47.7 (1,543)
Missing 0 (0) 0.03 (1)
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supplementary table 2. Characteristics of mothers, fathers and children included and not included in 
the study. (continued)
included
n = 5,205
not included
n = 3,239
P-value for 
difference
Gestational age at birth (weeks)† 40.1 (36.0–42.4) 39.7 (34.0–42.1) < 0.001
Missing 0 (0) 2.2 (70)
Birth weight (grams)* 3,450 (549) 3,316 (611) < 0.001
Missing 0.1 (4) 0.8 (27)
Breastfed ever (%) 0.67
No 8.1 (369) 8.5 (148)
Yes 91.9 (4,161) 91.5 (1,598)
Missing 13.0 (675) 46.1 (1,493)
Day care attendance until age 1 year (%) < 0.001
No 39.8 (1,407) 46.4 (411)
Yes 60.2 (2,131) 53.6 (475)
Missing 32.0 (1,667) 72.6 (2,353)
Values are *means (SD), †medians (2.5–97.5th percentile) or percentages (absolute numbers) based on ob-
served data. P-values for difference are calculated by independent samples T-test for continuous variables 
with a normal distribution, the Mann-Whitney U-test for continuous variables with a skewed distribution, 
and Pearson’s Chi-square test for categorical variables. Bold values indicate statistical significance at the 
α = 0.05 level.
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AbstrAct
background Exposure to low levels of vitamin D in fetal life might affect the developing 
immune system and, subsequently, the risk of childhood eczema. We examined whether 
25-hydroxyvitamin D levels in mid-gestation and at birth were associated with the risk 
of eczema until age 4 years.
methods In a population-based prospective cohort study of 3,019 mothers and 
their children, maternal blood samples in mid-gestation and umbilical cord blood 
samples at birth were used to determine 25-hydroxyvitamin D levels (severely deficient 
(< 25.0 nmol/L), deficient (25.0–49.9 nmol/L), sufficient (50.0–74.9 nmol/L) and optimal 
(≥ 75.0 nmol/L)). Eczema was prospectively assessed by annual questionnaires until age 
4 years. Eczema patterns included never, early (age ≤  1 year only), late (age >  1 year 
only) and persistent (age ≤ and > 1 year) eczema. Data were analyzed using generalized 
estimating equation and multinomial logistic regression models.
results Compared with optimal 25-hydroxyvitamin D levels, sufficient, deficient and 
severely deficient 25-hydroxyvitamin D levels in mid-gestation were not associated with 
the overall risk of eczema (adjusted odds ratio (95 % confidence interval): 0.94 (0.81, 
1.10), 1.04 (0.87, 1.25) and 1.09 (0.82, 1.43), respectively) (p-values for trend >  0.05), 
nor with the risk of eczema per year or eczema patterns in children until age 4 years. 
Similarly, we observed no association of 25-hydroxyvitamin D levels at birth with any 
eczema outcome.
conclusions Our results suggest that levels of 25-hydroxyvitamin D in mid-gestation 
and at birth are not associated with the overall risk of eczema, nor with the risk of ec-
zema per year or eczema patterns in children until age 4 years.
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introduction
Eczema is a common relapsing, inflammatory, pruritic skin condition with an estimated 
prevalence of up to 22.5 % among children at age 7 years.1 It has been suggested that its 
origin is partly in pregnancy and early infancy.2 Maternal vitamin and fatty acid status 
during pregnancy, including vitamin E, folate and n-3 or n-6 polyunsaturated fatty acid 
levels, have been associated with the risk of childhood eczema.3, 4 Also, exposure to low 
levels of vitamin D in fetal life might affect the developing immune system, leading to 
unbalanced inflammatory processes and skin barrier impairment and, subsequently, an 
increased risk of eczema.5 Animal studies have suggested that vitamin D has a role in 
regulating the innate and adaptive immune system.6 In vitro studies have shown that 
the treatment of various human cell lines with 1,25-dihydroxyvitamin D, the active form 
of 25-hydroxyvitamin D, promotes the development and maturation of type 2 T-helper 
cells and inhibits inflammatory activity such as that of immunoglobulin E (IgE)-activated 
mast cells.6–8 These processes might have a role in initiation and amplification of inflam-
matory process underlying the development of eczema. Also, systemic administration 
of vitamin D receptor agonists improved allergen-triggered eczema of mice and showed 
induction of skin barrier and antimicrobial peptide gene expression.9 Previous studies in 
humans reported inconsistent results for the associations of maternal 25-hydroxyvita-
min D levels during pregnancy and at birth with the risk of childhood eczema.5, 10–17 Dif-
ferences in results might be explained by different methods of vitamin D measurement 
or adjustment for different confounders. We hypothesized that lower 25-hydroxyvitamin 
D levels in early life lead to an increased risk of eczema at a young age.
Therefore, we examined among 3,019 mothers and their children participating in a 
population-based prospective cohort study whether 25-hydroxyvitamin D levels in mid-
gestation and at birth were associated with eczema from birth until age 4 years.
methods
general design
This study was embedded in the Generation R Study, a population-based prospec-
tive cohort study from fetal life until adulthood in Rotterdam, The Netherlands.18 The 
Medical Ethical Committee of the Erasmus Medical Center, Rotterdam, The Netherlands, 
approved the study protocol (MEC 217.595/2002/202). This study was performed in par-
ticipants of Dutch origin only to prevent confounding or effect modification by the large 
heterogeneity of other small ethnic groups with different skin types and diet. Written 
informed consent was obtained from 3,840 parents of participating children until age 4 
years (Supplementary Figure). Twins (n = 119) and children of whom we had no data on 
vitamin D levels in mid-gestation and at birth (n = 597) and on eczema at any time point 
(n = 105) were excluded, leaving a total of 3,019 children for the analyses.
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25-hydroxyvitamin d
We collected maternal venous blood samples in mid-gestation (median (2.5–97.5th 
percentile): 20.4 (18.8–22.9) weeks of gestation) and umbilical cord blood samples at 
birth (40.3 (37.0–42.3) weeks of gestation). Measurements of 25-hydroxyvitamin D levels 
from maternal and umbilical cord blood were conducted at the Eyles Laboratory at the 
Queensland Brain Institute, University of Queensland, Australia.19 Details are provided 
in the Supplementary Methods. Levels of 25-hydroxyvitamin D were categorized as 
‘severely deficient’ (<  25.0  nmol/L (<  10.0  mg/L)), ‘deficient’ (25.0–49.9  nmol/L (10.0–
19.9 mg/L)), ‘sufficient’ (50.0–74.9 nmol/L (20.0–29.9 mg/L)) and ‘optimal’ (≥ 75.0 nmol/L 
(≥ 30.0 mg/L)).20
eczema
Information on physician-diagnosed eczema was obtained by parental questionnaires 
at ages 6 months and 1, 2, 3 and 4 years based on questions adapted from the Interna-
tional Study on Asthma and Allergy in Childhood (ISAAC) (“Was your child diagnosed 
with eczema in the last 6 months/last year?”) (not as far as I know; yes, did not go to the 
doctor; yes, went to the general practitioner; yes, went to the hospital).21 Answers were 
categorized into ‘no’ (not as far as I know; yes, did not go to the doctor) or ‘yes’ (yes, went 
to the general practitioner; yes, went to the hospital). The response rates at 6 months 
and 1, 2, 3 and 4 years of follow-up were 73 %, 71 %, 76 %, 72 % and 73 %, respectively. 
Based on annual data on eczema, we defined the following eczema patterns: ‘never’ (no 
eczema from birth until age 4 years), ‘early’ (age ≤ 1 year only), ‘late’ (age > 1 year only), 
and ‘persistent’ (age ≤ and > 1 year) eczema.22
covariates
We obtained information on maternal age, education (primary; secondary; higher), his-
tory of eczema, allergy or asthma (no; yes), parity (nulliparous; multiparous), and pet 
keeping (no; yes) by a questionnaire at enrollment. Maternal body mass index (BMI) 
was calculated using weight and height measured at enrollment. Information on ma-
ternal smoking (no; yes) was obtained by postal questionnaires multiple times during 
pregnancy. Maternal folate level was measured in the first trimester of pregnancy (12.9 
(9.6–17.2) weeks of gestation), as previously described.23 Maternal psychiatric symptoms 
were assessed in the second trimester of pregnancy using the Global Severity Index of 
the Brief Symptom Inventory24, denoting overall psychiatric symptoms. Season of blood 
sampling was recorded at time of the blood sampling for 25-hydroxyvitamin D levels. 
We obtained information on child’s sex, gestational age at birth and birth weight from 
obstetric and midwife records at birth. Information on breastfeeding (never; non-exclu-
sive for 4 months; exclusive for 4 months) was collected by questionnaires at ages 2, 6 
and 12 months. Information on vitamin D supplementation (no; yes) was collected by 
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questionnaire at age 2 months. The Dutch Health Council recommends a daily vitamin D 
supplement of 10 µg for all children until age 4 years.25
statistical analysis
We used generalized estimating equation (GEE) models to examine the associations of 
25-hydroxyvitamin D levels in mid-gestation and at birth with the longitudinal odds 
of eczema at ages 6 months and 1, 2, 3 and 4 years independently and overall. GEE 
models take into account correlations between repeated measurements of eczema 
within the same child. We used multinomial logistic regression models for the associa-
tions of 25-hydroxyvitamin D levels in mid-gestation and at birth with eczema patterns. 
Models were adjusted for maternal age at enrollment, education, history of eczema, 
allergy or asthma, parity, pet keeping, BMI at enrollment, smoking, folate level, psychi-
atric symptoms, season of blood sampling in mid-gestation, and child’s sex, gestational 
age, birth weight, breastfeeding, vitamin D supplementation at age 2 months, season 
of blood sampling at birth, and mutually for mid-gestational and umbilical cord blood 
25-hydroxyvitamin D levels. Tests for trends were performed by including the catego-
rized 25-hydroxyvitamin D levels in mid-gestation and at birth as continuous variables 
in the models. The prevalence of missing data of covariates was ≤  20.0 %, except for 
maternal psychiatric symptoms during pregnancy (31.4 %) and folate level (22.2 %). 
To reduce potential bias from missing data and to increase precision, we performed a 
multiple imputation analysis of covariates, 25-hydroxyvitamin D levels in mid-gestation 
and at birth, and eczema outcomes generating 10 independent datasets using the Mar-
kov chain Monte Carlo method, and calculated pooled estimates.26 We present effect 
estimates based on imputed analyses only. Measures of association are presented as 
adjusted odds ratios (aOR) with their 95 % confidence intervals (CI). Statistical analyses 
were performed using SPSS 21.0.0.1 for Windows (IBM Corp., Armonk, NY, USA) and SAS 
9.3 (SAS Institute Inc., Cary, NC, USA).
results
general
Maternal and child characteristics are presented in Table  1. Observed data showed a 
median 25-hydroxyvitamin D level in mid-gestation of 66.3 nmol/L (19.4–125.4) and at 
birth 39.6 nmol/L (11.3–89.1) (p-value for difference < 0.05). The prevalence of eczema 
declined from 15.1 % (n = 319) at age 6 months to 7.2 % (n = 177) at age 4 years. Early, 
late or persistent eczema was present in 12.1 % (n = 210), 12.9 % (n = 222) and 13.1 % 
(n  =  225) of children, respectively. Because we imputed missing values of all subject 
characteristics, we present the imputed values in comparison with the observed values 
(Supplementary Table 1). Compared with those included in the study, all maternal and 
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table 1. Characteristics of mothers and their children.
n = 3,019
maternal characteristics
Age at enrollment (years)* 31.8 (4.1)
Education, higher (%) 64.0 (1,909)
History of eczema, allergy or asthma, yes (%) 34.7 (951)
Parity, ≥ 1 (%) 40.2 (1,209)
Pet keeping during pregnancy, yes (%) 41.6 (1,122)
Body mass index at enrollment (kg/m2)† 23.3 (18.9–35.0)
Smoking during pregnancy, yes (%) 23.7 (656)
Folate level in first trimester (nmol/L)† 19.7 (6.4–38.7)
Psychiatric symptoms during pregnancy† 0.12 (0–0.77)
Season of blood sampling in mid-gestation (%)
Spring 28.4 (787)
Summer 23.3 (646)
Autumn 23.4 (649)
Winter 24.9 (691)
25-hydroxyvitamin D level in mid-gestation (nmol/L)† 66.3 (19.4–125.4)
child characteristics
Sex, female (%) 49.1 (1,505)
Gestational age at birth (weeks)† 40.3 (36.0–42.4)
Birth weight (grams)* 3,513 (542)
Breastfeeding, exclusive for 4 months (%) 27.2 (696)
Vitamin D supplementation at age 2 months, yes (%) 71.0 (1,850)
Season of blood sampling at birth (%)
Spring 24.1 (727)
Summer 26.4 (797)
Autumn 27.9 (842)
Winter 21.6 (653)
25-hydroxyvitamin D level at birth (nmol/L)† 39.6 (11.3–89.1)
Eczema, yes (%)
Age 6 months 15.1 (319)
Age 1 year 18.2 (518)
Age 2 years 12.8 (340)
Age 3 years 8.1 (201)
Age 4 years 7.2 (177)
Eczema patterns (%)
Never 61.9 (1,066)
Early 12.1 (210)
Late 12.9 (222)
Persistent 13.1 (225)
Values are *means (SD), †medians (2.5–97.5th percentile) or percentages (absolute numbers) based on ob-
served data.
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child characteristics of those lost to follow-up differed, except for maternal history of 
eczema, allergy or asthma, BMI at enrollment and psychiatric symptoms, child’s sex and 
season of blood sampling of 25-hydroxyvitamin D levels (Supplementary Table 2).
25-hydroxyvitamin d and eczema
Compared with optimal 25-hydroxyvitamin D levels, sufficient, deficient and severely 
deficient 25-hydroxyvitamin D levels in mid-gestation were not associated with the 
overall risk of eczema in children until age 4 years (aOR (95 % CI): 0.94 (0.81, 1.10), 1.04 
(0.87, 1.25) and 1.09 (0.82, 1.43), respectively) (p-values for trend > 0.05) (Table 2). Also, 
per year analysis showed no association of 25-hydroxyvitamin D levels in mid-gestation 
with the risk of childhood eczema (Table 2). We observed no association of sufficient, de-
ficient and severely deficient 25-hydroxyvitamin D levels at birth with the overall risk of 
eczema, compared with optimal 25-hydroxyvitamin D levels (0.93 (0.70, 1.23), 0.92 (0.71, 
1.20) and 0.89 (0.69, 1.17), respectively) (p-values for trend >  0.05). Similarly, per year 
analysis showed no association of 25-hydroxyvitamin D levels at birth with childhood 
eczema (Table 2). Levels of 25-hydroxyvitamin D in mid-gestation and at birth were not 
associated with eczema patterns (Table 3).
discussion
The results of this population-based prospective cohort study suggested that levels of 
25-hydroxyvitamin D in mid-gestation and at birth were not associated with the overall 
risk of eczema, nor with the risk of eczema per year or eczema patterns in children until 
age 4 years.
comparison of main findings with other studies
Studies that explored the association of maternal 25-hydroxyvitamin D levels during 
pregnancy with childhood eczema reported inconsistent results.10, 14, 15 Two studies 
suggested that levels of 25-hydroxyvitamin D in pregnancy or at birth were not as-
sociated with the risk of eczema at age 2 or 7 years.10, 14 Other studies reported that 
higher maternal 25-hydroxyvitamin D levels in late pregnancy were associated with an 
increased risk of visible eczema at age 9 months or with a decreased risk of eczema at 
age 4 years.14, 15 Differences in results might be explained by the period of pregnancy 
when 25-hydroxyvitamin D was measured, method of eczema measurement such as 
the presence of visible eczema on physical examination or parental reporting of eczema 
by questionnaires, or adjustment for different confounding factors. Additional to these 
studies, we observed that levels of 25-hydroxyvitamin D in mid-gestation were not as-
sociated with the overall risk of eczema, nor with the risk of eczema per year or eczema 
patterns in children until age 4 years., taking also 25-hydroxyvitamin D levels at birth 
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into account. We hypothesized that lower 25-dihydroxyvitamin D levels in early life lead 
to an increased risk of eczema at a young age, but did not find such associations. We 
observed that levels of 25-hydroxyvitamin D levels at birth were not associated with the 
risk of childhood eczema. Our results are in contrast to a previous study that reported 
that higher 25-hydroxyvitamin D3 levels at birth were associated with a decreased risk 
of eczema at age 6 months.5 Differences in results might be explained by differences 
in sample size and type of vitamin D level measurement. Therefore, further studies are 
needed to replicate our findings before any strong conclusions can be drawn. Several 
prospective cohort studies examined associations of 25-hydroxyvitamin D levels at birth 
with the risk of childhood eczema at later ages and reported conflicting results.11–13 One 
study did not observe an association of 25-hydroxyvitamin D levels at birth with the 
risk of eczema, allergic sensitization and total IgE levels until age 7 years11, but others 
suggested that higher 25-hydroxyvitamin D levels at birth were associated with a lower 
risk of eczema in children until age 5 years.12, 13 Differences in results may be attributed 
to different sample sizes of the studies12, 13, use of 25-hydroxyvitamin D3 only13, or dif-
table 3. Associations of 25-hydroxyvitamin D levels with eczema patterns in children until age 4 years.
odds ratio (95 % confidence interval) for eczema patterns
early late Persistent
25-hydroxyvitamin D in mid-gestation*
Optimal (n = 1,187) Reference Reference Reference
Sufficient (n = 925) 1.23 (0.78, 1.94) 0.88 (0.58, 1.34) 0.89 (0.58, 1.37)
Deficient (n = 752) 1.02 (0.37, 3.06) 1.12 (0.69, 1.84) 0.90 (0.54, 1.50)
Severely deficient (n = 155) 0.99 (0.33, 2.92) 0.75 (0.28, 2.00) 0.90 (0.35, 2.26)
P-value for trend 0.62 0.71 0.66
25-hydroxyvitamin D at birth†
Optimal (n = 206) Reference Reference Reference
Sufficient (n = 775) 1.28 (0.54, 3.05) 1.21 (0.48, 3.01) 0.53 (0.25, 1.15)
Deficient (n = 1,375) 0.92 (0.38, 2.22) 0.96 (0.36, 2.30) 0.67 (0.31, 1.43)
Severely deficient (n = 663) 1.00 (0.36, 2.80) 0.98 (0.35, 2.74) 0.63 (0.25, 1.56)
P-value for trend 0.30 0.78 0.79
Values are odds ratios (95 % confidence interval) from multinomial logistic regression models based on im-
puted data. Reference group is children with optimal 25-hydroxyvitamin D levels who never (n = 1,557) had 
eczema. Levels of 25-hydroxyvitamin D are categorized as ‘severely deficient’ (< 25.0 nmol/L (< 10.0 mg/L)), 
‘deficient’ (25.0–49.9 nmol/L (10.0–19.9 mg/L)), ‘sufficient’ (50.0–74.9 nmol/L (20.0–29.9 mg/L)) and ‘optimal’ 
(≥ 75.0 nmol/L (≥ 30.0 mg/L)). Models are adjusted for maternal age at enrollment, education, history of 
eczema, allergy or asthma, parity, pet keeping, body mass index at enrollment, folate level, smoking, psychi-
atric symptoms, season of blood sampling in mid-gestation, and child’s sex, gestational age, birth weight, 
breastfeeding, vitamin D supplementation at age 2 months and season of blood sampling at birth. *Ad-
ditionally adjusted for 25-hydroxyvitamin D levels at birth. †Additionally adjusted for 25-hydroxyvitamin D 
levels in mid-gestation.
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ferent definitions of eczema patterns.12 Furthermore, a previous study that measured 
eczema at multiple time points during follow-up did not take repeated measurements 
of eczema within the same child into account nor adjustment for 25-hydroxyvitamin D 
levels during pregnancy.12
interpretation of results
Although the effects of 25-hydroxyvitamin D on the immune system have been well 
recognized6, its effects do not seem to have a role in the occurrence and persistence of 
eczema through childhood. In vivo experiments in mice suggested that the treatment of 
eczema with vitamin D receptor agonists results in improvement of allergen-associated 
eczema.9 However, findings in animal models indicated that vitamin D3 or its analogues 
display different effects on expression of molecules in mouse skin as opposed to human 
or primate skin.27 Namely, expression of thymic stromal lymphopoietin was observed 
in keratinocytes of mice after stimulation with vitamin D3, but not in keratinocytes 
of humans or primates.28 We observed no differences in results for the associations of 
25-hydroxyvitamin D during pregnancy or at birth with eczema outcomes. Levels of 
25-hydroxyvitamin D in mid-gestation and at birth might have been highly correlated 
due to similar lifestyle and dietary habits of mother during pregnancy. However, we ob-
served a lower median 25-hydroxyvitamin D level at birth than in mid-gestation (39.6 vs. 
66.3 nmol/L). This difference in 25-hydroxyvitamin D levels was not expected because 
pregnant women in the Netherlands are advised to take 10 µg of vitamin D supplement 
per day throughout pregnancy.25 Our study lacked information on adherence of vitamin 
D intake which could have explained the discrepancy between 25-hydroxyvitamin D 
levels in mid-gestation and at birth. Placental function or vitamin D receptor expression, 
and genetic susceptibility might have also affected the difference in 25-hydroxyvitamin 
D levels.29–32 We did not observe differences in results when we included or excluded 
supplementation of vitamin D in childhood (data not shown). The potential interme-
diating and protective role of child’s vitamin D supplementation for the associations 
of 25-hydroxyvitamin D levels in mid-gestation and at birth with eczema is difficult to 
study in countries, such as the Netherlands, where most preschool-age children take a 
vitamin D supplement because it is recommended.25 We did not observe associations of 
either maternal or fetal 25-hydroxyvitamin D levels with any eczema outcome, and we 
therefore speculate that other factors, such as genetic or other environmental factors, 
might have a more important role in the onset of childhood eczema. Eczema appears 
to have a complex genetic background. Mutations of the gene encoding filament-
aggregating protein, or filaggrin, have been strongly associated with the development 
of eczema.33 Also, a recent study suggested that microRNAs influence the inhibition 
of innate immune response in chronic skin inflammation.27 For environmental factors, 
climate and housing conditions, urban or rural living, dietary and feeding habits, air 
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pollution, microbial exposure, and socioeconomic status have been suggested to be as-
sociated with childhood eczema. Also, exposure to higher ultraviolet (UV) levels seems 
associated with higher 25-hydroxyvitamin D levels and a lower prevalence of eczema, 
compared with exposure to lower UV levels.34–36 Therefore, future studies are needed to 
explore the role of multiple genetic and environmental factors, and their interaction, in 
the development of eczema in childhood.
strengths and limitations
The strength of this study is its population-based prospective design. Participants were 
followed up from fetal life onwards, and a large number of potential confounding factors 
were recorded. Also, 25-hydroxyvitamin D levels were objectively measured in maternal 
blood in mid-gestation and in cord blood at birth, and categorized according to clinical 
cut-off values that would allow the comparison with other studies. However, selec-
tion bias in cohort studies arises from non-response or missing data of the exposure, 
and loss to follow-up. Subjects included in the current study were more affluent and 
healthier than those not included. This could have led to biased effect estimates if the 
associations of mid-gestational and umbilical cord blood 25-hydroxyvitamin D levels 
with eczema were different between those included and not included in the analyses. 
We used the same cut-off values for 25-hydroxyvitamin D levels in pregnant women as 
the documented levels for the general population, although there is no consensus on 
optimal 25-hydroxyvitamin D levels.20 Information on eczema was collected by parental 
questionnaires, and this method is commonly used in large epidemiological studies.37, 38 
However, some misclassification of eczema might still be present because the question-
naires were not validated against medical records or physical examination in our study 
population. We took many covariates into account, but lacked data on potential modi-
fying environmental factors, such as UV exposure or dietary patterns of the children, 
which could have affected our results. Our population for analysis comprised children 
of Dutch origin only and this may limit the generalizability of our findings to children of 
other ethnic origin or with heterogeneous skin types. Finally, we cannot exclude residual 
confounding from unmeasured exposures such as other vitamin or supplement intake, 
as in any prospective cohort study.
In conclusion, our results suggest that levels of 25-hydroxyvitamin D in mid-gestation 
and at birth are not associated with the overall risk of eczema, nor with the risk of ec-
zema per year or eczema patterns in children until age 4 years. Future studies focusing 
on other risk factors, such as environmental and genetic factors, are needed to explore 
the development of eczema in childhood.
Detailed acknowledgements and additional supporting information can be found in the 
published article online: http://onlinelibrary.wiley.com/doi/10.1111/pai.12530/suppinfo.
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supplementary methods
The total 25-hydroxyvitamin D level was reported as the sum of 25-hydroxyvitamin 
D2 and D3 species measured in plasma using a modification of a method previ-
ously described.19 Briefly, 50 µL milli-Q water and 500 µL of acetonitrile (ACN) contain-
ing 6,19,19-(2H3)-25-hydroxyvitamin D2 and 6,19,19-(2H3)-25-hydroxyvitamin D3 
at 10  nmol/L each were added to 3 µL plasma, sonicated, vortexed and centrifuged. 
The supernatant was filtered using a TiO2/ZrO2 filter plate (Glygen Corp., Columbia, 
MD, USA) and evaporated to dryness. Samples were derivatized using 4-phenyl-1,2,4-
triazoline-3,5-dione and reconstituted in ACN:H2O (1:3) prior to analysis. Samples were 
quantified using isotope dilution liquid chromatography-tandem mass spectrometry. 
The analytical system was comprised of a Shimadzu Nexera UPLC coupled to an AbSciex 
5500 QTRAP equipped with an APCI source. Chromatographic separation was achieved 
using a Kinetex XB-C18 column (50 x 2.1 mm, 1.7 µm; Phenomenex, Torrance, CA, USA), 
and 72 % acetonitrile/32 % aqueous 0.1 % formic acid at a flow rate of 0.5 mL/min. Linear-
ity was assessed using matrix-matched calibration standards, with R2 values of > 0.99 
across the calibration range (10–125  nmol/L). Inter-assay inaccuracy and imprecision 
were assessed at four concentration levels for 25-hydroxyvitamin D3 (48.3, 49.4, 76.4 and 
139.2 nmol/L) and a single level for 25-hydroxyvitamin D2 (32.3 nmol/L) using certified 
reference materials purchased from the National Institute of Standards and Technol-
ogy (NIST SRM 972a Levels 1–4), and were excellent at all concentration levels tested. 
Inter-assay inaccuracy and imprecision were both < 10 % for 25-hydroxyvitamin D3 and 
< 17 % for 25-hydroxyvitamin D2. Assay repeatability was assessed via replicate analysis 
of an independent reference material (NIST SRM1950, 61.9 nmol/L 25-hydroxyvitamin 
D3), with inter-assay inaccuracy and imprecision both <  11 % (n  =  343). The limit of 
quantification was 1 and 5 nmol/L for 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2, 
respectively.
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supplementary Figure. Flowchart of participants.
 
n = 105 
Children without data on eczema excluded 
n = 716 
Twins (n = 119) and children without data on 25-
hydroxyvitamin D level (n = 597) excluded 
n = 3,840 
Children of Dutch origin with consent until age 4 
years 
n = 3,124 
Children with data on 25-hydroxyvitamin D level 
available 
 
Mid-gestation  n = 2,771 
At birth   n = 2,087 
n = 3,019 
Children with any data on eczema available 
 
Eczema per year 
 Age 6 months  n = 2,113 
 Age 1 year  n = 2,841 
 Age 2 years  n = 2,661 
 Age 3 years  n = 2,478 
 Age 4 years  n = 2,475 
 
Eczema patterns  n = 1,723 
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supplementary table 1. Characteristics of mothers their children (n = 3,019).
observed imputed
maternal characteristics
Age at enrollment (years)* 31.8 (4.1) 31.8 (4.1)
Missing 0 (0) 0 (0)
Education (%)
Primary 2.3 (69) 3.0 (91)
Secondary 33.7 (1,006) 33.6 (1,014)
Higher 64.0 (1,909) 63.4 (1,914)
Missing 1.2 (35) 0 (0)
History of allergy, eczema or asthma (%)
No 65.3 (1,793) 65.2 (1,969)
Yes 34.7 (951) 34.8 (1,050)
Missing 9.1 (275) 0 (0)
Parity (%)
0 59.8 (1,804) 59.9 (1,807)
≥ 1 40.2 (1,209) 40.1 (1,212)
Missing 0.2 (6) 0 (0)
Pet keeping during pregnancy (%)
No 58.4 (1,578) 58.5 (1,765)
Yes 41.6 (1,122) 41.5 (1,254)
Missing 10.6 (319) 0 (0)
Body mass index at enrollment (kg/m2)† 23.3 (18.9–35.0) 23.3 (18–9-34.9)
Missing 0.5 (16) 0 (0)
Smoking during pregnancy (%)
No 76.3 (2,113) 76.3 (2,303)
Yes 23.7 (656) 23.7 (716)
Missing 8.3 (250) 0 (0)
Folate level in first trimester (nmol/L)† 19.7 (6.4–38.7) 19.6 (6.3–38.6)
Missing 22.2 (671) 0 (0)
Psychiatric symptoms during pregnancy† 0.12 (0–0.77) 0.12 (0–0.77)
Missing 31.4 (947) 0 (0)
Season of blood sampling in mid-gestation (%)
Spring 28.4 (787) 28.6 (864)
Summer 23.3 (646) 23.1 (696)
Autumn 23.4 (649) 23.3 (703)
Winter 24.9 (691) 25.0 (756)
Missing 8.1 (246) 0 (0)
25-hydroxyvitamin D level in mid-gestation (nmol/L)† 66.3 (19.4–125.4) 66.0 (19.4–124.8)
Missing 8.2 (248) 0 (0)
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supplementary table 1. Characteristics of mothers their children (n = 3,019). (continued)
observed imputed
child characteristics
Sex (%)
Male 50.9 (1,514) 50.9 (1,514)
Female 49.1 (1,505) 49.1 (1,505)
Missing 0 (0) 0 (0)
Gestational age at birth (weeks)† 40.3 (36.0–42.4) 40.3 (36.0–42.4)
Missing 0 (0) 0 (0)
Birth weight (grams)* 3,513 (542) 3,513 (542)
Missing 0 (0) 0 (0)
Breastfeeding (%)
Never 11.0 (283) 12.2 (369)
Non-exclusive for 4 months 61.8 (1,582) 60.6 (1,831)
Exclusive for 4 months 27.2 (696) 27.1 (819)
Missing 15.2 (458) 0 (0)
Vitamin D supplementation at age 2 months (%)
No 29.0 (757) 30.1 (910)
Yes 71.0 (1,850) 69.9 (2,109)
Missing 13.6 (412) 0 (0)
Season of blood sampling at birth (%)
Spring 24.1 (727) 24.1 (727)
Summer 26.4 (797) 26.4 (797)
Autumn 27.9 (842) 27.9 (842)
Winter 21.6 (653) 21.6 (653)
Missing 0 (0) 0 (0)
25-hydroxyvitamin D level at birth (nmol/L)† 39.6 (11.3–89.1) 40.2 (11.2–89.1)
Missing 30.9 (932) 0 (0)
Eczema last 6 months at age 6 months (%)
No 84.9 (1,794) 70.8 (2,136)
Yes 15.1 (319) 29.2 (883)
Missing 30.0 (906) 0 (0)
Eczema last 6 months at age 1 year (%)
No 81.8 (2,323) 79.8 (2,408)
Yes 18.2 (518) 20.2 (611)
Missing 5.9 (178) 0 (0)
Eczema last 12 months at age 2 years (%)
No 87.2 (2,321) 85.3 (2,576)
Yes 12.8 (340) 14.7 (443)
Missing 11.9 (358) 0 (0)
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supplementary table 1. Characteristics of mothers their children (n = 3,019). (continued)
observed imputed
Eczema last 12 months at age 3 years (%)
No 91.9 (2,277) 87.9 (2,655)
Yes 8.1 (201) 12.1 (364)
Missing 17.9 (541) 0 (0)
Eczema last 12 months at age 4 years (%)
No 92.8 (2,298) 87.8 (2,650)
Yes 7.2 (177) 12.2 (369)
Missing 18.0 (544) 0 (0)
Eczema patterns (%)
Never 61.9 (1,066) 49.6 (1,498)
Early 12.1 (210) 20.6 (622)
Late 12.9 (222) 15.4 (464)
Persistent 13.1 (225) 14.4 (435)
Missing 42.9 (1,296) 0 (0)
Values are *means (SD), †medians (2.5–97.5th percentile) or percentages (absolute numbers) based on ob-
served and imputed data.
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supplementary table 2. Characteristics of mothers and children included and not included in the study.
included
n = 3,019
not included
n = 105
P-value for 
difference
maternal characteristics
Age at enrollment (years)* 31.8 (4.1) 28.8 (5.9) < 0.001
Missing 0 (0) 0 (0)
Education (%) < 0.001
Primary 2.3 (69) 18.4 (19)
Secondary 33.7 (1,006) 47.6 (49)
Higher 64.0 (1,909) 34.0 (35)
Missing 1.2 (35) 1.9 (2)
History of allergy, eczema or asthma (%) 0.76
No 65.3 (1,793) 63.8 (60)
Yes 34.7 (951) 36.2 (34)
Missing 9.1 (275) 10.5 (11)
Parity (%) < 0.01
0 59.8 (1,804) 46.7 (49)
≥ 1 40.2 (1,209) 53.3 (56)
Missing 0.2 (6) 0 (0)
Pet keeping during pregnancy (%) < 0.01
No 58.4 (1,578) 43.6 (41)
Yes 41.6 (1,122) 56.4 (53)
Missing 10.6 (319) 10.5 (11)
Body mass index at enrollment (kg/m2)† 23.3 (18.9–35.0) 23.5 (19.1–37.1) 0.16
Missing 0.5 (16) 0 (0)
Smoking during pregnancy (%) < 0.001
No 76.3 (2,113) 53.7 (51)
Yes 23.7 (656) 46.3 (44)
Missing 8.3 (250) 9.5 (10)
Folate level in first trimester (nmol/L)† 19.7 (6.4–38.7) 13.6 (4.8–32.1) < 0.001
Missing 22.2 (671) 26 (24.8)
Psychiatric symptoms during pregnancy† 0.12 (0–0.77) 0.15 (0–1.74) 0.07
Missing 31.4 (947) 32 (30.5)
Season of blood sampling in mid-gestation (%) 0.75
Spring 28.4 (787) 32.6 (29)
Summer 23.3 (646) 24.7 (22)
Autumn 23.4 (649) 21.3 (19)
Winter 24.9 (691) 21.3 (19)
Missing 8.1 (246) 15.2 (16)
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supplementary table 2. Characteristics of mothers and children included and not included in the 
study. (continued)
included
n = 3,019
not included
n = 105
P-value for 
difference
child characteristics
Sex (%) 0.65
Male 50.9 (1,514) 52.4 (55)
Female 49.1 (1,505) 47.6 (50)
Missing 0 (0) 0 (0)
Gestational age at birth (weeks)† 40.3 (36.0–42.4) 40.0 (33.6–42.1) < 0.05
Missing 0 (0) 0 (0)
Birth weight (grams)* 3,513 (542) 3,378 (517) < 0.05
Missing 0 (0) 0 (0)
Breastfeeding (%) < 0.001
Never 11.0 (283) 43.5 (20)
Non-exclusive for 4 months 61.8 (1,582) 56.5 (26)
Exclusive for 4 months 27.2 (696) 0 (0)
Missing 15.2 (458) 56.2 (59)
Vitamin D supplementation at age 2 months (%) < 0.001
No 29.0 (757) 58.7 (27)
Yes 71.0 (1,850) 41.3 (19)
Missing 13.6 (412) 56.2 (59)
Season of blood sampling at birth (%) 0.97
Spring 24.1 (727) 23.8 (25)
Summer 26.4 (797) 26.7 (28)
Autumn 27.9 (842) 29.5 (31)
Winter 21.6 (653) 20.0 (21)
Missing 0 (0) 0 (0)
Values are *means (SD), †medians (2.5–97.5th percentile) or percentages (absolute numbers) based on ob-
served data. P-values for difference are calculated by independent samples T-test for continuous variables 
with a normal distribution, the Mann-Whitney U-test for continuous variables with a skewed distribution, 
and Pearson’s Chi-square test for categorical variables. Bold values indicate statistical significance at the 
α = 0.05 level.
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AbstrAct
background The prevalence of childhood eczema varies considerably between ethnic 
groups. However, data from longitudinal studies remain scarce.
methods We examined the associations of ethnic origin with the development of 
eczema from birth until age 4 years, and whether known environmental and genetic 
risk factors explain these associations. This study was performed in a multi-ethnic pop-
ulation-based prospective cohort among 5,082 children. Ethnic origin was based on the 
parents’ country of birth. Data on physician-diagnosed eczema were obtained by annual 
questionnaires. Information on environmental risk factors was mostly obtained by ques-
tionnaires. Filaggrin mutations (2282del4, R2447X, R501X and S3247X) were genotyped 
for 3,096 children. We used generalized estimating equation models to examine the 
associations of ethnic origin with the longitudinal odds of eczema at ages 6 months and 
1, 2, 3 and 4 years independently and overall.
results Compared with Dutch children, Cape Verdean, Dutch Antillean, Surinamese-
Creole, and Surinamese-Hindustani children had overall increased risks of eczema (odds 
ratio (95 % confidence interval): 1.53 (1.15, 2.03), 1.60 (1.21, 2.12), 1.95 (1.56, 2.44), and 
2.06 (1.65, 2.57), respectively). Effect estimates for the associations of Cape Verdean and 
Dutch Antillean origin with eczema became non-significant after adjustment for genetic 
risk factors or both environmental and genetic risk factors, respectively. Surinamese-
Creole and Surinamese-Hindustani children remained to have increased risks of eczema.
conclusions Cape Verdean, Dutch Antillean, Surinamese-Creole, and Surinamese-Hin-
dustani children had increased risks of eczema in the first 4 years of life. Environmental 
and genetic risk factors partly weakened these associations.
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introduction
The prevalence of childhood eczema varies considerably between ethnic groups.1 
Cross-sectional studies from the USA and the UK showed that black children had an 
up to 2.2-fold increased risk of eczema, while Hispanic children had a 28 % decreased 
risk, compared with white children.2–4 Other European studies demonstrated that 
Surinamese and Dutch Antillean children more frequently, and Moroccan and Turkish 
children less frequently had eczema than Caucasian children.5–7 Data from longitudinal 
studies remain scarce. We previously examined differences in the development of ec-
zema between ethnic groups longitudinally in children until age 2 years.8 We observed 
that Moroccan and Surinamese children more frequently had eczema in the first year 
of life, while Surinamese children more frequently and Turkish children less frequently 
had eczema in the second year of life, compared with Dutch children. Differences in the 
prevalence of eczema between ethnic groups must be explained by environmental and 
genetic factors. Known environmental risk factors for eczema include housing condi-
tions, urban or rural living, dietary and feeding habits, air pollution, and microbial expo-
sure.9 Loss-of-function mutations in the gene encoding filaggrin (FLG), an indispensable 
protein for epidermal differentiation and maintenance of an optimal skin barrier, are 
well known to be associated with eczema.10 Although 2282del4, R2447X, R501X, and 
S3247X are the most common FLG mutations in Caucasians11, the prevalence of these 
mutations in other ethnic groups is less clear.
Therefore, we examined among 5,082 children participating in a large multi-ethnic 
population-based prospective cohort in Rotterdam, The Netherlands, the associations of 
ethnic origin with the development of eczema from birth until age 4 years, and whether 
any association was explained by known environmental and genetic risk factors.
methods
general design
This study was embedded in the Generation R Study, an ongoing population-based 
prospective cohort study from fetal life onwards.12 The study has been approved by the 
Medical Ethical Committee of the Erasmus Medical Center, Rotterdam, The Netherlands 
(MEC 217.595/2002/202). Written informed consent was obtained from parents or legal 
guardians of 7,295 children. For the current study, a total of 5,082 children were available 
for analysis of which 3,096 children had data on FLG genotype available (Supplementary 
Figure).
ethnic origin
In accordance with Statistics Netherlands13, the ethnic origin of the child was based on 
the parents’ country of birth. This information was obtained by a questionnaire at enroll-
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ment. Children of whom both parents were born in the Netherlands were classified as 
being of Dutch origin. A child was considered of non-Dutch origin if one of the parents 
was born abroad. If both parents were born abroad, the country of birth of the mother 
was decisive. Children of non-Dutch origin were classified into ‘Cape Verdean’, ‘Dutch 
Antillean’, ‘Moroccan’, ‘Surinamese-Creole’, ‘Surinamese-Hindustani’, and ‘Turkish’.
eczema
Information on physician-diagnosed eczema in the last 6 months/last year (no; yes) 
was obtained by parental questionnaires at ages 6 months and 1, 2, 3 and 4 years; 
response rates were 73 %, 71 %, 76 %, 72 % and 73 %, respectively. Questions on eczema 
were adapted from the International Study of Asthma and Allergies in Childhood core 
questionnaires.14
environmental risk factors
Information on maternal age, education (primary or secondary; higher), history of al-
lergy, eczema or asthma (no; yes), parity (nulliparous; multiparous), pet keeping (no; yes) 
and body mass index (BMI) was obtained by a questionnaire, completed by the mother 
at enrollment. Information on maternal smoking (no; yes) was obtained by postal ques-
tionnaires sent during each trimester of pregnancy. Maternal psychiatric symptoms in 
the second trimester of pregnancy were assessed using the Global Severity Index of 
the Brief Symptom Inventory15, denoting overall psychiatric symptoms. We obtained 
information on child’s sex, gestational age at birth and birth weight from obstetric and 
midwife records at birth. Delivery reports and postal questionnaires completed by the 
mother when the child was 2, 6 and 12 months old provided data on ever breastfeeding 
(no; yes) or day care attendance (no; yes). The child’s BMI was calculated using weight 
and height measured at age 10–13 months during a visit to the research center. Informa-
tion on wheezing (no; yes) was obtained by annual questionnaires from birth until age 
4 years.
genetic risk factors
Four FLG mutations (2282del4, R2447X, R501X, and S3247X) were genotyped by modi-
fied Taqman allelic discrimination assays, using previously described primers.16 Children 
without any mutant alleles were classified as wild-type. Because we observed merely 
two children who carried a homozygous FLG mutation, we created a combined FLG 
genotype, meaning that children were classified as having a FLG mutation if they were 
heterozygous or homozygous for any of the four mutations.
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statistical analysis
We examined differences in population characteristics between ethnic groups by 
one-way ANOVA, Kruskal-Wallis tests, and Pearson’s Chi-square tests. We performed a 
non-response analysis by comparing children included in the analyses and those lost 
to follow-up using independent samples T-tests, Mann-Whitney U-tests, and Pearson’s 
Chi-square tests. We used generalized estimating equation models to examine the as-
sociations of ethnic origin with the longitudinal odds of eczema at ages 6 months and 
1, 2, 3 and 4 years independently and overall, taking into account correlations between 
repeated measurements of eczema within the same child. In addition to the crude 
model, we first adjusted for known environmental risk factors, including maternal age 
at enrollment, education, history of allergy, eczema or asthma, parity, pet keeping, BMI 
at enrollment, smoking, psychiatric symptoms, and child’s sex, gestational age, birth 
weight, breastfeeding, day care attendance, BMI at age 10–13 months, and wheezing 
(environmental model). Second, we adjusted for known genetic risk factors by means of 
the combined FLG genotype (genetic model). Third, we adjusted for both environmental 
and genetic risk factors (full model). Confounders were included in the models based on 
previous literature, if they were associated with both the determinant and the outcome, 
or if they changed the effect estimate with ≥ 10 %. Missing covariates were ≤ 20 %, ex-
cept for maternal psychiatric symptoms (21.8 %), and child’s day care attendance (26.6 %) 
and wheezing (36.0 %) (Supplementary Table 1). To reduce potential bias from missing 
data and to increase precision, we performed a multiple imputation analysis of covari-
ates and outcomes generating 25 independent datasets using the Markov chain Monte 
Carlo method, and calculated pooled estimates. We present results based on imputed 
analyses only. Measures of association are presented as odds ratios (OR) with their 95 % 
confidence intervals (CI). Statistical analyses were performed using SPSS 21.0.0.1 for 
Windows (IBM Corp., Armonk, NY, USA) and SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
results
general
Of the participating children, 73.9 % (n = 3,756) was of Dutch origin. Children of non-
Dutch origin were Cape Verdean (2.5 %; n  =  125), Dutch Antillean (3.1 %; n  =  156), 
Moroccan (5.8 %, n = 295), Surinamese-Creole (3.3 %, n = 168), Surinamese-Hindustani 
(2.9 %, n = 147) or Turkish (8.5 %, n = 435) (Table 1). All maternal and child characteristics 
differed between the ethnic groups, except for maternal history of allergy, eczema or 
asthma. Overall, the prevalence of eczema declined from 17.4 % at age 6 months to 8.9 % 
at age 4 years. The highest prevalence of eczema was 16.5 % at age 6 months for Dutch 
children, 22.2 % at age 2 years for Cape Verdean children, 23.3 % at age 2 years for Dutch 
Antillean children, 21.5 % at age 6 months for Moroccan children, 27.4 % at age 6 months 
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for Surinamese-Creole children, 24.5 % at age 1 year of Surinamese-Hindustani children, 
and 15.0 % at age 6 months for Turkish children (Figure 1). FLG mutations were present 
in 7.8 % (n = 243) of all children. None of the Moroccan and Surinamese-Creole children 
carried a mutation. All other children of non-Dutch origin less frequently carried FLG 
mutations, compared with children of Dutch origin (p-value for difference < 0.05). Two 
children carried a homozygous FLG mutation (R501X and 2282del4). Compound hetero-
zygosity was found in four different children. Differences between included children and 
their mothers and those lost to follow-up are listed in Supplementary Table 2.
ethnic origin and eczema
Crude models showed that, compared with Dutch children, Cape Verdean, Dutch Antil-
lean, Surinamese-Creole and Surinamese-Hindustani children had overall increased risks 
of eczema (OR (95 % CI): 1.53 (1.15, 2.03), 1.60 (1.21, 2.12), 1.95 (1.56, 2.44) and 2.06 (1.65, 
2.57), respectively) (Figure  2 and Supplementary Table  3), but Moroccan and Turkish 
children did not. When we adjusted for known environmental risk factors of mother and 
child separately, we observed that the maximum change in effect size for the associa-
tions of Cape Verdean, Dutch Antillean, Surinamese-Creole and Surinamese-Hindustani 
origin occurred when maternal education (1.44 (1.08, 1.92), 1.52 (1.15, 2.01), 1.85 (1.48, 
2.32) and 1.95 (1.56, 2.43), respectively) and psychiatric symptoms during pregnancy 
(1.44 (1.08, 1.92), 1.53 (1.15, 2.02), 1.88 (1.50, 2.35) and 1.97 (1.58, 2.46), respectively) 
were added to the crude models (Table  2). When we adjusted for all known environ-
mental risk factors, we observed that Cape Verdean, Dutch Antillean, Surinamese-Creole 
and Surinamese-Hindustani children remained to have increased risks of eczema. When 
Figure 1. Prevalence of eczema in children of different ethnic origin until age 4 years.
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Figure 2. Associations of Cape Verdean (A), Dutch Antillean (B), Moroccan (C), Surinamese-Creole (D), Suri-
namese-Hindustani (E), and Turkish (F) origin with eczema in children until age 4 years.
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(B)     Dutch Antillean
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(C)     Moroccan
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(D)     Surinamese-Creole
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(E)     Surinamese-Hindustani
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* *
Values are odds ratios (95 % confidence interval) from generalized estimating equation models based on 
imputed data. Reference group is children of Dutch origin (dotted line). The crude model is unadjusted. The 
environmental model (all environmental risk factors) is adjusted for maternal age at enrollment, education, 
history of allergy, eczema or asthma, parity, pet keeping, body mass index (BMI) at enrollment, smoking, 
psychiatric symptoms, and child’s sex, gestational age, birth weight, breastfeeding, day care attendance, 
BMI at age 10–13 months and wheezing. The genetic model (genetic risk factors) is adjusted for filaggrin 
genotype. The full model (all risk factors) is adjusted for both environmental and genetic risk factors. *P-
value < 0.05. Mo = months; y = year(s).
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we adjusted for genetic risk factors, we observed that only the effect estimate for the 
association of Cape Verdean origin with eczema became non-significant. After adjust-
ment for both environmental and genetic risk factors, our results showed that only 
Surinamese-Creole and Surinamese-Hindustani children had increased risks of eczema, 
compared with Dutch children. Effect estimates did not materially change when wheez-
ing was excluded from the models (data not shown).
discussion
We observed in a large multi-ethnic population-based prospective cohort that Cape 
Verdean, Dutch Antillean, Surinamese-Creole and Surinamese-Hindustani children 
had overall increased risks of eczema in the first 4 years of life, compared with Dutch 
children. Only Surinamese-Creole and Surinamese-Hindustani children had increased 
risks of eczema after adjustment for both environmental and genetic risk factors.
comparison of main findings with other studies
Previous birth cohort studies from the USA showed that black and Asian children had 
up to 2.58-fold increased risks of eczema17, 18, compared with Caucasian children. In line 
with these studies, we observed that Cape Verdean, Dutch Antillean, Surinamese-Creole 
and Surinamese-Hindustani children had increased risks of eczema, compared with 
Dutch children. European cross-sectional migrant studies demonstrated lower risks 
of eczema in Moroccan and Turkish than in Caucasian children.5–7 We found no differ-
ences in risk of eczema between these children. This discrepancy might be explained 
by differences in the definition of ethnic origin, the method of eczema measurement, 
and the age at which eczema was measured. In our previous study, we observed that 
Moroccan and Surinamese children more frequently had eczema in the first year of life, 
compared with Dutch children.8 In the second year of life, Surinamese children more 
frequently and Turkish children less frequently had eczema. In the current study, we 
examined associations of ethnic origin with eczema until age 4 years, took correlations 
between repeated measurements of eczema within the same child into account, and 
explored the role of known environmental and genetic risk factors. We observed that 
Dutch Antillean children had an increased risk of eczema at age 2 years, and Surinamese-
Creole and Surinamese-Hindustani children at ages 6 months to 4 years. Moroccan and 
Turkish children had similar overall risks of eczema and similar risks of eczema per year, 
compared with Dutch children. Results for these children seemed inconsistent, and, 
therefore, need to be replicated before any conclusion can be drawn. In our cohort, the 
overall carrier frequency of FLG mutations was 7.8 %, which is consistent with previously 
reported frequencies in European cohorts (range 6.6–13.5 %).19 Carrier frequencies of 
FLG mutations in children of non-Dutch origin was low. Furthermore, our results did 
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not materially change when FLG genotype was taken into account. This suggests that 
different mutations of the FLG gene and other genes might underlie the risk of the 
development of eczema in these children.11
interpretation of results
Our results showed that Cape Verdean, Dutch Antillean, Surinamese-Creole and 
Surinamese-Hindustani children had increased risks of eczema in the first 4 years of 
life, compared with Dutch children. Effect estimates for the association of Cape Verdean 
origin with eczema became non-significant after adjustment for genetic risk factors, and 
of Dutch Antillean origin with eczema after adjustment for both environmental and ge-
netic risk factors. The largest change in effect size for the associations of Cape Verdean, 
Dutch Antillean, Surinamese-Creole and Surinamese-Hindustani origin occurred when 
maternal education and psychiatric symptoms during pregnancy were added to the 
crude model separately. Mothers of Cape Verdean, Dutch Antillean, Surinamese-Creole 
and Surinamese-Hindustani children were lower educated and had higher psychiatric 
symptom scores during pregnancy, compared with mothers of Dutch children. However, 
precise quantification of attribution of each risk factor separately to the association of 
ethnic origin with eczema is difficult due to collinearity of environmental and genetic 
risk factors. Differences in the overall risk of eczema for children of different ethnic ori-
gin may result from residual, unmeasured variation in hygiene levels20, staphylococcal 
colonization21, sun exposure22, vitamin D levels23, and genetic factors.11, 24 Also, func-
tional and structural differences in skin barrier properties, such as transepidermal water 
loss25, natural moisturizing factor16, and stratum corneum lipid composition26, between 
children of different ethnic origin might have influenced the results. Recently, it was 
observed that skin barrier characteristics in adults of African American, Caucasian, and 
East Asian descent differ.27 East Asian skin seemed to have the most fragile skin barrier, 
but without dryness and scaliness due to high levels of stratum corneum lipids. African 
American skin had a stronger skin barrier, but dry skin due to low levels of stratum cor-
neum lipids. A dry skin is one of the hallmarks of eczema. We demonstrated that children 
of Dutch and non-Dutch origin had different carrier frequencies of FLG mutations (10.0 % 
vs. 1.4 %). Recently, it was found in a European population that 2282del4, R2447X, R501X 
and S3247X mutations accounted for > 90 % of the FLG mutation spectrum, while in an 
Asian population this spectrum contained 11 other FLG mutations.11 Further studies are 
needed to examine the underlying genetic mechanisms of other FLG mutations for the 
association of ethnic origin with the development of eczema.
strengths and limitations
The major strengths of this study are the use of a population-based prospective study 
design with a large number of children of different ethnic origin, detailed information 
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on eczema, and multiple known environmental and genetic risk factors. Our results 
could be applied to a general population of children of different ethnic origin. How-
ever, some methodological limitations should be considered. First, selection bias in 
longitudinal studies mainly arises due to subjects that are lost to follow-up, which was 
10 % in our study. Non-included subjects were more often of non-Dutch origin and non-
affluent background, and were less healthy. Loss to follow-up might have led to bias if 
the associations of ethnic origin with eczema were different between those included 
and not included in the study. This we do not know. Nearly 74 % of the participating 
children was of Dutch origin and the number of children in some of the non-Dutch 
ethnic groups was small. This may have underpowered our results. Second, the ethnic 
origin of the child was defined according to the Dutch standard classification.13 This 
classification is objective, reproducible and easily applicable in epidemiological studies. 
However, some misclassification might have occurred since third-generation migrants 
were defined as being of Dutch origin but might still have a different skin structure. 
This may have reduced the contrast between children of Dutch origin and other ethnic 
groups, and underestimated our effect estimates. Third, information on eczema was 
obtained by parental questionnaires, consisting widely accepted and commonly used 
questions that reliably reflect the prevalence of eczema in young children at the popula-
tion level.14, 28 Furthermore, self-reported diagnosis of eczema in the past year based 
on a single question demonstrates sufficient validity for the epidemiological study of 
childhood eczema.29 Nonetheless, we cannot rule out that parental reporting of eczema 
might be different among ethnic groups due to language difficulties and cultural differ-
ences, such as different attitudes toward health care utilization and different reporting 
of symptoms.30 We had no additional information on eczema from medical records or 
physical examinations. Fourth, we did not have data on other important environmental 
factors and possible intermediating factors, such as housing conditions, air pollution, 
and microbial exposure.9 In addition, environmental risk factors such as maternal BMI 
and history of allergy, eczema or asthma and child’s birth weight, BMI and wheezing 
have a genetic component of their own.31–33 These genetic components may also partly 
explain associations of environmental risk factors with eczema. Therefore, changing 
environmental factors might not be sufficient to lower the risk of childhood eczema. 
Fifth, we only genotyped four FLG mutations. Despite other known loci associated with 
eczema34, FLG mutations are known to be most prevalent in Caucasian populations and 
associations of these mutations with eczema in children have been replicated in many 
studies.10 Furthermore, the FLG gene is the only gene of which its function in relation 
with eczema has been studied. An in vitro study showed that knockout of FLG gene 
expression extensively alters keratinocyte differentiation and integrity and function of 
the stratum corneum.35 In non-Caucasian populations, specifically those born in the host 
country as in our study, the prevalence of other mutations and their role in the associa-
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tions of ethnic origin with the risk of childhood eczema is less clear36, and remains to be 
studied. Children without any mutant alleles were classified as wild-type, although their 
carrier status of other non-genotyped FLG mutations was unknown. Further studies 
are needed to explore the role of other mutations, which might be more prevalent in 
children of non-Dutch origin, in the association of ethnic origin with the development of 
childhood eczema. Last, we considered possible collider bias resulting from adjustment 
for child’s wheezing. This seems unlikely because effect estimates did not materially 
change when wheezing was excluded from the models.
In conclusion, we observed that Cape Verdean, Dutch Antillean, Surinamese-Creole 
and Surinamese-Hindustani children had increased risks of eczema in the first 4 years of 
life. Only the associations of Surinamese-Creole and Surinamese-Hindustani origin with 
eczema remained present when environmental and genetic risk factors were taken into 
account. Further studies are needed to explore the possible underlying mechanisms and 
the clinical relevance of our findings.
Detailed acknowledgements and additional supporting information can be found in the 
published article online: http://onlinelibrary.wiley.com/doi/10.1111/pai.12579/suppinfo.
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supplementary Figure. Flowchart of participants.
 
n = 518 
Children without data on eczema excluded 
n = 1,695 
Twins (n = 179) and children without data on 
ethnic origin (n = 292) or belonging to small or 
heterogeneous ethnic groups (Asian (n = 236), 
African (n = 173), European (n = 542) or other (n = 
273) origin) excluded 
n = 7,295 
Children with consent until age 4 years 
n = 5,600 
Children with data on ethnic origin available 
n = 1,986 
Children without data on filaggrin mutations 
excluded 
n = 5,082 
Children with any data on eczema available 
 
Age 6 months  n = 3,276 
Age 1 year  n = 4,022 
Age 2 years  n = 4,195 
Age 3 years  n = 3,872 
Age 4 years  n = 3,826 
n = 3,096 
Children with any data on filaggrin mutations 
available 
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supplementary table 1. Characteristics of mothers and their children (n = 5,082).
observed imputed
maternal characteristics
Age at enrollment (years)* 30.9 (4.9) 30.9 (4.9)
Missing 0 (0) 0 (0)
Education (%)
Primary or secondary 49.3 (2,406) 50.4 (2,559)
Higher 50.7 (2,479) 49.6 (2,523)
Missing 3.9 (197) 0 (0)
History of allergy, eczema or asthma (%)
No 61.4 (2,623) 62.2 (3,163)
Yes 38.6 (1,652) 37.8 (1,919)
Missing 15.9 (807) 0 (0)
Parity (%)
0 56.8 (2,809) 55.8 (2,837)
≥ 1 43.2 (2,136) 44.2 (2,245)
Missing 2.7 (137) 0 (0)
Pet keeping during pregnancy (%)
No 65.3 (2,653) 64.0 (3,253)
Yes 34.7 (1,409) 36.0 (1,829)
Missing 20.1 (1,020) 0 (0)
Body mass index at enrollment (kg/m2)† 23.7 (18.8–35.6) 23.8 (18.8–35.9)
Missing 9.4 (480) 0 (0)
Smoking during pregnancy (%)
No 76.0 (3,502) 76.0 (3,860)
Yes 24.0 (1,105) 24.0 (1,222)
Missing 9.4 (475) 0 (0)
Psychiatric symptoms during pregnancy† 0.13 (0–1.31) 0.15 (0–1.38)
Missing 21.8 (1,108) 0 (0)
child characteristics
Sex (%)
Male 50.3 (2,556) 50.3 (2,556)
Female 49.7 (2,526) 49.7 (2,526)
Missing 0 (0) 0 (0)
Gestational age at birth (weeks)† 40.1 (36.0–42.3) 40.1 (36.0–42.3)
Missing 0.3 (14) 0 (0)
Birth weight (grams)* 3,455 (556) 3,455 (556)
Missing 0.1 (3) 0 (0)
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supplementary table 1. Characteristics of mothers and their children (n = 5,082). (continued)
observed imputed
Breastfed ever (%)
No 8.6 (416) 8.8 (449)
Yes 91.4 (4,431) 91.2 (4,633)
Missing 4.6 (235) 0 (0)
Day care attendance until age 1 year (%)
No 40.6 (1,513) 44.4 (2,256)
Yes 59.4 (2,214) 55.6 (2,826)
Missing 26.6 (1,355) 0 (0)
Body mass index at age 10–13 months (kg/m2)† 17.4 (14.8–20.4) 17.4 (14.9–20.4)
Missing 20.2 (1,027) 0 (0)
Wheezing until age 4 years (%)
No 51.8 (1,685) 54.5 (2,771)
Yes 48.2 (1,566) 45.5 (2,311)
Missing 36.0 (1,831) 0 (0)
Ethnic origin (%)
Dutch 73.9 (3,756) 73.9 (3,756)
Cape Verdean 2.5 (125) 2.5 (125)
Dutch Antillean 3.1 (156) 3.1 (156)
Moroccan 5.8 (295) 5.8 (295)
Surinamese-Creole 3.3 (168) 3.3 (168)
Surinamese-Hindustani 2.9 (147) 2.9 (147)
Turkish 8.5 (435) 8.5 (435)
Missing 0 (0) 0 (0)
Eczema last 6 months at age 6 months (%)
No 83.8 (2,746) 82.6 (4,198)
Yes 16.2 (530) 17.4 (884)
Missing 35.5 (1,806) 0 (0)
Eczema last 6 months at age 1 year (%)
No 87.4 (3,515) 86.6 (4,402)
Yes 12.6 (507) 13.4 (680)
Missing 20.9 (1,060) 0 (0)
Eczema last 12 months at age 2 years (%)
No 86.5 (3,598) 86.0 (4,369)
Yes 13.5 (561) 14.0 (713)
Missing 18.2 (923) 0 (0)
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supplementary table 1. Characteristics of mothers and their children (n = 5,082). (continued)
observed imputed
Eczema last 12 months at age 3 years (%)
No 91.1 (3,527) 90.1 (4,578)
Yes 8.9 (345) 9.9 (504)
Missing 23.8 (1,210) 0 (0)
Eczema last 12 months at age 4 years (%)
No 92.2 (3,527) 91.1 (4,631)
Yes 7.8 (299) 8.9 (451)
Missing 24.7 (1,256) 0 (0)
Values are *means (SD), †medians (2.5–97.5th percentile) or percentages (absolute numbers) based on ob-
served and imputed data.
supplementary table 2. Characteristics of mothers and children included and not included in the study.
included
n = 5,082
not included
n = 518
P-value for 
difference
maternal characteristics
Age at enrollment (years)* 30.9 (4.9) 27.6 (5.7) < 0.001
Missing 0 (0) 0.02 (1)
Education (%) < 0.001
Primary or secondary 49.3 (2,406) 84.7 (388)
Higher 50.7 (2,479) 15.3 (70)
Missing 3.9 (197) 11.6 (60)
History of allergy, eczema or asthma (%) 0.36
No 61.4 (2,623) 59.0 (236)
Yes 38.6 (1,652) 41.0 (164)
Missing 15.9 (807) 22.8 (118)
Parity (%) < 0.001
0 56.8 (2,809) 43.9 (223)
≥ 1 43.2 (2,136) 56.1 (285)
Missing 2.7 (137) 1.9 (10)
Pet keeping during pregnancy (%) < 0.001
No 65.3 (2,653) 74.5 (306)
Yes 34.7 (1,409) 25.5 (105)
Missing 20.1 (1,020) 20.6 (107)
Body mass index at enrollment (kg/m2)† 23.7 (18.8–35.6) 24.4 (18.6–37.4) < 0.001
Missing 9.4 (480) 4.6 (24)
Smoking during pregnancy (%) < 0.001
No 76.0 (3,502) 64.7 (292)
Yes 24.0 (1,105) 35.3 (159)
Missing 9.4 (475) 12.9 (67)
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supplementary table 2. Characteristics of mothers and children included and not included in the 
study. (continued)
included
n = 5,082
not included
n = 518
P-value for 
difference
Psychiatric symptoms during pregnancy† 0.13 (0–1.31) 0.33 (0.02–2.07) < 0.001
Missing 21.8 (1,108) 42.9 (222)
child characteristics
Sex (%) < 0.05
Male 50.3 (2,556) 56.1 (290)
Female 49.7 (2,526) 43.9 (227)
Missing 0 (0) 0.2 (1)
Gestational age at birth (weeks)† 40.1 (36.0–42.3) 40.0 (35.5–42.3) < 0.05
Missing 0.3 (14) 0.4 (2)
Birth weight (grams)* 3,455 (556) 3,334 (546) < 0.001
Missing 0.1 (3) 0.4 (2)
Breastfed ever (%) 0.68
No 8.6 (416) 9.2 (36)
Yes 91.4 (4,431) 90.8 (356)
Missing 4.6 (235) 24.3 (126)
Day care attendance until age 1 year (%) < 0.05
No 40.6 (1,513) 84.6 (11)
Yes 59.4 (2,214) 15.4 (2)
Missing 26.6 (1,355) 97.5 (505)
Body mass index at age 10–13 months (kg/m2)† 17.4 (14.8–20.4) 17.5 (14.8–20.8) 0.19
Missing 20.2 (1,027) 39.8 (206)
Wheezing until age 4 years (%) 0.07
No 51.8 (1,685) 0 (0)
Yes 48.2 (1,566) 100.0 (3)
Missing 36.0 (1,831) 99.4 (515)
Ethnic origin (%) < 0.001
Dutch 73.9 (3,756) 34.9 (181)
Cape Verdean 2.5 (125) 12.2 (63)
Dutch Antillean 3.1 (156) 8.1 (42)
Moroccan 5.8 (295) 22.4 (116)
Surinamese-Creole 3.3 (168) 7.0 (36)
Surinamese-Hindustani 2.9 (147) 5.2 (27)
Turkish 8.5 (435) 10.2 (53)
Missing 0 (0) 0 (0)
Values are *means (SD), †medians (2.5–97.5th percentile) or percentages (absolute numbers) based on ob-
served data. P-values for difference are calculated by independent samples T-test for continuous variables 
with a normal distribution, the Mann-Whitney U-test for continuous variables with a skewed distribution, 
and Pearson’s Chi-square test for categorical variables. Bold values indicate statistical significance at the 
α = 0.05 level.
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AbstrAct
background Breastfeeding may have immune modulatory effects that influence the de-
velopment of childhood allergic sensitization and atopic diseases. We aimed to examine 
the associations of breastfeeding with childhood allergic sensitization, inhalant or food 
allergy and eczema, and whether any association was affected by disease-related modi-
fication of the exposure or modified by maternal history of allergy, eczema or asthma.
methods This study among 5,828 children was performed in a population-based 
prospective cohort from fetal life onwards. We collected information on duration (< 2 
months, 2–4 months, 4–6 months and ≥  6 months) and exclusiveness (non-exclusive 
vs. exclusive for 4 months) of breastfeeding in infancy by postal questionnaires. At age 
10 years, inhalant and food allergic sensitization were measured by skin prick tests, 
and physician-diagnosed inhalant and food allergy by a postal questionnaire. Data on 
parental-reported eczema were available from birth until age 10 years.
results We observed no association of breastfeeding with any allergic sensitization, 
physician-diagnosed allergy, or combination of these outcomes. Shorter breastfeed-
ing duration was associated with an overall increased risk of eczema (p-value for trend 
< 0.05). Non-exclusively breastfed children had an overall increased risk of eczema (ad-
justed odds ratio (95 % confidence interval): 1.11 (1.01, 1.23)), compared with children 
exclusively breastfed for 4 months. Risk period-specific sensitivity analyses, additional 
adjustment for ointment use for eczema at age 2 months, and cross-lagged modeling 
showed no consistent results for disease-related modification of the exposure. Results 
were not modified by maternal history of allergy, eczema or asthma (p-value for interac-
tion > 0.05).
conclusions Shorter duration or non-exclusiveness of breastfeeding is associated 
with a weak overall increased risk of eczema but not allergic sensitization or physician-
diagnosed allergy at age 10 years.
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introduction
Breastfeeding may affect the development of childhood allergic sensitization and atopic 
diseases such as allergy and eczema.1 Underlying biological mechanisms are not fully 
clear but might include various components of human milk that modulate the child’s 
immune system and alter the balance between pro-inflammatory and anti-inflammatory 
signals.1, 2 Also, human milk oligosaccharides are suggested to influence the develop-
ment of atopic diseases by modulating gut microbiota diversity.2, 3 Previous birth cohort 
studies showed that breastfeeding was not consistently associated with allergic sensi-
tization measured by skin prick tests.4–8 A recent meta-analysis of observational studies 
showed that longer duration and exclusiveness of breastfeeding were associated with 
an up to 26 % decreased risk of allergic rhinitis and eczema in preschool-age children, 
but not with food allergy.9 Furthermore, results from a cluster-randomized controlled 
trial among 13,889 children showed that children of mothers who were promoted to 
breastfeed longer and more exclusively did not have reduced prevalences of inhalant 
allergic sensitization, allergic rhinitis and eczema until age 6.5 years, compared with 
children of mothers who were not promoted.10 However, the effects of breastfeeding on 
allergic sensitization and atopic diseases at older age are less known.4, 6 Also, the effects 
of disease-related modification of the exposure, meaning that early symptoms of allergy 
or eczema in the child may encourage a mother to alter breastfeeding habits11, and the 
modifying effects of maternal history of allergy, eczema or asthma on the associations of 
breastfeeding with atopic diseases in school-age children are less clear.5, 6, 8
Therefore, we aimed to examine the associations of duration and exclusiveness of 
breastfeeding with allergic sensitization, inhalant or food allergy at age 10 years, and ec-
zema from birth until age 10 years among 5,828 children and their mothers participating 
in a population-based prospective cohort study. Additionally, we examined whether any 
association was affected by altered maternal breastfeeding habits due to early symptoms of 
allergy or eczema in the child or modified by maternal history of allergy, eczema or asthma.
methods
general design
This study was embedded in the Generation R Study, a population-based prospective 
cohort study from fetal life onwards.12 The study has been approved by the Medical 
Ethical Committee of the Erasmus Medical Center, Rotterdam, The Netherlands (MEC-
2012–165). Written informed consent was obtained from both parents or legal represen-
tatives. For the current study, twins (n = 208), and children without data on breastfeed-
ing (n = 2,111), and allergic sensitization, allergy and eczema (n = 297) were excluded, 
leaving a total of 5,828 children for the analyses (Supplementary Figure 1).
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breastfeeding duration and exclusiveness
Detailed information on breastfeeding initiation and continuation was obtained from 
parental postal questionnaires at ages 2, 6 and 12 months. Mothers were asked whether 
they ever breastfed their child (no; yes) and at what age (in months) of the child they 
stopped breastfeeding. Of mothers that started breastfeeding, duration of breastfeed-
ing was categorized into four groups: ‘< 2 months’, ‘2–4 months’, ‘4–6 months’, and ‘≥ 6 
months’.13 Exclusiveness of breastfeeding was defined using information on the intro-
duction of milk or solids, and categorized into ‘non-exclusive breastfeeding for 4 months’ 
and ‘exclusive breastfeeding for 4 months’. Analyses that focused on breastfeeding dura-
tion and exclusiveness were performed among children that were ever breastfed.
Allergic sensitization, allergy and eczema
Children visited the research center at a median age of 9.7 years (2.5–97.5th percentile: 
9.3–10.6). Inhalant and food allergic sensitization (no; yes) to house dust mite, 5-grass 
mixture, birch, cat and dog (ALK-Abelló B.V., Almere, The Netherlands), and hazelnut, 
cashew nut, peanut and peach were measured by skin prick tests using the scanned area 
method.14 We used a positive control (histamine dihydrochloride 10 mg/mL) in duplicate 
and a negative control (sodium chloride 9  mg/mL). Skin responses were considered 
positive if the area of the wheal was ≥ 40 % of the histamine response (i.e., histamine 
equivalent prick index area ≥ 0.40).14 The scanned area method does not require adjust-
ment for the negative control. However, children without a negative control or with 
any skin response to the negative control were omitted from the analyses. Questions 
adapted from the International Study of Asthma and Allergies in Childhood (ISAAC) core 
questionnaires provided information on physician-diagnosed inhalant (“Was your child 
ever diagnosed with an allergy to pollen (hay fever)/house dust mite/cat/dog?”) (no; yes) 
and food (“Was your child ever diagnosed with an allergy to cashew nut/peanut?”) (no; 
yes) allergy at age 10 years.15 We further combined allergic sensitization and physician-
diagnosed allergy into groups of ‘no allergic sensitization and no allergy’, ‘any allergic 
sensitization, but no allergy’, ‘no allergic sensitization, but any allergy’, and ‘any allergic 
sensitization and any allergy’. Physician-diagnosed eczema was parental-reported at 
ages 6 months and 1, 2, 3, 4 and 10 years (“Was your child diagnosed with eczema in the 
last 6 months/last year?”) (no; yes).
covariates
Information on maternal education (primary or secondary; higher), history of allergy, 
eczema or asthma (no; yes), parity (nulliparous; multiparous), pet keeping (no; yes) and 
body mass index (BMI) was obtained by postal questionnaires completed by the mother 
at enrollment. Information on maternal smoking was obtained by questionnaires mul-
tiple times during pregnancy and combined (no; yes). We assessed maternal psychiatric 
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symptoms in the second trimester of pregnancy using the Global Severity Index of the 
Brief Symptom Inventory16, denoting overall psychiatric symptoms. Information on 
child’s sex, gestational age at birth and birth weight was obtained from obstetric and 
midwife records at birth. We based ethnic origin (European; non-European) of the child 
on the country of birth of the parents.17 We obtained information on ointment use for 
eczema (no; yes) and day care attendance (no; yes) by questionnaires at ages 2 months 
and 1 year, respectively.
statistical analysis
We compared characteristics of children included and not included using independent 
samples T-tests, Mann-Whitney U-tests, and Pearson’s Chi-square tests. We used logistic 
regression or multinomial logistic regression models to examine the associations of 
duration and exclusiveness of breastfeeding with the risk of allergic sensitization and 
physician-diagnosed allergy or combined allergic sensitization and allergy groups, re-
spectively, at age 10 years. We used generalized estimating equation models to examine 
the associations of duration and exclusiveness of breastfeeding with the longitudinal 
odds of eczema at ages 6 months and 1, 2, 3, 4 and 10 years independently and overall, 
taking into account correlations between repeated measurements of eczema within 
the same child. Confounders were included in the models based on literature, if they 
were associated with both the determinant and the outcome, or if they changed the 
effect estimates with ≥ 10 % in bivariate analyses. Analyses with inhalant or food allergic 
sensitization or allergy as the outcomes were mutually adjusted for each other. Tests 
for trends were performed by including the categorized breastfeeding duration as a 
continuous variable in the models. We performed risk period-specific sensitivity analy-
ses by excluding children who developed eczema during the period of breastfeeding 
until age 6 months (n = 962) and additional adjustment for ointment use for eczema 
at age 2 months to account for possible altered maternal breastfeeding habits due to 
early eczema in the child. We applied an adjusted cross-lagged model to examine bidi-
rectional associations of breastfeeding with eczema.18, 19 More detailed information on 
cross-lagged modeling is provided in the Supplementary Methods. For these analyses, 
ointment use for eczema at age 2 months was used as a proxy for the presence of eczema 
at age 2 months. The modifying effect of maternal history of allergy, eczema or asthma 
and the time-varying effect of age at eczema measurement were tested by adding them 
as product terms with the breastfeeding variables in the models. Missing data of covari-
ates and eczema were multiple-imputed to reduce potential bias and improve efficiency 
(Supplementary Table 1). We assumed that missing data were missing at random.20 The 
best indicator for the presence or absence of eczema is an eczema measurement at a 
different age. Therefore, at least one eczema measurement was available in our popula-
tion for analysis to predict other eczema measurements. Because we lacked repeated 
116 Chapter 3.2
measurements on allergic sensitization and physician-diagnosed allergy, we did not 
impute missing data of these outcomes. The size or direction of the effect estimates did 
not materially differ between analyses with imputed data and complete cases only (data 
not shown). Therefore, we present results based on imputed analyses only. Measures of 
association are presented as adjusted odds ratios (aOR) with their 95 % confidence inter-
vals (CI). Statistical analyses were performed using SPSS 21.0.0.1 (IBM Corp., Armonk, NY, 
USA), SAS 9.3 (SAS Institute Inc., Cary, NC, USA), and Mplus 7.11 for Windows (Muthén & 
Muthén, Los Angeles, CA, USA).
results
general
Maternal and child characteristics are presented in Table 1 and Supplementary Table 2. 
Of the children, 92.1 % (n = 5,365) was ever breastfed, 25.6 % (n = 1,182) was breastfed 
for < 2 months, 21.2 % (n = 980) for 2–4 months, 11.8 % (n = 547) for 4–6 months, 31.4 % 
(n = 1,449) for ≥ 6 months, and 25.2 % (n = 1,201) exclusively breastfed for 4 months. In-
halant or food allergic sensitization was present in 32.1 % (n = 1,085) and 6.8 % (n = 230) 
of the children at age 10 years, respectively. Physician-diagnosed inhalant or food al-
lergy was present in 12.1 % (n = 467) and 2.3 % (n = 87) of the children at age 10 years, 
respectively. The prevalence of eczema declined from 16.5 % (n = 962) at age 6 months 
to 7.9 % (n = 460) at age 10 years. Participants without follow-up data had younger, lower 
educated mothers who had higher parity and BMI at enrollment, smoked more during 
pregnancy, and had more psychiatric symptoms during pregnancy. Children were more 
often of non-European origin and attended day care more often than those included in 
the study (Supplementary Table 3).
table 1. Characteristics of mothers and their children.
n = 5,828
maternal characteristics
Education, higher (%) 51.8 (3,017)
History of eczema, allergy or asthma, yes (%) 38.2 (2,228)
Parity, ≥ 1 (%) 43.8 (2,553)
Pet keeping during pregnancy, yes (%) 35.1 (2,047)
Body mass index at enrollment (kg/m2)† 23.7 (18.8–35.7)
Smoking during pregnancy, yes (%) 23.5 (1,372)
Psychiatric symptoms during pregnancy† 0.15 (0–1.40)
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table 1. Characteristics of mothers and their children. (continued)
n = 5,828
child characteristics
Sex, female (%) 50.1 (2,919)
Gestational age at birth (weeks)† 40.1 (36.0–42.3)
Birth weight (grams)* 3,455 (548)
Ethnic origin, European (%) 68.8 (4,012)
Ointment use for eczema at age 2 months, yes (%) 8.0 (464)
Day care attendance until age 1 year, yes (%) 55.9 (3,259)
Breastfed ever, yes (%) 92.1 (5,365)
Breastfeeding duration (%)
Never 10.0 (463)
< 2 months 25.6 (1,182)
2–4 months 21.2 (980)
4–6 months 11.8 (547)
≥ 6 months 31.4 (1,449)
Breastfeeding exclusiveness (%)
Never 9.7 (463)
Non-exclusive for 4 months 65.0 (3,095)
Exclusive for 4 months 25.2 (1,201)
Allergic sensitization at age 10 years, yes (%)
Inhalant 32.1 (1,085)
Food 6.8 (230)
Physician-diagnosed allergy at age 10 years, yes (%)
Inhalant 12.1 (467)
Food 2.3 (87)
Allergic sensitization and allergy combined at age 10 years (%)
No allergic sensitization and no allergy 66.3 (1,868)
Any allergic sensitization, but no allergy 22.6 (636)
No allergic sensitization, but any allergy 1.3 (36)
Any allergic sensitization and any allergy 9.9 (279)
Eczema, yes (%)
Age 6 months 16.5 (962)
Age 1 year 13.2 (768)
Age 2 years 14.2 (825)
Age 3 years 10.1 (586)
Age 4 years 8.7 (508)
Age 10 years 7.9 (460)
Values are *means (SD), †medians (2.5–97.5th percentile) or percentages (absolute numbers) based on im-
puted data. Data on breastfeeding duration and exclusiveness, allergic sensitizations and physician-diag-
nosed allergies are not imputed.
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breastfeeding and childhood atopic diseases
Never breastfeeding, duration and exclusiveness of breastfeeding were not associated 
with allergic sensitization, physician-diagnosed allergy or combined allergic sensitiza-
tion and allergy groups (Table 2 and Supplementary Table 4). Never breastfeeding was 
not associated with eczema per year or overall, compared with ever breastfeeding 
(Supplementary Table 5). A shorter breastfeeding duration was associated with a higher 
overall risk of eczema (p-value for trend < 0.05) (Figure A and Supplementary Table 5). 
Specifically, children breastfed < 2 months had an overall increased risk of eczema (aOR 
(95 % CI): 1.16 (1.02, 1.32)), compared with children breastfed ≥  6 months. Children 
non-exclusively breastfed for 4 months had an overall increased risk of eczema (1.11 
(1.01, 1.23), compared with children exclusively breastfed for 4 months. (Figure B and 
Supplementary Table 5). Sensitivity analyses excluding children who developed eczema 
during the period of breastfeeding until age 6 months showed that effect estimates 
for the associations of breastfeeding <  2 months and non-exclusive breastfeeding 
for 4 months with eczema overall attenuated to non-significant (1.10 (0.92, 1.32) and 
0.99 (0.86, 1.14), respectively). Effect estimates did not materially change when we 
table 2. Associations of duration and exclusiveness of breastfeeding with allergic sensitizations and physi-
cian-diagnosed allergies in children at age 10 years.
odds ratio (95 % confidence 
interval) for allergic 
sensitization
odds ratio (95 % confidence 
interval) for physician-
diagnosed allergy
inhalant
n = 3,381
Food
n = 3,369
inhalant
n = 3,771
Food
n = 3,846
Breastfeeding
Never (n = 463) 0.83 (0.60, 1.14) 0.83 (0.42, 1.66) 1.11 (0.73, 1.67) 0.83 (0.30, 2.29)
Ever (n = 5,365) Reference Reference Reference Reference
Breastfeeding duration
< 2 months (n = 1,182) 1.02 (0.80, 1.30) 1.05 (0.62, 1.76) 1.28 (0.93, 1.77) 1.54 (0.71, 3.32)
2–4 months (n = 980) 1.14 (0.89, 1.46) 1.26 (0.75, 2.12) 0.94 (0.67, 1.33) 1.53 (0.69, 3.39)
4–6 months (n = 547) 1.22 (0.92, 1.63) 0.57 (0.29, 1.13) 0.97 (0.64, 1.46) 1.08 (0.39, 3.01)
≥ 6 months (n = 1,449) Reference Reference Reference Reference
P-value for trend 0.79 0.53 0.20 0.22
Breastfeeding exclusiveness
Non-exclusive for 4 months 
(n = 3,095)
1.05 (0.86, 1.28) 1.38 (0.88, 2.14) 1.02 (0.78, 1.35) 0.76 (0.41, 1.40)
Exclusive for 4 months (n = 1,201) Reference Reference Reference Reference
Values are odds ratios (95 % confidence interval) from logistic regression models based on imputed data. 
Models are adjusted for maternal education, history of allergy, eczema or asthma, parity, pet keeping, body 
mass index at enrollment, smoking, psychiatric symptoms, and child’s sex, gestational age, birth weight, 
ethnic origin and day care attendance, and mutually for inhalant and food allergic sensitization or allergy.
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additionally adjusted for ointment use for eczema at age 2 months (data not shown). 
Cross-lagged modeling showed that effect estimates for the associations of eczema or 
ointment use for eczema with breastfeeding, which were considered as associations in 
the opposite direction, were non-significant (Supplementary Figure 2). We observed no 
modifying effect of maternal history of allergy, eczema or asthma, and no time-varying 
effect of age at eczema measurement on the associations of breastfeeding with child’s 
allergic sensitization, physician-diagnosed allergy, combined allergic sensitization and 
allergy groups or eczema (p-values for interaction > 0.05).
discussion
In this large prospective population-based study, we observed that shorter duration or 
non-exclusiveness of breastfeeding was associated with a weak overall increased risk 
of eczema, but not allergic sensitization or physician-diagnosed allergy at age 10 years.
comparison of main findings with other studies
Previous birth cohort studies showed conflicting results on the association of breast-
feeding with the risk of allergic inhalant or food sensitization.4–8, 21 Recently, observa-
tional studies that examined the associations of breastfeeding with allergic rhinitis, 
food allergy and eczema were meta-analyzed.9 Longer duration of breastfeeding was 
associated with a 21 % decreased risk of allergic rhinitis, and exclusive breastfeeding for 
3–4 months with a 26 % decreased risk of eczema in children until age 5 and 2 years, re-
Figure. Associations of duration (A) and exclusiveness (B) of breastfeeding with eczema in children until 
age 10 years.
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Values are odds ratios (95 % confidence interval) from generalized estimating equation models based on 
imputed data. Reference group is children who were (A) breastfed ≥ 6 months or (B) exclusively breastfed 
for 4 months. Models are adjusted for maternal education, history of allergy, eczema or asthma, parity, pet 
keeping, body mass index at enrollment, smoking, psychiatric symptoms, and child’s sex, gestational age, 
birth weight, ethnic origin and day care attendance. *P-value < 0.05. Mo = months; y = year(s).
120 Chapter 3.2
spectively, but not at older ages and effect estimates generally had high heterogeneity.9 
Our results suggest that shorter duration or non-exclusiveness of breastfeeding is asso-
ciated with an overall increased risk of eczema until age 10 years. In line with the results 
of the meta-analysis, we found no association of breastfeeding with food allergy, and no 
modifying effect of maternal history of allergy, eczema or asthma on the associations of 
breastfeeding with allergic sensitization or atopic diseases. Differences in results might 
be explained by recall bias of feeding history, different study populations (general popu-
lation vs. full-term born children only vs. high-risk children), definitions of breastfeeding 
(never vs. ever, duration, degree of exclusiveness), types of inhalant or food allergens 
that were measured, age at which measurements were performed (preschool-age vs. 
school-age), and measurement of and adjustment for potential confounders. Further 
studies are needed to examine whether early introduction of allergenic foods might 
prevent the development of food allergy.22–24
interpretation of results
Our results showed that duration or exclusiveness of breastfeeding was not associated 
with allergic sensitization or physician-diagnosed allergy at age 10 years. Children breast-
fed during a shorter period or non-exclusively had an up to 1.16-fold overall increased 
risk of eczema until age 10 years. For exclusiveness of breastfeeding, aORs translate to 
an estimated number of 17–122 children that would need to be breastfed exclusively 
for 4 months to prevent one case of eczema at age 6 months to 10 years.25 Our findings 
partly support current breastfeeding guidelines of the European Academy of Allergy 
and Clinical Immunology and the Dutch Youth Health Centre.26, 27 We observed associa-
tions of duration or exclusiveness of breastfeeding with eczema overall but not per year. 
This might be explained by increased statistical power when using eczema overall rather 
than a chance finding. Differences in observed associations of breastfeeding with eczema 
and allergic sensitizations or physician-diagnosed allergies might be due to differences 
in timing of these outcome measurements. Eczema was assessed longitudinally, while 
allergic sensitizations and physician-diagnosed allergies were measured at one time 
point only. Future studies focusing on associations of breastfeeding with potential shifts 
in allergic sensitization and allergy patterns using skin prick tests and measurements of 
physician-diagnosed allergy longitudinally from early childhood onwards are needed.28 
Underlying biological mechanisms for the associations of breastfeeding with allergic 
sensitization, allergy and eczema might involve complex interactions of secretory im-
munoglobulin A, cytokines, chemokines, polyamines, sensitizing and tolerance promot-
ing allergens, and eosinophil-derived granular proteins in human milk, which modulate 
the infant’s developing immune system.1 N-3 polyunsaturated fatty acids in breast milk 
are suggested to play a mediating role in the development of allergic sensitization, al-
lergy and eczema, but evidence on this topic is rather conflicting.29 Also, human milk 
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oligosaccharides with prebiotic properties are suggested to influence the development 
of atopic diseases by modulating gut microbiota diversity.3 The impact of human milk on 
the diversity of the infant’s gut microbiota in relation to allergic sensitization and atopic 
diseases requires further investigation in population-based cohorts.
Risk period-specific sensitivity analyses, additional adjustment for ointment use for 
eczema at age 2 months and cross-lagged modeling were used to examine potential 
disease-related modification of the exposure.11, 18, 30 Failure to account for disease-related 
modification of the exposure could erroneously suggest that shorter or non-exclusive 
breastfeeding leads to eczema, while it could have been that the development of early-
onset eczema encouraged mothers to extend breastfeeding. For risk period-specific 
sensitivity analyses, the effect estimates attenuated to non-significant, but this might 
have mainly been due to power issues and less likely due to differences in etiology, 
severity and further development of atopic diseases between children with early and 
later onset of eczema.31, 32 The size and direction of the effect estimates did not materi-
ally change. Therefore, we consider our results most probably not affected by disease-
related modification of the exposure.
We found no modifying effect of maternal history of allergy, eczema or asthma on 
the associations of breastfeeding with allergic sensitization or atopic diseases. Genetic 
studies are needed to fully explore the role of maternal history of atopic diseases.
strengths and limitations
Strengths of this study are the use of a population-based prospective study design 
from fetal life onwards with a large number of participants, detailed information on 
breastfeeding status, allergic sensitization, allergy and eczema, and longitudinal mea-
surements of eczema over time. However, some methodological limitations should be 
considered. First, selection bias in longitudinal studies mainly arises due to participants 
that are lost to follow-up. Characteristics of non-included subjects differed from those 
included in the study. This might have led to bias if the associations of breastfeeding with 
allergic sensitization, allergy and eczema were different between those included and 
not included in the study. Response rates of questionnaires ranged from 71 % to 82 %. 
The main reason for this was that not all children received each questionnaire due to 
logistical constraints and delayed implementation of some questionnaires after children 
reached the target age for those questionnaires. Second, we used an advanced software 
tool to calculate the histamine equivalent prick index. The scanned area method cor-
rects for interobserver variability and ethnic differences in skin response to histamine 
and is recommended in research settings.14 The histamine equivalent prick index area 
cut-off value was based on skin response to food allergens but assumed similar for 
inhalant allergens. We evaluated inhalant and food allergens that we considered most 
relevant to children of age 10 years at the population level. Other allergens, such as milk 
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and egg, were not taken into account because of low sensitization rates at this age.33 
This may have resulted in non-differential misclassification and, subsequently, a dilution 
of the effect. It might be of interest to further explore the effects of breastfeeding on 
allergic sensitization to specific inhalant and food allergens with low sensitization in 
high-risk populations. Third, we used parental questionnaires to obtain data on child’s 
allergy and eczema, which may have led to non-differential misclassification of these 
outcomes, specifically food allergy. This most probably led to an underestimation of the 
effect estimates. Also, breastfeeding mothers are likely to be more health-conscious and 
might, therefore, be more likely to have allergic symptoms or skin rashes in their children 
presented for medical review, thus increasing the probability of diagnosing allergy or 
eczema. This may have resulted in differential misclassification and, subsequently, also 
an underestimation of the true effect. To reduce potential underestimation of the effect 
estimates, we opted for a self-reported physician’s diagnosis of eczema to maximize the 
number of children without eczema correctly classified (i.e., specificity) at the expense 
of misclassifying children with stable disease not requiring medical attention as non-
cases (i.e., sensitivity).34 We used widely accepted, validated questions adapted from 
the ISAAC core questionnaire that reliably reflect the prevalence of eczema in young 
children at the population level.15, 35 Self-reported diagnosis of eczema in the last year 
based on a single question seems sufficiently valid for studying current childhood ec-
zema in epidemiological studies when compared with a physician’s diagnosis.36 Fourth, 
we aimed to reduce potential bias due to missing data by using multiple imputation 
methods assuming that missing data were missing at random. However, it remains 
difficult to quantify the effect of missing data that were missing not at random, partly 
due to computational limitations and current statistical software availability. Fifth, as 
in any observational study, residual confounding due to insufficiently or unmeasured 
confounders might be an issue.
In conclusion, we observed that shorter duration or non-exclusiveness of breastfeed-
ing was associated with a weak overall increased risk of eczema, but not allergic sensi-
tization or physician-diagnosed allergy at age 10 years. Results seemed not affected by 
disease-related modification of the exposure, and not modified by maternal atopic dis-
ease history. Despite its small protective effect, breastfeeding is encouraged because of 
its nutritional, immunological and psychosocial benefits. Further studies using detailed 
information on human milk components are needed to explore the specific underlying 
pathophysiological mechanisms.
Detailed acknowledgements and additional supporting information can be found in the 
published article online: http://onlinelibrary.wiley.com/doi/10.1111/all.13195/suppinfo.
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supplementary methods
With a cross-lagged model, bidirectional associations of breastfeeding (i.e., exposure) 
with childhood eczema (i.e., outcome) can be studied within the same model. In this 
model, we used logistic regression models to study associations of breastfeeding at 
age 2 months with ointment use for eczema at age 2 months and eczema at ages 6 
months to 10 years. Similarly, we studied associations of breastfeeding at age 6 months 
with eczema at ages 6 months to 10 years, and of breastfeeding at age 12 months with 
eczema at ages 1 to 10 years. In addition, we studied the associations of ointment use 
for eczema at age 2 months with breastfeeding at ages 6 and 12 months, and of eczema 
at age 6 months with breastfeeding at age 12 months. Furthermore, the cross-lagged 
model takes associations of eczema measurements over time into account.
supplementary Figure 1. Flowchart of participants.
 
n = 297 
Children without data on allergic sensitization, 
allergy or eczema excluded 
n = 2,319 
Twins (n = 208) and children without data on 
breastfeeding (n = 2,111) excluded 
n = 8,444 
Children with consent until phase 3 of the 
Generation R Study 
n = 6,125 
Children with data on breastfeeding available 
n = 5,828 
Children with any data on allergic sensitization, 
allergy or eczema available 
 
Allergic sensitization at age 10 years 
 Inhalant  n = 3,381 
 Food   n = 3,369 
Physician-diagnosed allergy at age 10 years 
 Inhalant  n = 3,771 
 Food   n = 3,846 
Eczema 
 Age 6 months  n = 3,800 
 Age 1 year  n = 4,511 
 Age 2 years  n = 4,666 
 Age 3 years  n = 4,367 
 Age 4 years  n = 4,327 
 Age 10 years  n = 3,925 
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supplementary Figure 2. All hypothesized directions of the associations of breastfeeding with eczema using 
cross-lagged modeling.
 
Breastfeeding 
age 2 months 
Breastfeeding 
age 6 months 
Breastfeeding 
age 12 months 
Eczema 
age 2-10 years 
Ointment use 
for eczema age 
2 months 
Eczema 
age 6 months 
Eczema 
age 1 year 
1.27 
(0.73, 2.21) 
0.84 
(0.54, 1.31) 
0.85 
(0.61, 1.15) 
Values are odds ratios (95 % confidence interval) from logistic regression models based on imputed data, 
using cross-lagged modeling which takes all potential directions of associations into account. Reference 
group is children who were not breastfed, did not use ointment for eczema or did not have eczema. Models 
are adjusted for maternal education, history of allergy, eczema or asthma, parity, pet keeping, body mass 
index at enrollment, smoking, psychiatric symptoms, and child’s sex, gestational age, birth weight, ethnic 
origin and day care attendance. Arrows indicate the direction of the associations and whether they are 
significant (bold) or non-significant (dashed). Only odds ratios (95 % confidence interval) for associations of 
eczema with breastfeeding, the opposite direction of the hypothesis, are presented.
supplementary table 1. Details of the multiple imputation model.
software used: SPSS 21.0.0.1 for Windows (IBM Corp., Armonk, NY, USA)
imputation method used: fully conditional specification
model type for scale variables used: predictive mean matching
number of imputed datasets created: 25
maximum number of iterations: 20
imputed variables*:
Outcomes: eczema at ages 6 months and 1, 2, 3, 4 and 10 years
Covariates:  maternal education, history of allergy, eczema or asthma, parity, pet keeping during pregnancy, 
body mass index at enrollment, smoking during pregnancy, and psychiatric symptoms during 
pregnancy; child’s sex, gestational age at birth, birth weight, ethnic origin, day care attendance until 
age 1 year, ever asthma at age 10 years, and ointment use for eczema at age 2 months
Additional indicator variables:
Outcomes:  ever eczema at age 10 years; histamine equivalent intracutaneous coefficient value for house dust 
mite, birch, 5-grass mixture, dog, cat, cashew, peanut and peach
Covariates:  paternal education, history of allergy, eczema or asthma, body mass index at enrollment, and 
smoking during pregnancy; household income
treatment of binary or categorical variables: logistic
statistical interactions included in imputation models: none
*Also included in the multiple imputation model as indicator variables.
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supplementary table 2. Characteristics of mothers and their children (n = 5,828).
observed imputed
maternal characteristics
Education (%)
Primary or secondary 46.7 (2,558) 48.2 (2,811)
Higher 53.3 (2,919) 51.8 (3,017)
Missing 6.0 (351) 0 (0)
History of allergy, eczema or asthma (%)
No 60.9 (2,922) 61.8 (3600)
Yes 39.1 (1,873) 38.2 (2228)
Missing 17.1 (1,033) 0 (0)
Parity (%)
0 57.2 (3,264) 56.2 (3,275)
≥ 1 42.8 (2,445) 43.8 (2,553)
Missing 2.0 (119) 0 (0)
Pet keeping during pregnancy (%)
No 66.4 (3,064) 64.9 (3,781)
Yes 33.6 (1,553) 35.1 (2,047)
Missing 20.8 (1,211) 0 (0)
Body mass index at enrollment (kg/m2)† 23.7 (18.8–35.7) 23.7 (18.8–35.7)
Missing 9.2 (537) 0 (0)
Smoking during pregnancy (%)
No 76.7 (3,986) 76.5 (4,456)
Yes 23.3 (1,213) 23.5 (1,372)
Missing 10.8 (629) 0 (0)
Psychiatric symptoms during pregnancy† 0.13 (0–1.31) 0.15 (0–1.40)
Missing 22.4 (1,303) 0 (0)
child characteristics
Sex (%)
Male 49.9 (2,909) 49.9 (2,909)
Female 50.1 (2,919) 50.1 (2,919)
Missing 0 (0) 0 (0)
Gestational age at birth (weeks)† 40.1 (36.0–42.3) 40.1 (36.0–42.3)
Missing 0.1 (8) 0 (0)
Birth weight (grams)* 3,455 (548) 3,455 (548)
Missing 0.1 (3) 0 (0)
Ethnic origin (%)
European 69.9 (4,006) 68.8 (4,012)
Non-European 30.1 (1,726) 31.2 (1,816)
Missing 1.6 (96) 0 (0)
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supplementary table 2. Characteristics of mothers and their children (n = 5,828). (continued)
observed imputed
Ointment use for eczema at age 2 months (%)
No 92.8 (3,548) 92.0 (5,364)
Yes 7.2 (274) 8.0 (464)
Missing 34.4 (2,006) 0 (0)
Day care attendance until age 1 year (%)
No 40.5 (1,714) 44.1 (2,569)
Yes 59.5 (2,518) 55.9 (3,259)
Missing 27.4 (1,596) 0 (0)
Breastfed ever (%)
No 7.9 (463) 7.9 (463)
Yes 92.1 (5,365) 92.1 (5,365)
Missing 0 (0) 0 (0)
Breastfeeding duration (%)
Never 10.0 (463) 10.0 (463)
< 2 months 25.6 (1,182) 25.6 (1,182)
2–4 months 21.2 (980) 21.2 (980)
4–6 months 11.8 (547) 11.8 (547)
≥ 6 months 31.4 (1,449) 31.4 (1,449)
Missing 20.7 (1,207) 20.7 (1,207)
Breastfeeding exclusiveness (%)
Never 9.7 (463) 9.7 (463)
Non-exclusive for 4 months 65.0 (3,095) 65.0 (3,095)
Exclusive for 4 months 25.2 (1,201) 25.2 (1,201)
Missing 18.3 (1,069) 18.3 (1,069)
Allergic sensitization at age 10 years – inhalant (%)
No 67.9 (2,296) 67.9 (2,296)
Yes 32.1 (1,085) 32.1 (1,085)
Missing 42.0 (2,447) 42.0 (2,447)
Allergic sensitization at age 10 years – food (%)
No 93.2 (3,139) 93.2 (3,139)
Yes 6.8 (230) 6.8 (230)
Missing 42.2 (2,459) 42.2 (2,459)
Physician-diagnosed allergy at age 10 years – inhalant (%)
No 87.9 (3,379) 87.9 (3,379)
Yes 12.1 (467) 12.1 (467)
Missing 34.0 (1,982) 34.0 (1,982)
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supplementary table 2. Characteristics of mothers and their children (n = 5,828). (continued)
observed imputed
Physician-diagnosed allergy at age 10 years – food (%)
No 97.7 (3,684) 97.7 (3,684)
Yes 2.3 (87) 2.3 (87)
Missing 35.3 (2,057) 35.3 (2,057)
Allergic sensitization and allergy combined at age 10 years (%)
No allergic sensitization and no allergy 66.3 (1,868) 66.3 (1,868)
Any allergic sensitization, but no allergy 22.6 (636) 22.6 (636)
No allergic sensitization, but any allergy 1.3 (36) 1.3 (36)
Any allergic sensitization and any allergy 9.9 (279) 9.9 (279)
Missing 51.6 (3,009) 51.6 (3,009)
Eczema last 6 months at age 6 months (%)
No 83.9 (3,188) 83.5 (4,866)
Yes 16.1 (612) 16.5 (962)
Missing 34.8 (2,028) 0 (0)
Eczema last 6 months at age 1 year (%)
No 87.2 (3,933) 86.8 (5,060)
Yes 12.8 (578) 13.2 (768)
Missing 22.6 (1,317) 0 (0)
Eczema last 12 months at age 2 years (%)
No 86.5 (4,034) 85.8 (5003)
Yes 13.5 (632) 14.2 (825)
Missing 19.9 (1,162) 0 (0)
Eczema last 12 months at age 3 years (%)
No 90.8 (3,966) 89.9 (5,242)
Yes 9.2 (401) 10.1 (586)
Missing 25.1 (1,461) 0 (0)
Eczema last 12 months at age 4 years (%)
No 92.2 (3,991) 91.3 (5,320)
Yes 7.8 (336) 8.7 (508)
Missing 25.8 (1,501) 0 (0)
Eczema last 12 months at age 10 years (%)
No 93.3 (3,663) 92.1 (5,368)
Yes 6.7 (262) 7.9 (460)
Missing 32.7 (1,903) 0 (0)
Values are *means (SD), †medians (2.5–97.5th percentile) or percentages (absolute numbers) based on ob-
served and imputed data. Data on breastfeeding duration and exclusiveness, allergic sensitizations and 
physician-diagnosed allergies are not imputed.
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supplementary table 3. Characteristics of mothers and children included and not included in the study.
included
n = 5,828
not included
n = 297
P-value for 
difference
maternal characteristics
Education (%) < 0.001
Primary or secondary 46.7 (2,558) 86.0 (190)
Higher 53.3 (2,919) 14.0 (31)
Missing 6.0 (351) 25.6 (76)
History of allergy, eczema or asthma (%) 0.69
No 60.9 (2,922) 62.4 (121)
Yes 39.1 (1,873) 37.6 (73)
Missing 17.1 (1,033) 34.7 (103)
Parity (%) < 0.001
0 57.2 (3,264) 45.9 (135)
≥ 1 42.8 (2,445) 54.1 (159)
Missing 2.0 (119) 1.0 (3)
Pet keeping during pregnancy (%) 0.19
No 66.4 (3,064) 70.8 (143)
Yes 33.6 (1,553) 29.2 (59)
Missing 20.8 (1,211) 32.0 (95)
Body mass index at enrollment (kg/m2)† 23.7 (18.8–35.7) 24.5 (17.9–37.4) < 0.05
Missing 9.2 (537) 7.4 (22)
Smoking during pregnancy (%) < 0.001
No 76.7 (3,986) 64.9 (146)
Yes 23.3 (1,213) 35.1 (79)
Missing 10.8 (629) 24.2 (72)
Psychiatric symptoms during pregnancy† 0.13 (0–1.31) 0.27 (0–1.48) < 0.001
Missing 22.4 (1,303) 47.8 (142)
child characteristics
Sex (%) 0.12
Male 49.9 (2,909) 54.5 (162)
Female 50.1 (2,919) 45.5 (135)
Missing 0 (0) 0 (0)
Gestational age at birth (weeks)† 40.1 (36.0–42.3) 39.9 (36.2–42.3) 0.05
Missing 0.1 (8) 0.3 (1)
Birth weight (grams)* 3,455 (548) 3,393 (494) 0.06
Missing 0.1 (3) 0 (0)
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supplementary table 3. Characteristics of mothers and children included and not included in the 
study. (continued)
included
n = 5,828
not included
n = 297
P-value for 
difference
Ethnic origin (%) < 0.001
European 69.9 (4,006) 36.9 (90)
Non-European 30.1 (1,726) 63.1 (154)
Missing 1.6 (96) 17.8 (53)
Day care attendance until age 1 year (%) < 0.05
No 40.5 (1,714) 85.7 (6)
Yes 59.5 (2,518) 14.3 (1)
Missing 27.4 (1,596) 97.6 (290)
Breastfed ever (%) < 0.05
No 7.9 (463) 11.8 (35)
Yes 92.1 (5,365) 88.2 (262)
Missing 0 (0) 0 (0)
Breastfeeding duration (%) < 0.001
Never 10.0 (463) 35.0 (35)
< 2 months 25.6 (1,182) 52.0 (52)
2–4 months 21.2 (980) 11.0 (11)
4–6 months 11.8 (547) 1.0 (1)
≥ 6 months 31.4 (1,449) 1.0 (1)
Missing 20.7 (1,207) 66.3 (197)
Breastfeeding exclusiveness (%) < 0.001
Never 9.7 (463) 27.3 (35)
Non-exclusive for 4 months 65.0 (3,095) 71.9 (92)
Exclusive for 4 months 25.2 (1,201) 0.8 (1)
Missing 18.3 (1,069) 56.9 (169)
Values are *means (SD), †medians (2.5–97.5th percentile) or percentages (absolute numbers) based on ob-
served data. P-values for difference are calculated by independent samples T-test for continuous variables 
with a normal distribution, the Mann-Whitney U-test for continuous variables with a skewed distribution, 
and Pearson’s Chi-square test for categorical variables. Bold values indicate statistical significance at the 
α = 0.05 level.
132 Chapter 3.2
supplementary table 4. Associations of duration and exclusiveness of breastfeeding with combined al-
lergic sensitization and physician-diagnosed allergy groups in children at age 10 years.
odds ratio (95 % confidence interval) for any allergic 
sensitization and any physician-diagnosed allergy 
combined
Any allergic 
sensitization, but 
no allergy
n = 636
no allergic 
sensitization, but 
any allergy
n = 36
Any allergic 
sensitization and 
any allergy
n = 279
Breastfeeding
Never (n = 463) 0.90 (0.63, 1.29) 0.32 (0.04, 2.43) 0.94 (0.56, 1.57)
Ever (n = 5,365) Reference Reference Reference
Breastfeeding duration
< 2 months (n = 1,182) 0.97 (0.73, 1.28) 1.71 (0.58, 5.01) 1.22 (0.83, 1.78)
2–4 months (n = 980) 1.16 (0.88, 1.52) 2.30 (0.80, 6.59) 0.96 (0.64, 1.45)
4–6 months (n = 547) 1.04 (0.74, 1.45) 1.49 (0.36, 6.14) 1.13 (0.72, 1.79)
≥ 6 months (n = 1,449) Reference Reference Reference
P-value for trend 0.93 0.26 0.43
Breastfeeding exclusiveness
Non-exclusive for 4 months (n = 3,095) 1.08 (0.86, 1.36) 1.60 (0.58, 4.69) 1.04 (0.76, 1.42)
Exclusive for 4 months (n = 1,201) Reference Reference Reference
Values are odds ratios (95 % confidence interval) from multinomial logistic regression models based on 
imputed data. Reference group is children without any allergic sensitization or physician-diagnosed allergy 
(n = 1,868). Models are adjusted for maternal education, history of allergy, eczema or asthma, parity, pet 
keeping, body mass index at enrollment, smoking, psychiatric symptoms, and child’s sex, gestational age, 
birth weight, ethnic origin and day care attendance.
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introduction
Eczema is a chronic inflammatory skin disease that inflicts important health and eco-
nomic effects at the population level.1 Eczema may occur solely or coincide with allergic 
sensitization and symptoms of allergy as part of an atopic constitution.2 It is suggested 
that eczema might have at least part of its origin in fetal life and infancy.3, 4 This phenom-
enon of early-life exposures that modulate the susceptibility to chronic diseases in later 
life is commonly referred to as ‘developmental programming’ or the ‘Developmental 
Origins of Health and Disease (DOHaD)’ hypothesis.5 Adverse exposures may result in 
specific adaptations with short-term developmental and survival benefits, but may 
eventually lead to disease.
The aim of this thesis was to identify fetal and infant exposures that affect the develop-
ment of eczema, allergic sensitization or allergy in childhood. In previous chapters, the 
main findings, merits and limitations of the studies presented in this thesis have already 
been discussed in detail. This chapter provides a general overview of the main findings, 
highlights methodological considerations in epidemiological studies, discusses the 
clinical implications of the main findings and suggests directions for future research.
mAin Findings
Previous epidemiological research has identified important early-life risk and protective 
factors associated with the development of eczema, allergic sensitization or allergy, but 
studies have focused primarily on preschool-age and high-risk children of Caucasian 
origin.6, 7 Data from multi-ethnic longitudinal studies relating early-life environmental 
and genetic exposures with eczema, allergic sensitization and allergy in older children 
from the general population remain scarce. The main findings of the studies presented 
in this thesis are summarized in the Table.
Fetal exposures
In the studies presented in this thesis, we examined the associations of two important 
fetal exposures with childhood eczema, allergic sensitization or allergy.
First, maternal psychiatrics symptoms during pregnancy is suggested to increase the 
risk of childhood eczema or allergy via developmental adaptations of the hypothalamic-
pituitary-adrenal (HPA) axis, the sympathetic adrenomedullary system and immune re-
sponses in the offspring.8 We observed that maternal overall and anxiety symptoms dur-
ing pregnancy were associated with an up to 1.21-fold increased risk of eczema until age 
10 years. Furthermore, maternal overall psychiatric, depressive and anxiety symptoms 
during pregnancy were associated with an up to 1.96-fold increased risk of physician-
diagnosed inhalant allergy at age 10 years. These associations were independent of 
maternal psychiatric symptoms after delivery, paternal psychiatric symptoms during or 
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after delivery, and a large set of potential confounding factors such as maternal educa-
tion, ethnic origin and history of allergy, eczema or asthma. We observed no association 
of maternal psychiatric symptoms during pregnancy with allergic sensitization or food 
allergy. Our findings suggest a possible intrauterine programming effect of maternal 
psychiatric symptoms that increases the child’s risk of developing atopic diseases.
Second, vitamin D is suggested to influence immune regulation, epidermal barrier 
function and bacterial defense.9, 10 However, the role of vitamin D in the development of 
childhood eczema remains controversial as previous cohort studies, that varied greatly 
in sample size, method and timing of vitamin D measurement, definition of eczema, 
and confounder adjustment reported conflicting results.9 We observed among 3,019 
preschool-age children of Dutch origin that 25-hydroxyvitamin D levels in mid-gestation 
and at birth were not associated with the risk of childhood eczema. Other environmen-
tal factors, such as dietary and feeding habits and microbial exposure, or genetic factors 
might have a more important role in the onset of childhood eczema.
In summary, we identified adverse effects of maternal psychiatric symptoms on eczema 
and physician-diagnosed inhalant allergy in school-age children, but no effect of vitamin 
D levels in mid-gestation and at birth on eczema in preschool-age children. Future studies 
are needed to develop intervention strategies focused on reducing maternal psychiatric 
symptoms during pregnancy to prevent the occurrence of eczema and allergy.
infant exposures
In the studies presented in this thesis, we examined the associations of three important 
common infant exposures with childhood eczema, allergic sensitization or allergy.
First, the prevalence of eczema varies considerably among children of different ethnic 
groups.11 Also, it was recently observed that differences in structural and functional 
epidermal barrier characteristics exist between adults of African American, Caucasian 
and East Asian descent.12 In our multi-ethnic population-based prospective cohort, 
we observed that Cape Verdean, Dutch Antillean, Surinamese-Creole and Surinamese-
Hindustani children had an up to 2.06-fold increased risk of eczema until age 4 years. 
The maximum change in effect size for these associations occurred when we adjusted 
separately for maternal education and overall psychiatric symptoms during pregnancy. 
Surinamese-Creole and Surinamese-Hindustani children remained to have increased 
risks of eczema after adjustment for environmental and genetic risk factors. However, 
precise quantification of attribution of each of these factors separately to the associa-
tion of ethnic origin with the risk of eczema is difficult due to collinearity.
Second, breastfeeding might have immune modulatory effects that influence the devel-
opment of childhood eczema, allergic sensitization and allergy via complex interactions of 
human milk components such as immunoglobulin A, cytokines, chemokines, long-chain 
polyunsaturated fatty acids, polyamines, and sensitizing and tolerance promoting al-
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lergens.13 Recently, a meta-analysis of observational studies showed that longer duration 
and exclusiveness of breastfeeding were associated with an up to 26 % decreased risk of 
eczema and allergic rhinitis in preschool-age children.14 Using more detailed informa-
tion on breastfeeding status, we showed that shorter duration or non-exclusiveness of 
breastfeeding is associated with an up to 1.16-fold increased risk of eczema until age 10 
years. However, we observed no association of breastfeeding with allergic sensitization 
or physician-diagnosed allergy. Our results seemed neither affected by disease-related 
modification of the exposure nor modified by maternal history of eczema, allergy or 
asthma. Despite the small observed protective effect, breastfeeding should be encour-
aged because of its nutritional, immunological and psychosocial benefits.
Third, the role of timing and diversity of allergenic food introduction in the develop-
ment of childhood eczema, allergic sensitization and allergy has been a much debated 
topic in the past decades. An accumulating body of evidence suggests that a critical 
window of immunological opportunity exists at age 4–6 months to expose children 
to food proteins and induce immune tolerance.15, 16 However, we showed that neither 
timing nor diversity of allergenic food introduction, including the introduction of cow’s 
milk, hen’s egg, peanut, tree nuts, soy and gluten, at age ≤  6 months is consistently 
associated with eczema, allergic sensitization or allergy in children until age 10 years. 
Children introduced to gluten at age ≤ 6 months had a 16 % decreased risk of eczema, 
and children introduced to ≥ 3 allergenic foods at age ≤ 6 months had a 36 % decreased 
risk of physician-diagnosed inhalant allergy. To some extent, disease-related modifica-
tion of the exposure was present within our study, particularly for the association of 
early gluten introduction with eczema until age 10 years. Overall, our results do not 
provide strong evidence to adapt current international feeding guidelines.
In summary, we observed that in our multi-ethnic cohort the risk of developing ec-
zema at preschool-age varies among children of different ethnic origin. Furthermore, we 
identified adverse effects of shorter and non-exclusive breastfeeding, but no consistent 
protective effect of timing or higher diversity of allergenic food introduction at early age 
on eczema in school-age children. Further research is warranted to replicate our findings 
and to explore the underlying biological mechanisms.
methodologicAl considerAtions
The research presented in this thesis was embedded in the Generation R Study, a large 
multi-ethnic population-based prospective cohort study from fetal life onwards in 
Rotterdam, The Netherlands.17 Specific methodological considerations for individual 
studies have been discussed in the respective chapters of this thesis. In the following 
paragraphs, general methodological issues with regard to internal and external validity 
are discussed.
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selection bias
Selection bias may occur if the association of the exposure with the outcome of interest 
is different between study participants and those who are eligible but do not participate 
in the study. The overall response rate of participating children eligible at birth was 
61 %.17 It is unlikely that this non-response at baseline is at random. Participating chil-
dren were less often of non-Dutch origin. Parents of participating children had a higher 
household income and higher educational attainment18, which is in line with data from 
other large prospective cohort studies.19 Also, parents of participating children had 
less depressive symptoms than expected from the population figures in Rotterdam.20 
Altogether, the non-response at baseline suggests a selection toward a relatively more 
affluent and healthier study population, which might have resulted in lower prevalence 
rates of diseases and, subsequently, reduced statistical power. However, several studies 
have shown that in cohort studies associations are not markedly influenced by selective 
non-participation at baseline.21, 22 Therefore, we consider it less likely that our results are 
biased by selective non-response at baseline.
Selection bias may also occur if the association of the exposure with the outcome of 
interest is different between those included in the analyses and those lost to follow-up. 
Of all live born children enrolled in the Generation R Study (n = 9,749), 75.8 % (n = 7,393) 
participated in the follow-up studies at age 10 years17, of whom 76.4 % (n = 5,645) had 
information available on eczema, allergic sensitization or physician-diagnosed allergy. 
Mothers who did not answer questionnaires related to specific research questions or 
did not visit the research center for skin prick testing of their child were younger, lower 
educated and had lower folate levels during pregnancy, and their children were more 
often of non-Dutch origin and less often breastfed. This selective loss to follow-up 
toward a more affluent and healthier population might have biased the observed ef-
fect estimates, but quantifying this bias is difficult. We performed multiple imputation 
analyses to minimize the risk of selection bias due to missing values of covariates.23, 24
information bias
Information bias refers to a systematic error due to misclassification of participant data. 
Misclassification is differential (i.e., non-random) if it is different for participants with 
and without the exposure or outcome of interest. Misclassification is non-differential 
(i.e., random) if it is unrelated to the occurrence or presence of the exposure or outcome. 
Differential misclassification may result in an over- or underestimation of the true ef-
fect, while non-differential misclassification usually leads to underestimated effect 
estimates.25
Participant information on exposures of interest to the studies described in this thesis, 
including maternal psychiatric symptoms during pregnancy, maternal and fetal vitamin 
D levels in mid-gestation and at birth, respectively, child’s ethnic origin, breastfeeding 
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and allergenic food introduction, were collected longitudinally and before assessment 
of most outcomes. Both researchers and participants were unaware of specific research 
questions, which limits the probability of differential misclassification. Although the 
classification of the child’s ethnic origin is objective, reproducible and easily applicable 
in epidemiological studies, some non-differential misclassification might have occurred 
as third-generation migrants were defined as being of Dutch origin but might still have 
a different skin structure. This might have reduced the contrast between children of 
Dutch origin and other ethnic groups and, as a result, diluted our effect estimates. Also, 
non-differential misclassification of maternal psychiatric symptoms during pregnancy 
or breastfeeding or complementary feeding habits might have occurred due to socially 
desirable responding. It is difficult to speculate on the direction of the bias introduced 
by this random measurement error.
Childhood eczema, allergic sensitization and allergy were the outcomes examined in 
this thesis. For eczema, we relied on data derived from parental questionnaires, consist-
ing widely accepted and commonly used questions that reliably reflect the prevalence 
of eczema in children at the population level.26 A parental-reported physician diagnosis 
of eczema in the past year based on a single question has demonstrated sufficient valid-
ity for the epidemiological study of childhood eczema.27 For allergy, we were not able 
to use an accepted and validated questionnaire but used questions adapted from the 
International Study of Asthma and Allergies in Childhood core questionnaires instead.28 
Parental-reported disease may give rise to non-differential misclassification, which 
most probably resulted in an underestimation of the true effects. Also, mothers with 
psychiatric symptoms or breastfeeding mothers may be more anxious or aware of their 
child’s health and, therefore, be more likely to have skin rashes or allergic symptoms in 
their child presented for medical review, thus increasing the probability of diagnosing 
eczema or allergy. This might have resulted in differential misclassification and, sub-
sequently, an overestimation of the harmful effect of maternal psychiatric symptoms 
during pregnancy and an underestimation of the protective effect of breastfeeding. 
Allergic sensitization was measured by skin prick tests using the scanned area method.29 
Because this method is objective, computerized and corrects for interobserver variabil-
ity and ethnic differences in skin response to histamine, it is unlikely that differential or 
non-differential misclassification occurred.
confounding
A confounder is an extraneous factor associated with both the exposure and the 
outcome, and is not an intermediary step in the causal pathway. If not controlled for, 
confounding may cause biased effect estimates and lead to erroneous conclusions. In 
this thesis, we used two approaches to account for confounding.
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First, we adjusted our analyses for multiple potential confounders. We selected covari-
ates based on previous literature and further examined their potential confounding 
effect using statistical models. In most studies presented in this thesis, adjustment for 
potential confounders only moderately affected the effect estimates, which suggests 
that the observed associations of the exposures with the outcomes are possibly true 
associations. Although we adjusted for many potential confounders in our studies, 
we cannot rule out that specific results were affected by residual confounding due to 
insufficiently or unmeasured confounders, such as housing conditions, air pollution, 
vitamin or supplement intake, and microbial exposure.6 Residual confounding might 
have resulted in an overestimation of the effect estimates.
Second, we used information on both maternal and paternal psychiatric symptoms to 
disentangle potential intrauterine and confounding mechanisms.30, 31 Stronger effect es-
timates for the association of maternal than paternal psychiatric symptoms during preg-
nancy with childhood eczema or allergy suggest underlying intrauterine mechanisms, 
while similar effect estimates indicate that these associations may result from residual 
confounding of unmeasured factors. We observed that children of mothers with overall 
psychiatric, depressive or anxiety symptoms during pregnancy had an increased risk of 
physician-diagnosed inhalant allergy, and children of mothers with overall psychiatric 
or anxiety symptoms during pregnancy an increased risk of eczema. These results were 
independent of maternal psychiatric symptoms after delivery, and of paternal psychiat-
ric symptoms during pregnancy and after delivery, suggesting a possible intrauterine 
programming effect of maternal psychiatric symptoms that increases the child’s risk of 
developing atopic diseases.
external validity
External validity is the extent to which results of a study can be generalized to other 
populations. The Generation R Study is conducted in the general population of Rot-
terdam, The Netherlands. The largest ethnic groups were formed by children of Dutch, 
Surinamese, Turkish and Moroccan origin, but the distribution of ethnic groups differed 
moderately from that of the study area.18 In our cohort, children were more often of 
Dutch origin, and in particular children of Moroccan origin were underrepresented. Both 
household income and educational attainment suggest a selection toward a population 
with a higher socioeconomic status. As discussed previously, parents of participating 
children had less depressive symptoms than expected from the population figures in 
Rotterdam.20 This selection toward a more affluent and healthier population is similar 
in our follow-up assessments until age 10 years and may affect the generalizability of 
our findings. Therefore, caution is advised when extrapolating the results to other, less 
ethnically diverse, less affluent or less healthy populations.
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cAusAlity
We described associations, but not causal relationships, of fetal and infant exposures 
with childhood eczema, allergic sensitization and allergy because of the observational 
design of the Generation R Study. The Bradford Hill criteria provide a widely recognized 
basis for inferring causality in epidemiological studies.32 These criteria include the 
strength, specificity, consistency and temporality of an association. Evidence for a causal 
relationship is further strengthened if a biological gradient or dose-response effect, a 
plausible mechanism between cause and effect, coherence with current knowledge 
on the biology of the disease, analogy with comparable exposures or experimental 
evidence is present.
When we apply the Bradford Hill criteria to our studies, we observed small to moder-
ate overall effects estimates for the associations of fetal and infant exposures with child-
hood eczema, our main outcome of interest. Effect estimates were adjusted for a large 
number of confounders, and in general consistency with results reported by previous 
studies. A clear temporal relationship, meaning that the disease must occur after the 
exposure, is present in our study on the associations of maternal psychiatric symptoms 
during pregnancy with childhood eczema. However, ensuring temporality in our studies 
on breastfeeding and complementary feeding habits is more difficult. Early signs and 
symptoms of eczema or allergy in the child might have encouraged parents to alter 
breastfeeding or complementary feeding habits, because they might have been aware 
of a possible association of breastfeeding or complementary feeding habits with child-
hood eczema or allergy.33 Similarly, breastfeeding or complementary feeding habits may 
be influenced by a family history of eczema, allergy or asthma. Mothers with a history of 
eczema, allergy or asthma may be more motivated or advised to prolong breastfeeding 
or avoid delayed introduction of allergenic foods and might have been more aware of 
symptoms of eczema or allergy in their children. Failure to account for this disease-related 
modification of the exposure may erroneously suggest that, for example, shorter dura-
tion of breastfeeding or delayed allergenic food introduction leads to eczema or allergy, 
while it might have been that the early onset of eczema or allergy encouraged mothers 
to extend breastfeeding or expedite complementary feeding. Therefore, we performed 
risk period-specific sensitivity analyses, additional adjustments, tests for interaction or 
cross-lagged modeling.34, 35 For analyses on breastfeeding, the size and direction of the 
effect estimates did not materially change and, therefore, we consider our results most 
probably not affected by disease-related modification of the exposure. For analyses 
on timing or diversity of allergenic food introduction, to some extent disease-related 
modification of the exposure existed within our study. More specifically, for the associa-
tion of early gluten introduction with eczema until age 10 years, we observed that the 
effect estimate attenuated toward the null and was no longer significant. Furthermore, 
we observed a dose-response effect for maternal psychiatric symptoms during preg-
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nancy and breastfeeding duration on the risk of developing childhood eczema. For all 
observed associations of fetal and infant exposures with childhood eczema, plausible 
underlying biological mechanisms and coherence with animal studies or laboratory 
findings are available. We observed that gluten was the only allergenic food associated 
with a decreased risk of eczema when introduced at age < 6 months. However, studies 
that assessed analogue factors for the allergenic foods investigated in our study may 
strengthen the evidence for a causal relationship. For example, early introduction of fish 
has been associated with a decreased risk of childhood eczema.36 Theoretically, a causal 
effect of fetal or infant exposures on childhood eczema, allergic sensitization or allergy 
can be proven using a randomized controlled trial (RCT). However, randomized expo-
sure to factors with known adverse or beneficial health effects, such as maternal stress 
during pregnancy and breastfeeding, respectively, is unethical. Instead, experimental 
interventions that promote breastfeeding or early introduction of allergenic foods in 
conformity with current guidelines may provide additional insight into the causality of 
these exposures on childhood eczema or allergy. This is illustrated by the PROBIT, LEAP, 
LEAP-On and EAT trials. The PROBIT trial showed that children of mothers who were 
intensively promoted to breastfeed according to guidelines of the World Health Orga-
nization (WHO) had a decreased risk of eczema during the first year of life.37 The LEAP 
and LEAP-On trials showed that peanut introduction in high-risk children aged 4–11 
months was associated with a decreased frequency of peanut allergy that persisted after 
1 year of peanut avoidance38, 39, which resulted in recent addendum guidelines for the 
prevention of peanut allergy in high-risk children.40 However, the EAT trial did not show 
an effect of early introduction of common allergenic foods on the frequency of food al-
lergies at age 1–3 years among a selected group of exclusively breast-fed children from 
the general population.41 In summary, our epidemiological studies provide moderate 
to good evidence for causal relationships of fetal and infant exposures with childhood 
eczema based on the Bradford Hill criteria and the results from previous animal and 
experimental studies.
clinicAl imPlicAtions
We identified several fetal and infant exposures associated with an increased risk of 
childhood eczema or allergy, supporting the hypothesis that atopic diseases might 
partly have their origin in fetal life and infancy.3, 4 Our results might have clinical implica-
tions, including the development of lifestyle interventions for the primary prevention 
of atopic diseases already from fetal life onwards, and the identification of high-risk 
children.
Specifically, our observation that children of mothers with psychiatric symptoms dur-
ing pregnancy have increased risks of eczema and physician-diagnosed inhalant allergy 
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could be encouraging to develop public preventive intervention strategies aimed at 
stress reduction or elimination.42 Strategies such as physical relaxation and meditation, 
stress assessment and education, and counseling and social support have shown prom-
ising results on reducing the risk of preterm birth, low birth weight and intrauterine 
growth retardation.43 Pregnancy is an important period where women are likely to be 
more motivated to make beneficial lifestyle changes.
Eczema is more difficult to diagnose in children with skin of colour because erythema 
may be less noticeable.44 Therefore, our observation that Cape Verdean, Dutch Antil-
lean, Surinamese-Creole and Surinamese-Hindustani children have an increased risk of 
eczema, compared with Dutch children, should raise clinicians’ awareness of the disease 
among these ethnic groups.
Currently, the European Academy of Allergy and Clinical Immunology, the European 
Society for Pediatric Gastroenterology, Hepatology and Nutrition and the Dutch Youth 
Health Centre recommend exclusive breastfeeding for 4–6 months and not to avoid or 
delay the introduction of potentially allergenic foods beyond age 4 months, irrespective 
of atopic heredity.45–47 The WHO and the American Academy of Pediatrics recommend 
exclusive breastfeeding until age 6 months.48, 49 Our studies on the effects of breast-
feeding and allergenic food introduction do not provide strong evidence to change the 
contrary feeding guidelines of these expert bodies.
Our observations that vitamin D levels in mid-gestation and at birth are not associated 
with the risk of eczema, that children introduced to gluten at age ≤ 6 months have a 
decreased risk of eczema and that children introduced to ≥ 3 allergenic foods at age ≤ 6 
months have a decreased risk of physician-diagnosed inhalant allergy require further 
replication and exploration of underlying pathophysiological mechanisms.
Future PersPectives
We examined associations of fetal and infant exposures with childhood eczema, allergic 
sensitization and allergy based on data collected in an observational study. Therefore, 
we cannot establish causality of the observed associations. Although an RCT is the 
preferred study design to infer causal relationships, using this study design to assess 
the causal effects of some of the exposures studied in this thesis might have ethical 
limitations. Alternative designs, such as the aforementioned PROBIT, LEAP, LEAP-On 
and EAT trials, might provide additional evidence for causality of the observed associa-
tions. The heterogeneous findings from observational studies regarding the effects of 
maternal and fetal vitamin D levels on childhood eczema emphasize the need for well-
designed RCTs. Thus far, two RCTs have showed no effect of vitamin D supplementation 
in pregnant women on allergy-related outcomes in their offspring at age 3 years.50, 51 
One trial among 158 pregnant women showed that daily supplementation with 800 
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IU of ergocalciferol or a single bolus of 200,000 IU of cholecalciferol during the third 
trimester of pregnancy was not associated with eczema, allergic sensitization, allergic 
rhinitis or food allergy in the child.50 A recent trial among 581 pregnant women showed 
that daily supplementation with 2,400 IU of vitamin D3 from 24 weeks of pregnancy 
until one week after delivery was not associated with the risk eczema or allergic sensiti-
zation in the child.51 Results from the ongoing VDAART trial, which specifically explores 
the effect of higher dose vitamin D3 supplementation earlier in pregnancy, have not 
yet been published.52 Although stress-alleviating interventions during pregnancy has 
yielded promising results regarding adverse birth outcomes, intervention strategies fo-
cused on the reduction of maternal psychiatric symptoms during pregnancy to prevent 
the occurrence of eczema and allergy should be carefully evaluated using RCTs before 
widespread implementation is feasible.
Genome-wide association studies represent a relatively new research technique to 
examine genetic variants involved in human disease. Recently, a large genome-wide as-
sociation study identified 10 new risk loci related to innate immune signaling and T-cell 
activation that were robustly associated with eczema.53 However, the identification of 
the causal variants that underlie these associations is challenging. Expanding studies to 
include allele-specific analyses may be a promising strategy to improve the identification 
of causal variants in a diversity of tissues and cell types.54 Further evidence for causality 
may be derived from knockout models, in which disease occurrence after inactivation 
of the target gene is suggestive of a causal relationship.55 An in vitro study showed that 
knockout of the filaggrin (FLG) gene extensively alters human keratinocyte differentia-
tion and stratum corneum function.56 Filaggrin is an essential protein for maintaining 
the epidermal barrier and FLG mutations are well known to be associated with eczema.57 
We studied four FLG mutations (2282del4, R2447X, R501X and S3247X) that are common 
in Caucasians, and observed that none of the Moroccan and Surinamese-Creole children 
carried these mutations. All other children of non-Dutch origin carried a FLG mutation 
less frequently than children of Dutch origin. In non-Caucasian children, specifically 
those born in the host country as in our study, the prevalence of other FLG mutations and 
their role in the development of childhood eczema is less clear and remains to be further 
studied.58 Also, filaggrin plays a central role in the hydration of the stratum corneum, 
because it is the precursor protein for hygroscopic amino acids and their derivatives, 
known as natural moisturizing factor (NMF).59 It was demonstrated that adult carriers of 
FLG mutations have reduced NMF levels in the stratum corneum, compared with non-
carriers.60 Measurement of NMF levels using in vivo Raman spectroscopy is much less 
demanding than genotyping and may serve as a marker of the FLG genotype in future 
research.
Although many susceptibility genes for eczema have been identified, only a few stud-
ies on gene-gene and gene-environment interactions have been performed. A previous 
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birth cohort study found interactive effects of single nucleotide polymorphisms in the 
IL13 and STAT6 genes on the occurrence of eczema.61 Also, early-life cat exposure is sug-
gested to substantially increase the risk of eczema in the first year of life in children 
with FLG mutations, but not in those without these mutations.62, 63 Both gene-gene and 
gene-environment interactions require further investigation.
Epigenetics is increasingly receiving attention as a potential mechanism underlying 
the DOHaD hypothesis.64 Epigenetic modifications include DNA methylation in pro-
moter regions of specific genes and may affect gene activity, thereby altering epidermal 
barrier function and the susceptibility for eczema development.65 Maternal anxiety and 
depressive symptoms during pregnancy are associated with DNA methylation of the 
glucocorticoid receptor gene NR3C1 in newborns and HPA axis stress reactivity at age 
3 months.66 This may be an underlying pathophysiological mechanism for the observed 
association of maternal psychiatric symptoms during pregnancy with the child’s risk 
of developing atopic diseases. Also, it is suggested that mammalian milk may induce 
epigenetic modifications of the FOXP3 gene required for regulatory T-cell maturation 
and the prevention of atopy.67 The epigenetic origins of childhood eczema, allergic 
sensitization and allergy should be further explored in epigenome-wide association and 
functional genomic studies.
Changes in gut microbiota diversity might affect the risk of developing childhood 
allergic sensitization and atopic diseases.68 Maternal stress during pregnancy was found 
to be associated with the child’s intestinal microbiota composition and colonization 
pattern, predisposing the child to allergic reactions.69 Also, dietary factors such as 
human milk oligosaccharides may serve as substrates for the production of microbial 
metabolites that regulate immune activity and immune tolerance mechanisms.70, 71 Fu-
ture studies are needed to explore these complex microbial, dietary and immunological 
interactions.
Several prediction models have been developed to predict the probability of hav-
ing eczema at preschool-age based on environmental and genetic factors and other 
biological markers.72, 73 Future prediction studies should be extended to school-age 
children, and it should be assessed whether the risk and protective factors examined 
in the studies presented in this thesis are of additional value in the prediction models. 
Subsequently, the newly obtained prediction models should be validated in specific 
clinical settings such as pediatric hospitals, general practices and youth health centers. 
There is increasing recognition that eczema, like asthma, is a heterogeneous disease 
with multiple phenotypes that might have different underlying pathophysiological 
mechanisms.74 It would be of additional value to this thesis to focus on the prediction 
of eczema phenotypes, taking age of onset and persistence over time into account. 
Similarly, population-based studies on allergic sensitization patterns over time and their 
relation with comorbidity of eczema and allergy are warranted.75, 76
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conclusions
Findings from this thesis suggest that fetal and infant exposures are associated with the 
development of childhood eczema and allergy, supporting the hypothesis that atopic 
diseases might have at least part of their origin in fetal life and infancy. Although some 
of the observed effects were relatively small to moderate, they may be important for the 
burden of eczema and allergy at the population level. The fetal and infant exposures 
that were examined in this thesis were not associated with allergic sensitization. Our 
results may contribute to the identification of high-risk children and the development of 
primary prevention strategies focused on pregnant women and young children. Further 
research is needed to explore underlying biological pathways, including the roles of 
genetic and epigenetic mechanisms and the human microbiota.
table. Overview of results of studies on fetal and infant exposures and eczema, allergic sensitization and 
allergy as presented in this thesis.
eczema Allergic sensitization Physician-diagnosed 
allergy
inhalant Food inhalant Food
Fetal exposures
Maternal psychiatric symptoms during pregnancy
Overall psychiatric symptoms ↑ = = ↑ =
Depressive symptoms = = = ↑ =
Anxiety symptoms ↑ = = ↑ =
25-hydroxyvitamin D
Mid-gestation = N.S. N.S. N.S. N.S.
At birth = N.S. N.S. N.S. N.S.
infant exposures
Ethnic origin ↑/= N.S. N.S. N.S. N.S.
Breastfeeding
Duration ↑ = = = =
Exclusiveness ↑ = = = =
Allergenic food introduction
Timing ↓/= = = = =
Diversity = = = ↓ =
For associations of 25-hydroxyvitamin D levels and ethnic origin with eczema, data on eczema were ob-
tained from age 6 months until age 4 years. For associations of other fetal and infant exposures with ec-
zema, data on eczema were obtained from 6 months until age 10 years. Data on allergic sensitization and 
allergy were obtained at age 10 years. Arrows represent the direction of the associations; arrows pointing 
upwards represent positive associations, while arrows pointing downwards represent negative associa-
tions. Equal signs represent null associations. N.S. = not studied.
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summAry
Eczema is a common chronic inflammatory skin disease in childhood that inflicts a 
substantial physical, psychosocial and economic burden. Eczema may occur solely or 
coincide with allergic sensitization and symptoms of allergy as part of an atopic consti-
tution. Because the developmental origins of childhood eczema, allergic sensitization 
and allergy may partly lie in pregnancy and infancy, it is from an etiological perspective 
crucial to study fetal and infant exposures that may affect the risk of these entities. Also, 
insight into the role of fetal and infant exposures may provide opportunities for preven-
tion strategies at times when their effect is expected to be greatest.
chapter 1 is a general introduction and provides the main objectives and the biological 
hypothesis underlying this thesis. Briefly, we aimed to assess the associations of fetal 
and infant exposures with childhood eczema, inhalant and food allergic sensitization or 
allergy. We hypothesized that exposures in fetal life and infancy may affect the child’s 
developing immune system or epidermal barrier function and, subsequently, the risk of 
eczema, allergic sensitization and allergy. The research was embedded in the Generation 
R Study, a large multi-ethnic population-based prospective birth cohort in Rotterdam, 
The Netherlands.
chapter 2 describes the associations of fetal exposures with eczema, allergic sensitiza-
tion or allergy in childhood. From Chapter 2.1, we concluded that maternal psychiatric 
symptoms during pregnancy were associated with increased risks of eczema and 
physician-diagnosed inhalant allergy in school-age children. Results were independent 
of maternal psychiatric symptoms after delivery and of paternal psychiatric symptoms, 
suggesting a possible intrauterine programming effect of maternal psychiatric symp-
toms that increases the child’s risk of developing eczema and allergy. In Chapter 2.2, we 
observed no association of vitamin D levels in mid-gestation and at birth with the risk of 
eczema in preschool-age children.
chapter 3 describes the associations of infant exposures with eczema, allergic sensi-
tization or allergy in childhood. In Chapter 3.1, we observed that Cape Verdean, Dutch 
Antillean, Surinamese-Creole and Surinamese-Hindustani children had increased risks 
of eczema in the first 4 years of life. After adjustment for environmental and genetic 
risk factors, Surinamese-Creole and Surinamese-Hindustani children remained to have 
increased risks of eczema. The findings described in Chapter 3.2 suggest that shorter 
duration or non-exclusiveness of breastfeeding is associated with a modest increased 
risk of eczema, but not allergic sensitization or physician-diagnosed allergy in school-
age children. From Chapter 3.3, we concluded that neither timing nor diversity of al-
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lergenic food introduction is consistently associated with eczema, allergic sensitization 
or physician-diagnosed allergy in school-age children. However, children introduced to 
gluten at age ≤ 6 months had a decreased risk of eczema until age 10 years. Children 
introduced to ≥ 3 allergenic foods at age ≤ 6 months had a decreased risk of physician-
diagnosed inhalant allergy at age 10 years.
Finally, in chapter 4, we provide a general overview of the main findings, highlight 
methodological considerations in epidemiological studies, discuss the clinical implica-
tions of the main findings and suggest directions for future research.
Samenvatting 187
sAmenvAtting
Eczeem is de meest voorkomende chronische inflammatoire huidaandoening bij kinde-
ren en kent aanzienlijke fysieke, psychosociale en economische gevolgen. Eczeem kan 
afzonderlijk voorkomen of gepaard gaan met allergische sensibilisatie en symptomen 
van allergie als onderdeel van een atopische constitutie. Omdat de oorsprong van 
eczeem, allergische sensibilisatie en allergie op de kinderleeftijd mogelijk ten dele in 
de zwangerschap en de zuigelingenperiode ligt, is het vanuit etiologisch perspectief 
van belang om foetale en vroegpostnatale factoren te bestuderen die het risico op deze 
entiteiten kunnen beïnvloeden. Inzicht in de rol van foetale en vroegpostnatale factoren 
biedt tevens mogelijkheden voor preventieve interventies.
hoofdstuk 1 is een algemene introductie en beschrijft de belangrijkste doelstellingen 
alsmede de biologische hypothese waarop dit proefschrift is gebaseerd. We stelden ons 
ten doel onderzoek te doen naar de relaties tussen foetale en vroegpostnatale factoren 
enerzijds en eczeem, allergische sensibilisatie en allergie op de kinderleeftijd anderzijds. 
We veronderstelden dat foetale en vroegpostnatale factoren het in ontwikkeling zijnde 
immuunsysteem van het kind of diens huidbarrière beïnvloeden en, dientengevolge, 
het risico op eczeem, allergische sensibilisatie en allergie. Het onderzoek maakt deel uit 
van een grootschalig bevolkingsonderzoek in Rotterdam, genaamd Generation R.
hoofdstuk 2 beschrijft de relaties tussen foetale factoren en de ontwikkeling van 
eczeem, allergische sensibilisatie of allergie op de kinderleeftijd. Uit het onderzoek 
beschreven in Hoofdstuk 2.1 kunnen we concluderen dat psychiatrische symptomen 
bij de moeder tijdens de zwangerschap geassocieerd zijn met een verhoogd risico op 
eczeem en een inhalatieallergie bij het kind tot de leeftijd van 10 jaar. Deze resultaten 
blijken onafhankelijk van psychiatrische symptomen bij de moeder na de bevalling en 
van psychiatrische symptomen bij de vader. Dit suggereert dat psychiatrische sympto-
men bij de moeder mogelijk een programmeringseffect op het kind in de baarmoeder 
hebben dat het risico op eczeem en allergie op latere leeftijd verhoogt. In Hoofdstuk 
2.2 laten we zien dat vitamine D-serumwaarden gemeten halverwege de zwangerschap 
en bij de bevalling niet geassocieerd zijn met het risico op eczeem bij kinderen tot de 
leeftijd van 4 jaar.
hoofdstuk 3 beschrijft de relaties tussen vroegpostnatale factoren en de ontwikkeling 
van eczeem, allergische sensibilisatie of allergie op de kinderleeftijd. In Hoofdstuk 3.1 
laten we zien dat kinderen met een Kaapverdische, Antilliaanse, Surinaams-Creoolse 
of Surinaams-Hindoestaanse achtergrond een verhoogd risico hebben op eczeem tot 
de leeftijd van 4 jaar. Na correctie voor omgevingsfactoren en genetische factoren 
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blijven Surinaams-Creoolse en Surinaams-Hindoestaanse kinderen een verhoogd risico 
op eczeem hebben. De resultaten uit Hoofdstuk 3.2 suggereren dat kortdurende of 
niet-exclusieve borstvoeding geassocieerd is met een bescheiden verhoogd risico op 
eczeem bij kinderen tot de leeftijd van 10 jaar, maar niet met allergische sensibilisatie 
of allergie. Uit het onderzoek beschreven in Hoofdstuk 3.3 kunnen we concluderen dat 
noch de timing van introductie noch de diversiteit van allergene voedingsmiddelen 
consistent geassocieerd is met eczeem, allergische sensibilisatie of allergie bij kinderen 
tot de leeftijd van 10 jaar. Kinderen bij wie gluten in de eerste 6 levensmaanden worden 
geïntroduceerd, hebben echter een verlaagd risico op eczeem tot de leeftijd van 10 jaar. 
Kinderen bij wie in de eerste 6 levensmaanden 3 of meer allergene voedingsmiddelen 
worden geïntroduceerd, hebben een verlaagd risico op een inhalatieallergie op de 
leeftijd van 10 jaar.
Ten slotte geven we in hoofdstuk 4 een overzicht van de belangrijkste resultaten uit 
voornoemde studies, benadrukken we de methodologische beperkingen van epide-
miologische studies, bediscussiëren we de klinische implicaties van onze bevindingen 
en doen we suggesties voor toekomstig onderzoek.
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